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SUMMARY 
It is well established that strong immune responses by cytotoxic CD8 T cells are often 
key for the clinical outcome of patients with viral infection and cancer. In recent years, 
novel immunotherapies to activate the patient’s immune system have shown 
unprecedented benefits for the treatment of cancer patients. However, immune 
responses are still often insufficient, even despite immunotherapy, which therefore 
must be optimized. 
Our group has elaborated clinical studies on vaccination against Yellow Fever virus 
(YFV) with the YF-17D vaccine, because this live-attenuated virus vaccine is the most 
potent vaccine in humans, and it is increasingly renowned as a unique opportunity to 
study human CD8 T cells to model optimal immunotherapies. 
First, I characterized the molecular basis of the high frequency and prevalence of an 
immunodominant HLA-A*02- restricted YFV-specific epitope, in analogy to the HLA-
A*02-restricted Melan-A epitope in melanoma. Secondly, I focused on the 
characterization of a longitudinal study in healthy individuals before and up to six 
months after YF-17D vaccination, analyzing various innate and adaptive parameters 
using multiparameter flow cytometry. We gained insights into key parameters involved 
in strong, protective and long-term immune responses in humans. Furthermore, we 
compared primary and booster response to YF-17D with respect to CD8 T cell 
heterogeneity and the proportion and profiles of all major immune cell populations. 
Overall, I obtained detailed and broad insight of the optimal acute immune response in 
humans based on vaccination against Yellow Fever virus (YFV) with YF-17D. This 
knowledge supports the identification of optimal immune parameters that may 
transcend and sustain optimization of anti-cancer T cell-based therapies.  
	 9	
RÉSUMÉ  
Il est maintenant établi que les cellules CD8 T cytotoxiques sont un élément clé de 
l’issue clinique des patients souffrant d’infection virale ou de cancer. Ces dernières 
années, de nouvelles immunothérapies ont vu le jour et ont apportés des bénéfices 
sans précédent et l’espoir de traiter des cas très avancés. Cependant, les réponses 
immunitaires contre les tumeurs restent le plus souvent insuffisantes malgré 
l’immunothérapie. Il est donc primordial de trouver des moyens de les améliorer. 
Notre groupe de recherche a élaboré des études cliniques portant sur la vaccination 
contre le virus de la fièvre jaune avec le vaccin vivant atténué YF-17D. Il s’agit du 
vaccin le plus efficace qui existe à ce jour chez l’humain. Il offre l’opportunité unique 
d’étudier les réponses immunitaires dans un contexte contrôlé chez l’être humain, en 
particulier les cellules T cytotoxiques. Ce vaccin est donc considéré comme un modèle 
optimal pour améliorer les immunothérapies. 
Durant ma thèse, j’ai d’abord caractérisé les bases moléculaires de la haute fréquence 
and prévalence de l’épitope immunodominant spécifique à la fièvre jaune et restreint à 
la molécule HLA-A*02. Deuxièmement, j’ai analysé les échantillons sanguins 
d’individus sains avant et après avoir reçu le vaccin YF-17D pour la première fois ou le 
rappel après 10 ans. J’ai analysé les différents paramètres de la réponse immunitaire 
innée et adaptive grâce à la cytométrie de flux. Le but de ma thèse est de déterminer 
quels sont les paramètres associés à une réponse immunitaire robuste, protectrice et 
durable. Ces connaissances permettront d’identifier les paramètres immunitaires qui 
serviront à optimiser les immunothérapies contre le cancer. 
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RÉSUMÉ (large public) 
Il est maintenant établi que certains types cellulaires du système immunitaire sont 
capables de reconnaître et de tuer non seulement les agents pathogènes externes tels 
que les virus et les bactéries mais également les cellules tumorales. Ces dernières 
années, de nouvelles stratégies visant à mobiliser efficacement les propres cellules 
immunitaires de patients atteints de cancer ont vu le jour. Appelées “immunothérapies”, 
ces thérapies ont apportés des bénéfices sans précédent et l’espoir de traiter des cas 
très avancés. Cependant, les réponses immunitaires contre les tumeurs restent le plus 
souvent insuffisantes malgré l’immunothérapie. Il est donc primordial de trouver des 
moyens de les améliorer. 
Ma thèse de doctorat porte sur le vaccin contre la fièvre jaune car il s’agit du vaccin le 
plus efficace qui existe à ce jour chez l’humain. Il offre l’opportunité unique d’étudier les 
réponses immunitaires dans un contexte contrôlé chez l’être humain, en particulier les 
cellules T cytotoxiques, une classe de globules blancs capables d’éradiquer les 
tumeurs. Ce vaccin est donc considéré comme un modèle optimal pour améliorer les 
immunothérapies. 
Le but de ma thèse est de déterminer quels sont les paramètres associés à une 
réponse immunitaire robuste, protectrice et durable. Pour ce faire, j’ai utilisé une 
combinaison de techniques à la fois moléculaires et fonctionnelles. J’ai analysé les 
échantillons sanguins d’individus avant et après avoir reçu le vaccin pour la première 
fois ou le rappel après 10 ans. J’ai ainsi pu examiner de manière détaillée la 
dynamique et l’activation des principaux types cellulaires du système immunitaire 
tenant compte d’une large combinaison de paramètres immunitaires pour obtenir un 
portrait détaillé de la réponse immunitaire optimale chez l’humain. 
  
	 11	
LIST OF ABBREVIATIONS 
 
A2 HLA-A2*0201 
Ag Antigen 
APC Antigen-Presenting Cell 
Bcl-2 B cell lymphoma protein-2 
C Core 
CAR chimeric antigen receptor 
CD Circular Dichroism 
CDR Complementarity- Determining Region 
CM Central Memory 
CMV Cytomegalovirus 
CPL Combinatorial Peptide Library 
CSnT Cytometer Set-up and Tracking 
CTLA-4 Cytotoxic T-Lymphocyte Associated Protein 4 
DAG Diacylglycerol 
DC Dendritic cell 
E Envelope 
EBV Epstein-Barr Virus 
EM Effector Memory 
ER Endoplasmic Reticulum 
FDA Food and Drug Administration 
FDA Functional Data Analysis 
FTOC Fetal Thymus Organ Culture 
HTLV-1 Human T-cell leukemia virus type 1 
IB Inclusion Body 
IFA Incomplete Freud’s Adjuvant 
ILC Innate Lymphoid Cell 
IP3 Inositol triphosphate 
LLW LLWNGPMAV 
M Membrane 
mDC Myeloid dendritic cell 
MHC-I Major Histocompatibility Complex class I 
	 12	
nAbs neutralizing antibodies 
NK Natural Killer 
NS Non-Structural 
NTA Ni2+-nitrilotriacetic acid  
PBMCs Peripheral Blood Mononuclear Cells 
PBS Phosphate Buffered Saline 
PD1 Programmed cell Death 1 
pDC plasmacytoid DC 
PIP2 Phosphatidylinositol triphosphate 
PLC-γ1 phospholipase C gamma 1 
pMHC peptide: Major Histocompatibility Complex 
PRNT Plaque Reduction Neutralizing Test 
RAG Recombinase Activating Gene 
RNA RiboNucleic Acid 
S1PR Sphingosine 1-Phosphate Receptor 1 
SAGE Strategic Advisory Group of Experts 
Sca-1 Stem Cell Antigen-1 
SCM Stem Cell Memory 
scRNA single-cell RNA sequencing 
SPR Surface Plasmon Resonance 
SWATH-
MS 
Sequential Window Acquisition of all Theoretical Mass 
Spectra 
T Thymus 
t-SNE t-stochastic neighbor embedding 
TAP Transporter associated with Antigen Processing 
TCR T-Cell Receptor 
TIL Tumor-Infiltrating lymphocyte 
TraCeR T cell receptor sequence Reconstruction 
WHO World Health Organization 
YEL-AND YF-17D vaccine-associated neurotropic disease 
YEL-AVD YF-17D vaccine-associated viscerotropic disease 
YF Yellow Fever 
YFV Yellow Fever Virus 
  
	 13	
PREFACE 
My PhD thesis work can be divided into two main axes. The first axis consisted in 
characterizing the molecular and functional aspects of the TCR:pMHC interaction in 
HLA-A2/LLW-specific CD8 T cells. The second axis focused on the longitudinal clinical 
protocol, in which we collected blood samples before and several time-points after YF-
17D vaccination, in order to uncover the major immune parameters and their 
relationships during this strong human acute T cell response. 
 
The work conducted during my PhD thesis has led to an accepted first-author paper 
and several manuscripts are currently in preparation: 
 
• Bovay A, Zoete V, Dolton G, Bulek Am, Cole DK, Rizkallah PJ, Fuller A, Beck K, 
Michielin O, Speiser DE, Sewell AK, Fuertes Marraco SA. T cell Receptor Alpha 
Variable 12-2 bias in the immunodominant response to Yellow fever virus. Eur J 
Immunol. 2018 Feb; 48(2):258-272. doi: 10.1002/eji.201747082. 
This article was selected for the journal front cover. 
 
• Rius C*, Attaf M*, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Straten PT, 
Peakman M, Svane IM, Ott A, Connor T, Szomolay B, Dolton G, Sewell AK. Peptide-
MHC class I multimer staining can fail to detect relevant functional T-cell clonotypes 
and underestimate antigen-specific T cell populations. J Immunol. 2018 Feb 26;. doi: 
10.4049/jimmunonol.1700242. 
 
• Fuertes Marraco SA, Bovay A, Nassiri S, Maby-El HAjjami H, Ouertatani-Sakouhi H, 
Held W, Speiser DE. Human stem cell-like memory CD8 T cells establish early in the 
acute response to Yellow Fever virus. In preparation. 
 
• Bovay A, Zoete V, Rizkallah PJ, Beck K, Delbreil P, Speiser DE, Cole DK, Fuertes 
Marraco SA. Functionally optimized peptide rigidity in a novel superagonist mutant of 
the immunodominant Yellow Fever Virus epitope NS4b214-222. In preparation. 
 
• Bovay A, Nassiri S, Maby-El Hajjami H, Marcos Mondéjar P, Akondy AS, Ahmed R, 
Lawson B, Speiser DE, Fuertes Marraco SA. Pre-existing neutralizing antibodies 
restricts adaptive and innate immune responses to Yellow Fever virus YF-17D 
vaccination. In preparation. 
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I structured the present PhD report in the format “thesis without published articles”, 
keeping all data output and report as maintext, and the corresponding manuscripts are 
found as Appendixes at the end of the report. 
 
My thesis was conducted in a collaborative framework coordinated by my direct 
supervisor Dr. Silvia Fuertes and closely supported by Prof. Daniel Speiser, with 
specific projects led by myself. The specific contributions are stated in each chapter of 
the results. Briefly, the work of the first axis was predominantly achieved and led by 
myself, including a 9-month scientific visit in Prof. Andrew Sewell’s laboratory in Cardiff. 
I also mainly conducted the collaborations that subsequently arose from this project. 
The work that I carried out for the second axis was wired within a collaborative network 
of world-leading experts involving multiple analyses using comprehensive and cutting-
edge technology. 
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1. INTRODUCTION 
1.1 BASIC PRINCIPLES OF INNATE AND ADAPTIVE IMMUNITY 
 
To protect the human body against disease, the immune system must fulfill several 
tasks. The initial defenses against pathogens are the physical and chemical barriers, 
such as the skin and mucous membranes. When an individual encounters an infectious 
agent, its presence inside the body must be detected as a foreign component by cells 
from both the innate and adaptive systems. Then, an effector response is mounted to 
contain the infection and eliminate it. The innate immune response occurs rapidly and 
in a non-specific manner. In contrast, the adaptive immune response takes longer to 
develop but is more efficient at eliminating infections, as it is highly specific (antigen-
specific). The main functions of the various cell types of both the innate and adaptive 
response are illustrated in Figure 1. 
Concurrently, the immune response must be tightly and finely regulated to overcome 
pathogenic invasion while avoiding tissue damage, allergy and autoimmune diseases. 
A remarkable property of the adaptive immune system is the generation of an 
immunological memory, providing long-lasting specific protection. As a result, the 
immune system can react more efficiently to a secondary exposure to a particular 
antigen. As my work largely focused on the immune responses mediated by cytotoxic 
CD8 T cells, I will give particular attention to major concepts concerning the function 
and quality of these cells. 
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Figure 1 Overview of the primary functions of the main innate and adaptive immune. Adapted from [1] 
 
1.2 T CELL DEVELOPMENT 
1.2.1 T CELL DIFFERENTIATION 
 
T cells derive from the hematopoietic stem cells found in the bone marrow. Unlike B 
lymphocytes that continue their development in the bone marrow (hence named “B” 
cells), T cell progenitors migrate to and colonize the thymus, hence their name thymus-
dependent (T) lymphocytes. Developing T cells, known as thymocytes, undergo a 
series of maturation steps across thymic compartments, which are marked by changes 
in cell surface proteins such as the CD3 complex and the co-receptor molecules CD4 
and CD8. Importantly, it is here that thymocytes rearrange their T-cell receptor (TCR) 
genes (this process is described in more detail below). Then, immature T cells face 
positive and negative selection depending on the interaction of the TCR with antigenic 
peptide in the context of major histocompatibility complex (peptide:MHC complex, 
pMHC). In the thymus cortex, epithelial cells present self MHC molecules. For positive 
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selection, only thymocytes that recognize self MHC with sufficient strength receive 
signals to survive. Autoimmune regulator (AIRE) is an important transcriptional 
regulator mainly expressed by thymic epithelial cells in the medulla of the thymus 
(mTECs). AIRE functions in immune central tolerance by clearance of auto-reactive T 
cells. Through negative selection, AIRE enhances the clonal deletion of thymocytes 
that recognize self antigens (self pMHC) and are thus potentially auto-immune. AIRE 
also induces the production of regulatory T cells (Tregs) which are tolerogenic. Mature 
T cells exit the thymus and enter the blood circulation: recirculate in blood and migrate 
in the blood to the peripheral lymphoid tissues, where they encounter foreign antigens 
and are activated. In addition to central tolerance, not all self-reactive lymphocytes are 
eliminated, in part because not all self-antigens are expressed in the thymus. 
Therefore, both anergy (tolerance mechanism by which a lymphocyte is intrinsically 
functionally inactivated following antigen encounter) and deletion of self-reactive T cells 
can occur in the periphery. 
 
MHC class I molecules are expressed on all nucleated cell types (i.e. with the 
exception of red blood cells) and can load relatively small peptides derived from 
proteins degraded in the cytosol. The resulting pMHC class I complexes are presented 
at the surface of the cell for interaction with the CD8 co-receptor and the T cell 
receptor, namely to cytotoxic CD8+ T cells (Figure 2a). In this process, intracellular 
antigens are processed into peptides by the immunoproteasome. Peptides are 
transported by the Transporter associated with antigen processing (TAP) complex into 
the endoplasmic reticulum (ER). They are then loaded into the groove the MHC class I 
complex composed of a heavy chain and a smaller subunit β2-microglobulin. Cytotoxic 
CD8 T cells are able to eliminate virally-infected or malignant cells.  
 
Conversely, CD4 T cells recognize antigens associated with MHC class II molecules 
that are expressed on professional antigen-presenting cells (APCs) such as B cells, 
dendritic cells (DCs), monocytes and macrophages (Figure 2b). These antigens 
originate from extracellular proteins endocytosed into vesicles (e.g bacteria) and are 
processed by endolysosomal enzymes into peptides. These peptides bind to the MHC 
class II complex by displacing the class II-associated invariant chain peptide (CLIP), 
which is derived from the MHC class II-associated invariant chain (li). 
	 18	
Although direct cytotoxicity has also been found in a subset of CD4 T cells, the effector 
qualities attributed to CD4 T cells rather serve “helper” functions and are thus called 
“CD4 helper T (Th) cells”. CD4 Th cells may produce a large variety of cytokines and 
chemokines to support the immune response in various tasks: stimulate the production 
of antibodies by B cells, enhance the antimicrobicidal mechanisms of macrophages, 
recruit neutrophils, eosinophils, and basophils. Upon activation, and depending on the 
immune cues, naïve CD4 T cells can differentiate into several Th subtypes, associated 
with particular transcription factors, and cytokine sensitivity, cytokine production 
potential, and helper function. The two major traditional Th1/Th2 polarizations can be 
distinguished: Th1 CD4 T cells secrete IFN-γ and are involved in the immunity against 
intracellular pathogens and autoimmunity, whereas Th2 CD4 T cells secrete IL-4, IL-5, 
IL-10 and IL-13 and function in the response to large extracellular organisms, asthma 
and allergy. Relatively more recent Th types have been described: Th9 secrete the 
cytokines IL-9, IL-10 and IL-21 and participate in the response to parasite infections 
and large extracellular pathogens. Th17 secrete IL-17, IL-21 and IL-22 and are 
involved in the response to fungi and extracellular bacteria. Th22 secrete IL-13 and IL-
22 and potentially contribute to host defense against microbial infection in the skin. T 
Follicular helper cells are specialized to help B cells produce antibody. Tregs maintain 
homeostasis and tolerance during an immune response. 
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Figure 2 The MHC class I (a) and class II (b) antigen-presentation pathways. From [2] 
 
Certain APCs such as a highly specialized subset of dendritic cells (Clec9A+ in 
humans, CD8+ or the cDC1 subset in mice) can phagocytize and process extracellular 
antigens then load these onto MHC class I molecules for presentation to CD8 T cells. 
This process is known as antigen cross-presentation, it allows CD8 T cells to be “cross-
primed” to respond to extracellular antigens as opposed to the traditionally attributed 
response to intracellular antigens.  
 
I will now focus on the CD8 T cells as they are at the center of the first axis of my PhD 
thesis and a major component of my studies in Axis 2; the TCR:pMHC interaction is 
also central to Axis 1 and thus given particular introductory attention further below. 
	 20	
Naïve antigen-specific CD8 T cells are activated after receiving at least three signals: 
TCR engagement (by binding to cognate pMHC on the APC), co-stimulation (binding 
co-stimulatory molecules on the T cell such as CD28 by co-stimulatory ligands such as 
CD80/CD86 on APC), and stimulation with inflammatory cytokines such as type 1 IFN 
and IL-12. When all three signals are delivered to a naïve cell, the latter is induced to 
massively proliferate by clonal expansion, and further differentiate into a heterogeneity 
of cells, with varying degrees of memory and effector functions. CD8 T cell effector 
function comprises cytotoxic cytokine production: the expression of perforin and 
granzyme molecules. Upon encounter with a target cell presenting cognate antigen, the 
release of these cytokines by degranulation leads to cytolytic activity. T cells migrate 
throughout the body based on patterns of chemokine receptor and selectin expression, 
and thus differential response to chemotactic and retention cues. Typically for example, 
naïve and memory cells express the chemokine receptor CCR7, responding to the 
secondary lymphoid ligands CCL19 and CCL21, and the L-selectin (CD62L) allowing 
the homing of these cells into lymph nodes. Differentiated cells express high levels of 
CXCR3 which responds to the inflammatory chemokines CXCL9, CXCL10 and 
CXCL11, supporting the recruitment of effector cells into sites of inflammation.  
Initially, the view on CD8 T cell differentiation was very simplistic and cells were 
classified into effector or memory subsets. Conventionally, the expression of the 
surface markers CCR7 and CD45RA has been used to define the differentiation 
subsets in human CD8 T cells (Figure 3). Thanks to new broad-spectrum technologies 
such as transcriptomic and epigenetic analyses, recent studies have highlighted the 
heterogeneity of CD8 T cells expressing varying phenotypes of both effector and 
memory-associated molecules [3]–[5] (Figure 3). While effector cells have potent 
cytotoxicity, memory cells retain high proliferative capacity and potential to generate an 
effector progeny, together with long-term persistence and self-renewal. 
 
Elucidating the differentiation path of a naïve T cell into this heterogeneity of CD8 T cell 
phenotypes and functions has been debated for a long time. Although difficult to 
assign, the generation of memory T cells and the plasticity among subsets have 
cumulated increasing knowledge especially in the last decade and a number of CD8 T 
cell differentiation models have been proposed. Initially, the linear model suggested 
sequential differentiation: first from naïve cells into effector cells in the acute phase, 
then upon antigen clearance the effector cells contract (the majority die) while a 
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fraction of effectors serve as precursors for memory cells [6] [7]. The observation in 
mouse models that both memory precursors (MPECs) and effector cells could be 
observed in the early response, before viral clearance and the contraction phase, 
challenged this view [8]. Today, markers such as the IL7Ra and the transcription factor 
T cell factor 1 (TCF1) allow distinguishing acute precursors of long-lived memory and 
activated cells [9]–[13]. Recent studies have therefore proposed non-linear models, 
where memory cells arise directly from naïve cells, e.g. by asymmetric cell division 
leaving one daughter cell committed to the memory fate, the other to become an 
effector cell [14]–[16]. These studies have mainly been driven in mouse models of 
acute immune responses. While some aspects of CD8 T cell differentiation might be 
shared between mice and humans, there are fundamental differences in the markers 
used to classify CD8 T cell subsets. 
 
 
Figure 3 Properties and qualities of T cells across differentiation. The latest gradual model proposes that naïve 
T cells are driven towards progressive stages of differentiation: memory stem cells (SCM), central memory (CM), 
transitional memory (TM), effector memory (EM), terminally effector (TE). Adapted from Mahnke et al, 2013 [17] 
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1.2.2 TCR GENE ASSEMBLY AND SOMATIC RECOMBINATION 
 
A TCR is a heterodimer composed of one α- and one β- chains. Each consists of a 
variable (V) amino-terminal region and a constant (C) region. The TCR α locus 
contains V and J gene segments (Vα and Jα). The TCR β locus contains D gene 
segments (2 TRBD genes) in addition to Vβ and Jβ gene segments (52 TRBV and 13 
TRBJ genes respectively) [1]. The process of functional TCR gene assembly is called 
somatic recombination (or somatic rearrangement) and takes place as part of the T cell 
development process in the thymus (Figure 4). It involves the sequential random 
germline DNA rearrangement of a Vα gene segment (among 70-80 TRAV genes) with 
a Jα gene segment (among 61 TRAJ genes) to create a functional V- region exon [1]. 
This is controlled by the Recombinase-activating gene 1 and 2 (RAG-1 and RAG-2) 
[18]. Transcription and splicing of the VJα exon to Cα generates the complete mRNA 
translated into the TCR α-chain protein. The same somatic recombination principle 
applies to the β- chain. The α- and β- chains are linked by a disulfide bond and pair to 
form the αβ TCR heterodimer. The overall variety of αβ TCRs produced during somatic 
recombination is the result of both combinatorial and junctional diversity [19]. The 
combinatorial diversity relies on both the number of combinations of both the germline 
gene segments that can rearrange at the TCR loci and the pairing of the α- and β- 
chains. Junctional diversity further increases TCR variety by the presence of P-
nucleotides (making up palindromic sequences) and N-nucleotides (non-template 
encoded) in the junctions between the V, (D), and J gene segments [1] [19]. 
Nucleotides can also be deleted at gene segments junctions. The junctional diversity is 
believed to produce most of the TCR genetic variability. It has been estimated that 
somatic recombination is able to generate 1015-1020 unique TCRs [20]–[23]. 
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Figure 4 Description of TCR gene assembly steps. Functional TCRs are heterodimers consisting of an α- and a 
β-chain that are generated by somatic rearrangement of variable (V), diversity (D) and junctional (J) gene segments 
for the β- chain, and V and J gene segments for the α- chain. During T-cell development, gene segments recombine 
and are splice together with the constant (C) region to form the functional αβ TCR. 
 
1.2.3 TCR:pMHC RECOGNITION 
 
As previously mentioned, TCRs expressed on the surface of CD8 T cells recognize 
foreign antigens derived from intracellular degradation of proteins in the cytosol and 
presented by MHC class I (MHC-I) molecules. MHC-I molecules are formed by one α 
chain encoded in the MHC gene and a non-covalently associated smaller protein, the 
invariant β2-microglobulin. MHC genes are highly polymorphic. MHC-I molecules 
usually bind short peptides (8-13 amino acids) lying in an elongated conformation along 
the MHC cleft, with the termini and anchor residues (typically residues 2 and the C-
terminus of MHC-I peptides) buried in pockets within the peptide-binding groove of 
MHC. The peptide side chains are therefore pointing outwards of the pMHC complex 
for interaction with the TCR. Furthermore, the peptides are bulging out of the groove 
providing additional surface area for TCR recognition. Within the TCR, there are six 
hypervariable complementarity-determining regions (CDRs) that mediate recognition, 
with 3 CDRs per TCR chain (Figure 5) [24]. The CDR1 and CDR2 loops are encoded 
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within the germline TRAV and TRBV genes. The CDR3 loops are formed at the 
junction of the V(D)J gene rearrangements and are therefore the most variable regions 
of the TCR [25]. The diversity of the naïve TCR repertoire is further increased by a lack 
of precision during V(D)J gene rearrangement, therefore adding or deleting N-
nucleotides at the V(D)J junction [26] [27]. 
 
 
Figure 5 Protein structure of TCR chains. Regions of hypervariability, known as complementarity-determining 
regions (CDRs), are encoded in the V gene segments. The CDR1 and CDR2 regions are germline-encoded, 
whereas the CDR3 region is created by the juxtaposition of different V(D)J germline segments after somatic 
rearrangement. The diversity of the CDR3 region is further increased by the addition or deletion of N- nucleotides at 
the V(D)J junction. 
 
The first X-ray crystallographic structures of TCR:pMHC-I complexes have provided a 
lot of information on T cell recognition [28]–[30]. They show that most TCRs align 
diagonally over the peptide with the CD3 loops of both α and β TCR chains meeting 
over the central amino residues of the peptide (Figure 6). The CDR1α and CDR2α 
loops primarily mediate MHC contacts at the amino terminus of the bound peptide, 
whereas the CDR1β and CDR2β loops interact with the complex around at the carboxy 
terminus of the bound peptide. As discussed in the 3.1.1, this general view regarding 
the TCR binding mode has been challenged by the growing database of TCR:pMHC 
structures as the TCR:pMHC interface presented a poor fit, which is consistent with the 
generally weak affinity of the interaction [31], and interaction with the pMHC complex 
induced a conformational change in the CDR3 loops [32]. 
 
	 25	
 
Figure 6 Strutural view of the pMHC-TCR interface. The germline- encoded CDR1 and CDR2 loops mainly 
interact with the MHC, whereas the rearranged CDR3 loops is placed centrally above the peptide. Figure from [33]. 
 
The TCR is located in close proximity to a complex of signaling molecules, 
including the CD3 family of proteins (CD3δ, CD3ε, and CD3γ) as well as a TCR 
zeta (ζ) chain [34]. Upon TCR engagement by an agonist peptide, the TCR transmits 
a signal to the CD3 complex, which subsequently triggers intracellular signaling 
cascades that regulate cytokine production, cell survival, proliferation, and 
differentiation. An early event in TCR activation is the phosphorylation of the 
immunoreceptor tyrosine-based activation motifs (ITAMs) on the cytosolic side of the 
TCR/CD3 complex by lymphocyte protein tyrosine kinase (Lck) [35] [36]. The TCR ζ 
chain is also phosphorylated upon TCR engagement. Zeta-chain associated protein 
kinase (Zap-70) is recruited to the TCR/CD3 complex where it becomes activated, 
promoting recruitment and phosphorylation of downstream adaptor or scaffold proteins 
[37]. This promotes phosphorylation of the effector molecule phospholipase C 
gamma 1 (PLC-γ1). PLC-γ1 transduces TCR signals by hydrolyzing 
phosphatidylinositol triphosphate (PIP2) in the plasma membrane to generate the 
second messengers diacylglycerol (DAG) and inositol trisphosphate (IP3). DAG 
activates several isoforms of protein kinase C and the MAPK/Erk pathways, promoting 
transcription factor NF-κB activation [37]. IP3 triggers the efflux of Ca2+ from the ER 
into the cytosoplasm [38]. Elevated Ca2+ activates the phosphatase calcineurin, which 
promotes IL-2 gene transcription through the transcription factor NFAT. 
Signaling exclusively through the TCR is not sufficient for T cell activation, and can 
result in induction of an anergic state in which T cells fail to respond to antigen 
stimulation. Therefore, the cellular interface is reinforced by T cell surface 
	 26	
glycoproteins. The CD8 co-receptor binds to invariant regions of the MHC-I molecules. 
The binding is further stabilized by co-stimulatory and adhesion molecules, such as 
CD2-CD58, and the CTLA-4/CD28 and CD80/CD86 interaction. This combination of 
interactions and events lead to an effective T cell response. 
 
Several parameters have been used to described the strength of TCR:pMHC 
interactions, including TCR affinity, TCR avidity and functional avidity (Figure 7). The 
potency of a T cell response described in terms of biological outcomes is called 
functional avidity. The functional avidity of a given T cell clone is measured by 
assessing its functions in vitro (cytotoxicity, cytokine production) after exposure to 
titrating amounts of antigen concentration. TCR avidity is impacted by the TCR affinity 
(binding strength between one TCR and one pMHC molecule), expression levels of the 
TCR and coreceptors, the expression of signaling molecules, and the overall dynamic 
functions of the immune synapse. 
The TCR affinity is measured by surface plasmon resonance (SPR) to calculate the 
dissociation constant (KD) in the interaction between pMHC complex immobilized on a 
sensor surface and the TCR molecule added in soluble form (Figure 7). The TCR 
avidity concerns the measure of the strength of TCR:pMHC interaction involving 
multiple TCRs and pMHC molecules; it can be assessed for instance by dually labeled 
pMHC multimers built on NTA-Ni2+-His-tag interactions called NTAmers, assessing 
interaction with multiple TCR molecules on the surface of cells. Monomeric dissociation 
constant rates koff can therefore be determined. KD and koff are related as following: 𝐾!  =  𝑘!""𝑘!"  
Several studies suggested that a potent T cell response is related to a lower KD and/or 
a longer koff [39]–[44]. A recent report on self/tumor and virus-specific CD8 T cell clones 
showed that koff values offer a better prediction of the CD8 T cell potency [45]. TCRs 
often weakly interact with pMHC complexes (1-100 µM) and with fast dissociation 
kinetics (t1/2 < 60 s) [46]–[48]. 
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Figure 7 Description of TCR affinity, TCR avidity and functional avidity. Figure from [49] 
 
1.2.4 DIVERSITY OF THE TCR REPERTOIRE 
 
The generation and maintenance of an effective repertoire of TCRs are crucial for the 
effectiveness of the adaptive immune system, as the organism might encounter a wide 
variety of foreign antigens. It means that the size and diversity of the pre-immune T cell 
repertoire are critical in shaping the immune response to a given antigen. Theoretically, 
as mentioned above (1.2.2.), the V(D)J somatic recombination is able to produce 1015-
1020 unique TCR sequences and therefore to recognize as many potential antigens 
[23]. However, there are only 1013 T cells in humans and the pre-immune T cell 
repertoire has been estimated to 108 distinct αβ TCRs [20] [50]. Therefore, in order to 
provide a full antigenic protection, TCR are able to recognize more than one pMHC 
molecule, a phenomenon defined as cross-reactivity [23]. 
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Despite this enormous TCR diversity, several studies showed that TCR repertoires 
generated during an immune response are biased for the preferential use of particular 
TCRs. Examples of TCR bias were observed in infectious diseases, autoimmunity and 
cancer (reviewed in [51]–[55]). Turner et al proposed a classification for TCR bias into 
three main categories. Type I bias is characterized by selecting a single TCR gene 
family (TRBV or TRAV gene), still with diversity in the CDR3 loops. Type II bias refers 
to the selection of conserved residue motifs in antigen-specific TCR Vα or Vβ chains. 
Type III bias, the least common category, indicates a complete TCRα and/or TCRβ 
sequence similarity. 
The parameters resulting to the generation of TCR bias are emerging. First of all, 
studies demonstrated that TCR gene usage is already highly biased [56] [57]. 
Therefore, only a fraction of the theoretical diversity is generated during somatic 
rearrangement. The TCR bias can also result from convergent recombination 
producing the same amino acid sequence from multiple nucleotide sequences [58]. 
The naïve T-cell repertoire is also shaped during thymic selection. The TCR bias can 
be generated during the initiation of an immune response by mechanisms including 
affinity, antigen load and duration of the TCR:pMHC interaction [51] [59] [60]. Structural 
studies revealed the importance of the pMHC structural landscape in skewing the TCR 
repertoire (e.g. bulged or featureless peptides). Persistent infection may also favor 
TCR bias. For instance, dominant T-cell clones present in the early response to HIV 
tend to be lost during the course of the infection [61]. Studies on immune responses to 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) indicates that TCRs with high 
affinity for their cognate antigen are preferentially used [60] [62]. 
1.3 CANCER IMMUNOTHERAPIES 
For a long time, the conventional anticancer treatment strategies have been surgery, 
chemotherapy, and radiotherapy [63] [64]. However, patients often experience relapses 
from residual malignant cells or metastasis, or become resistant to therapy [65] [66]. 
Therefore, optimized and new approaches to achieve durable and complete remission 
are needed. 
 
Multiple studies showed that anti-cancer CD8 T cells have the potential to limit cancer 
progression and to eradicate a wide variety of tumors, with vast evidence that CD8 T 
cell infiltration inside the tumor mass is a solid good prognostic indicator [67]. However, 
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immunosuppressive mechanisms are inherent to anti-cancer T cell responses [68]. 
First, cancer antigens being close to the “self”, anti-cancer T cells are deleted by the 
negative selection. Therefore, the low frequency of precursor anticancer T cells 
hampers the outcome of the response. Besides, these anti-cancer T cells harbor TCRs 
of low affinity. Secondly, unlike APCs, cancer cells poorly trigger activation of CD8 T 
cells due to limited antigen priming and inefficient co-stimulation. Finally, T cells 
become functionally deficient due to the hostile tumor microenvironment and the 
chronic inflammation and stimulation. They are driven to “exhaustion”, characterized by 
poor effector function and sustained expression of inhibitory receptors. 
 
Several T cell extrinsic mechanisms lead to the hyporesponsiveness of anticancer T 
cells. Tumors can escape the immune surveillance by downregulation of MHC 
molecules, hiding surface antigens, releasing immunosuppressive factors or inducing T 
cell apoptosis [69]. Other cell types such as regulatory T cells, tolerogenic DCs, so-
called M2 macrophages and Myeloid-Derived Suppressor Cells can inhibit the 
anticancer response [70]–[73]. Also, cancer-associated fibroblasts can secrete tumor-
promoting factors or retain T cells at the tumor edge [74]. 
 
Immunotherapy has emerged as an exciting strategy in cancer treatment in recent 
years, appointed breakthrough of the year by the Science journal in 2013 and meriting 
the Nobel Prize for Medicine or Physiology to James P. Allison and Tasuku Honjo in 
2018. This approach is based on the ability of the immune system to recognize tumor 
antigens and supports thus the own body’s capacity to detect and destroy tumor cells. 
First, active immunization aims at generating or boosting anti-cancer T cell responses 
to kill tumor cells. This includes vaccination with tumor antigens or enhancement of 
antigen presentation. Secondly, passive immunization, also known as adoptive cell 
transfer, relies on the administration of immune cells directly to the patient. It uses 
autologous peripheral blood mononuclear cells (PBMCs) or tumor-infiltrating 
lymphocytes (TILs) that are expanded in vitro and selected for tumor reactivity before 
being infused back into the patient [75]. T cells can be modified before adoptive cell 
transfer. This comprises modifications in cytokine and/or signaling pathways, inserting 
T cell receptors (TCRs), or chimeric antigen receptors (CARs) [76] [77]. Finally, one 
approach to trigger antitumor immune responses includes T-cell immune receptor 
modulating monoclonal antibodies. It consists either in blocking immune-inhibitory 
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pathways activated by cancer cells with antibodies, which is called “checkpoint 
blockade”, or using agonistic antibodies to target and activate the co-stimulatory 
molecules such as 4-1BB, OX40 or CD28 [78]. The first targets to be discovered were 
the inhibitory molecules Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and 
Programmed cell death 1 (PD1) and its ligand PD-L1 (Figure 8). Ipilimumab (Yervoy®) 
is a monoclonal antibody that blocks the inhibitory receptor CTLA-4 expressed on T 
cells. It was approved by the Food and Drug Administration (FDA) in 2011 as a first-line 
therapy for melanoma patients with metastatic disease [79] [80]. Unfortunately, only a 
relatively small fraction of patients obtains clinical benefit and severe immune-related 
adverse events have been observed. More recently, antibodies targeting PD1 
(Nivolumab, Pembrolizumab) or its ligand PD-L1 demonstrated remarkable benefit in a 
variety of cancer types including melanoma, kidney and lung [81]–[83].  
 
 
Figure 8 Blockade of CTLA-4 and PD1 and PD-L1 induces antitumor responses. From [84] 
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1.4 YELLOW FEVER VACCINTATION AS A MODEL OF OPTIMAL 
IMMUNOGENICITY IN HUMANS 
1.4.1 YELLOW FEVER VIRUS VACCINE (YF-17D) 
Yellow Fever disease is caused by the Yellow Fever Virus (YFV) and occurs 
predominantly in sub-Saharan African regions as well as tropical and subtropical 
regions of South America [85] [86]. The YFV is transmitted by a mosquito belonging to 
the genus Aedes [87]. Yellow fever illness can present subclinical infection to acute 
hemorrhagic disease, including fever, hemorrhagic shock and multi-organ failure of the 
liver, kidneys and myocardial tissues [87]. The liver is a major target organ and liver 
dysfunction results in jaundice-like symptoms, hence the name “yellow fever”. While a 
majority of infected people develop no or minor symptoms, an estimated 1 in 7 infected 
people enter a toxic phase which half of them do not survive 1. 
The YFV is the prototype of the family of Flaviviridae. It is a single-stranded, positive 
sense RNA virus that varies in size between 40-60nm. The virus consists of three 
structural proteins (core C, membrane M and envelope E), and seven non-structural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) that are necessary for viral 
replication [85] [86]. The virus particle consists of the C protein that surrounds the 
genome (approximately 10’800 nucleotides) and the viral proteins (M- and E-proteins) 
are imbedded in the virus envelope. 
 
There is no antiviral therapy to treat the disease but prophylaxis is maximized by a live-
attenuated virus vaccine that is considered as one of the most efficient vaccines ever 
made for humans: the YF-17D vaccine strain. The YF-17D vaccine has been applied to 
more than 600 million people worldwide [85] [86]. The original 17D strain was 
developed in 1937 by Max Theiler and his colleagues [88]. It included isolation of the 
virus from a cured African patient (Mr. Asibi) and 176 passages of this wild-type strain 
Asibi in mouse and chicken tissue. This process led to viral attenuation while 
maintaining the immunogenicity. This discovery was awarded with the Nobel Prize in 
Physiology or Medicine in 1951. Two substrains are currently used for vaccine 
production, 17D-204 and 17DD, originating from the 17D strain. Although the genomes 
of Asibi, 17D-204 and 17DD viruses have been determined, the molecular mechanism 																																																								1	https://www.who.int/news-room/fact-sheets/detail/yellow-fever; 
https://www.cdc.gov/yellowfever/symptoms/index.html 
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leading to attenuation remains unclear. The mutations observed in the gene encoding 
the E protein are thought to have a role in attenuation [89]–[91]. The vaccine substrains 
show only subtle nucleotide variations (ca. 99.9% nucleotide sequence identity) [92]. 
Immunogenicity and protection by YF-17D vaccination have mainly been assessed by measuring neutralizing 
antibodies (nAbs). Since May 2013, the Strategic Advisory Group of Experts on 
immunization (SAGE) of the WHO organization concluded that a single dose of the YF-
17D vaccine is sufficient for life-long protection [93]. This was supported by several 
studies on the duration of nAbs and T cell responses following vaccination with YF-17D 
showing that neutralizing antibodies can last up to 38 years and that T cell responses 
can still be detected after decades [94]–[99]. However, contrasting studies conducted 
in Brazil have raised concerns over T cell responses and nAbs titers as they observed 
reduction over time [100] [101]. To date, the Brazilian national immunization policy still 
includes a booster dose every 10 years [102]. Interestingly, Hepburn et al showed that 
the humoral efficacy of booster vaccination depends on the pre-booster level of 
antibodies. If the serological levels are low, the booster induces a 4-fold increase in the 
vast majority of the 35 vaccinees. On the contrary, if the antibody titers are high, only 
10% have an appropriate secondary response [96]. 
 
In addition to its exceptional efficacy, the YF-17D vaccine has an acceptable safety 
record. Neurotropic and viscerotropic serious adverse events occur rarely (1 in 250’000 
cases). However, YF-17D vaccine-associated neurotropic and viscerotropic disease 
(YEL-AND and YEL-AVD, respectively) are often lethal [103]–[108] and thus although 
rare, these adverse events do tilt the balance of benefit/risk and limits vaccination to 
the strictest minimum with a strong weight of epidemiological and operational 
considerations in endemic versus non-endemic countries. E.g.: in endemic countries, 
vaccination is given to children at 9-12 months, while only travelers aged ≥ 9 months, 
traveling to and from risk-areas receive it. 
 
1.4.2 HUMAN IMMUNE RESPONSE TO YF-17D VACCINATION 
While many vaccines in clinical practice are subunit or inactivated vaccines, the YF-
17D vaccine is a live attenuated vaccine. Because of the process of attenuation, even 
live-attenuated viral strains (such as measles and oral polio vaccines) show usually 
only limited replication [109] [110]. However, the YF-17D vaccine causes a systemic 
viral infection [111]–[116]. This is thought to be the major reason for the strong CD8 T 
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cell responses seen with this vaccine, in contrast to most other vaccines that are 
inefficient activators of CD8 T cells [116]. 
The immune response to YD-17D vaccination has attracted high interest and several 
studies have revealed snapshots of the immune events and parameters that constitute 
such strong T cell immunogenicity (Figure 9, Table 9). 
In vitro studies and mouse models showed that the YF-17D strain infects DCs for about 
one week without excessive multiplication, allowing immune stimulation for up to two 
weeks [112] [113] [115]. It delivers adequate antigen levels to the DC resulting in 
effective antigen processing and presentation to both CD4 and CD8 T cells [112] 
featuring multiple overlapping epitopes [117] [118]. Together with strong innate immune 
activation, this vaccine induces a strong adaptive response resulting into potent T cell 
responses [116]–[120] and protective antibody responses [94] [95] [98] [121]. 
 
The YF-17D vaccine is outstanding for the nAbs raised, which can persist for 30-40 
years [94] [95] [98] [121]. A study showed that a protective humoral response (Plaque 
Reduction Neutralization Test, PRNT titers ≥ 1:20) was detected in all vaccinees (238 
healthy individuals tested) [117]. After vaccination, viremia reaches a peak within the 
first 10 days, after which it declines rapidly [118]. Recent studies showed a pivotal role 
of the innate immune system underlying specific immune activation induced by the YF-
17D vaccine. It triggers multiple pattern recognition receptors, in particular Toll-like 
receptors, activating distinct subsets of dendritic cells (DC) that the virus can infect 
[111]–[113] [115]. Myeloid dendritic cells (mDCs defined as CD11c+ HLA-DR+ CD45+ 
CD19- CD14- CD56- BDCA-2-; note: to our knowledge this gating includes CD14neg/lo 
CD16+ monocytes, a point relevant later in my analyses) were reported to increase in 
number at day 7 after primary vaccination and up-regulated the activation marker HLA-
DR [122]. In contrast, plasmacytoid DCs (pDCs) did not increase in number and did not 
get activated [122]. An other study showed that the frequencies of CD14+ CD16+, 
CD14+ CD16++ and inflammatory (CD14++ CD16+) monocytes were increased at day 7 
after vaccination [123]. In addition, monocytes were activated upon YF-17D vaccination 
as shown by a higher percentage of CD14+ CD16+ cells expressing HLA-DR [123]. In 
contrast, the frequency of CD56+ natural killer (NK) cells slightly decreased at that time-
point. The frequency of cytotoxic NK cells (CD56+ CD16+) was increased at day 7 after 
primary vaccination, whereas the percentage of cytokine-producing NK cells (CD56+ 
CD16-) was decreased [123]. NK cells showed an activated phenotype at day 6 and 
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proliferation at day 10 after vaccination [124]. Regarding the adaptive response, the 
YF-17D vaccine induces a mixed T helper type 1 (Th1)-Th2 CD4 T cell response which 
precedes the cytotoxic CD8 T cell response [120] [125]. In addition, the CD8 T cell 
response is robust, broad and polyfunctional [117] [118] [120]. Interestingly, the 
magnitude of the CD8 T cell response is determined by the initial viral load, highlighting 
the relevance of strong innate stimulation by a high viral load [119]. In particular, an 
HLA-A*02-restricted immunodominant epitope was found as the antigen for most 
reactive CD8 T cells and it mapped to the NS4b214-222 protein region of the virus: the 
nonamer epitope LLWNGPMAV (hereafter, A2/LLW) [97] [113] [118]. Our group and 
other studies showed that the A2/LLW-specific CD8 T cell response is highly prevalent. 
Already the naïve A2/LLW-specific CD8 T cells are present at high frequency, often 
detectable even directly ex vivo with tetramers in ca. 30% of unvaccinated HLA-A*02 
positive individuals [97]. Studies on the B cell response showed that total circulating B 
cells decreased at day 7 after vaccination, followed by activation (CD69, IL-10R) after 2 
weeks. In contrast, CD19low CD27high plasmablasts transiently increased at day 14 
[122] [125]. 
 
	 35	
 
Figure 9 Major findings of the immune responses following YF-17D vaccination. Although the YF-17D vaccine 
was developed in 1937, studies highlighted mechanistic aspects only in the last decade. Figure courtesy of Silvia 
Fuertes- Marraco. 
 
1.4.3 YELLOW FEVER AS A MODEL 
 
Despite the major breakthroughs provided by immunotherapies, there is still a major 
and continuous need for further clinical improvements. Research in anti-viral immunity 
plays a central role in the comprehension of immune regulation in malignant disease as 
similar mechanisms may apply to the control of both infection and cancer. Furthermore, 
scientific principles of the optimal functioning of the immune system are often better 
determined in models of acute infection (transient and clearing back to healthy 
homeostasis) rather than tumor (chronic and pathological) models. 
 
Recent advances have arisen from the use of vaccines as tools to investigate the 
immune responses in humans. Especially, live virus vaccines provide a unique 
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opportunity to study human immune responses in the context of a controlled 
immunological setting of a resolving acute infection [86] [114]. This, together with the 
possibility to acquire frequent blood samples over a span of several years after 
vaccination, allows characterizing the dynamics of the immune responses. 
Furthermore, vaccines are administrated to large populations, and potentially allow for 
broader coverage of observations, in perspective and retrospective. 
 
The YF-17D vaccine is widely accepted as an excellent model for human immunology 
research. Especially, the YF-17D strain causes a systemic viral infection, which leads 
to a robust CD8 T cell response in contrast to most other vaccines [111]–[116] [118]. 
While the YF-17D vaccine was developed in the 1930’s, learning how it stimulates such 
robust and persistent immune responses has gained force especially only in the last 
decade. Despite the large number of studies and efforts already published (Figure 9, 
Table 9), the overall understanding of the immunogenicity and response to the YF-17D 
vaccine remains only partially defined. Furthermore, these studies focused mainly on 
the primary response to YF-17D vaccination and on the antibody response to booster 
vaccination, whereas there is a lack of evidence for the cellular responses following 
revaccination (Table 9). 
 
The comparison of data originating from two groups of volunteers, receiving the 
vaccine for the first time or receiving a booster vaccine, might provide information 
regarding the effects of a recall response to YF-17D. In addition, the comparison of 
priming with booster vaccination represents a uniquely controlled experimental system 
in humans to assess whether and how the long-term memory immune cells react to 
antigen-specific re-challenge. The identification of key cellular and molecular 
components that sustain the potency and durability of immunity raised by YF-17D, will 
potentially improve the knowledge and the rationale for the design of more powerful 
immunotherapies in humans. 
 
In the field of T cell-based therapies such as anti-cancer treatments, a more 
comprehensive knowledge of the mechanisms and dynamics governing the generation 
of T cell responses, including Stem Cell-like Memory (SCM) T cells as well as their 
relationship to other immune parameters, is needed in order to guide the design of new 
immunotherapies that can raise powerful and long-lasting T cell responses. The 
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argument that YF-17D vaccination is a particularly suitable and excellent model is 
justified because it generates life-long immune protection with a robust T cell 
compartment. In addition to the evidence on the robust acute CD8 T cell peak of 
effectors, our group discovered that SCM CD8 T cells persist for decades [97].  
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2. PROJECT NETWORK OVERVIEW AND AIMS OF THESIS 	
My PhD thesis work can be divided into two main axes (Figure 10). The first axis is 
centered on the so-called “TRAV12-2 bias” in the immunodominant CD8 T cell 
response to YFV. It arose from a first, cross-sectional study elaborated in our group 
(the “YF1” study), where a genome-wide analysis showed that A2/LLW-specific CD8 T 
cells are highly enriched for the T-cell receptor (TCR) alpha chain family TRAV12-2. 
The second axis focused on a second, longitudinal clinical protocol, the “YF2” study, in 
which we collected blood samples before and at several time-points after YF-17D 
vaccination in subjects receiving the vaccine either for the first time or as a booster 
vaccine. 
 
Figure 10 PhD project network overview. The aims of the two axes arising from the two clinical protocols “YF1” 
and “YF2” are detailed. The associated manuscripts are indicated. 
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The specific aims of my PhD project are the following: 
 
Axis 1: TRAV12-2 bias and TCR:pMHC studies 
 
i) Functionally and structurally characterize the TRAV12-2 bias in A2/LLW-specific 
CD8 T cells (3.1.1). Is the TCR bias dependent on the epitope? Is the TCR bias 
already present in naïve CD8 T cells, before YF-17D vaccination? Are CD8 T cells 
expressing TRAV12-2 functionally superior? Is there a structural basis explaining the 
TRAV12-2 bias in A2/LLW-specific CD8 T cells? 
 
ii) Study the TCR diversity of these cells based on clonotyping (3.1.1). Are 
A2/LLW-specific CD8 T cells indeed biased for particular α, and also potentially β -
chains? What type of bias is it (TCR gene family, amino acid motif in the CDR3 
sequence or exact same TCR sequence but different α – β pairing)? 
The points i-ii above were addressed and reported in my first author publication in the 
European Journal of Immunology [126].  
In the development of this study [126], a major effort was directed to attempting the 
crystallization of the TCR:pMHC (YF5048), which I describe in:  
 
iii) Detailed description of the soluble TCR:pMHC production process (3.1.3) 
Within the work described above, two further aims were needed and led to 
corresponding projects: 
 
iv) Optimize multimer staining protocol (3.1.2). Is it possible to detect new A2/LLW-
specific clonotypes using an optimized multimer staining protocol? What are the 
functional differences between the clones recovered from both protocols? 
 
v) Define and characterize potential superagonists of the A2/LLW epitope (in the 
context of crystallography work on a TRAV12-2+ TCR) (3.1.5). Is it possible to enhance 
the response to an already potent viral antigen? What aspects of the TCR:pMHC 
interaction allow to achieve better functionality? 
Finally, a parallel project was to 
vi) Analyze the TRAV12-2 bias and LLW immunodominance in vivo using a mouse 
model (ABabDII mice) (3.1.4). Do these mice mount an A2/LLW-specific CD8 T cell 
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response and does it recapitulate the human CD8 T cell response, in particular 
regarding the A2/LLW epitope (prevalence in naïve population and immunodominance, 
TCR usage, generation of SCM CD8 T cells)? 
 
Axis 2: Longitudinal analysis of the human immune response to YF-17D 
vaccination, including prime versus boost 
 
i) Uncovering the immune events in the acute immune response following primary 
and booster YF-17D vaccination. What are the kinetics, dynamics and magnitudes of 
the main components of the immune system? What are the differences upon priming 
versus booster vaccination? To what extent are the innate and adaptive components 
mobilized upon boosting? Can we observe and study prominent recall responses? 
What is the impact of pre-existing antibodies on the recall responses? Is there a need 
for a booster dose after 10 years? 
 
ii) Identify the relationship between the various immune components using 
bioinformatics analyses. What are the immune determinants that correlate with 
protection (measured by nAb titers and viral clearance) and with a strong T cell 
response? Are there any factors at baseline (before vaccination) that may predict the 
magnitude of the immune response or a subset of immune events after vaccination? 
 
iii) Characterize the generation of such remarkable SCM CD8 T cell population and 
pinpoint their relationship to other immune components. When do they arise? How do 
they relate in activation and kinetic development to the other CD8 T cell subsets? What 
immune components do negatively / positively correlate with generation of stem cell-
like memory CD8 T cells?  
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3. RESULTS 
3.1 AXIS 1: TRAV12-2 bias and TCR:pMHC studies 
 
The first axis of my PhD work consisted in characterizing the molecular and functional 
aspects of the TCR:pMHC interaction in A2/LLW-specific CD8 T cells. First, we 
analyzed the TCR repertoire of A2/LLW-specific CD8 T cells. In particular, we 
discovered and characterized the genetic and structural basis of the TRAV12-2 bias in 
A2/LLW-specific TCR. This work was carried out between the groups of Prof. Daniel 
Speiser and Prof. Andrew Sewell (Cardiff University, Wales), including my scientific 
visit to Cardiff for 9 months with an SNF mobility grant (being myself the applicant and 
grantee). Also, A2/LLW-specific CD8 T cells were clonotyped using different multimer 
staining protocols. 
We further investigated the TCR-pMHC interaction with peptide variants of the A2/LLW 
epitope. 
Finally, we attempted to use an animal model to study the TCR bias in more details 
with the transgenic ABabDII mouse model. The aim here was also to inevstigate 
whether a mouse model would recapitulate the events of the immune response to YF-
17D vaccination as seen in the human system. This was done in collaboration with the 
group of Prof. Thomas Blankenstein (Max Delbrück Center for Molecular Medicine 
Berlin, Germany).  
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3.1.1 TRAV12-2 bias in the immunodominant response to YFV 
3.1.1.1 Background 
 
The YF-17D vaccine harbors an HLA-A*02-restricted NS4b214-222 epitope: 
LLWNGPMAV (hereafter, A2/LLW) that induces a highly prevalent and dominant CD8 
T cell response [118]. Work from our group has revealed that YF-17D vaccination 
induces SCM specific for A2/LLW: these cells have a Naïve-like profile (CD45RA+ 
CCR7+) expressing SCM markers (CD95, CD58, CXCR3) and remarkably persist at 
stable frequencies for at least 25 years [97]. Incidentally, genome-wide analysis of 
A2/LLW-specific CD8 T SCM and various differentiation subsets in total CD8 T cells 
showed that A2/LLW-specific CD8 T cells are highly enriched for the T-cell receptor 
(TCR) alpha chain family TRAV12-2. This is highly reminiscent of the TRAV12-2 
enrichment and immunodominance in CD8 T cells specific for the HLA-A*02-restricted 
Melan-A analog epitope ELAGIGILTV (A2/ELA) found in melanoma patients [127]–
[129]. Remarkably, naïve A2/ELA-specific CD8 T cells in healthy individuals are also 
relatively frequent and heavily biased for TRAV12-2 [130]. TCR diversity and specificity 
is largely acquired through somatic gene rearrangements of the α and β chains. There 
is particularly high diversity in the complementarity determining region (CDR)-3 
(hypervariable, unique to each TCR following somatic recombination) while CDR-1 is 
shared amongst TCR chain families (each family featuring a given fully germline-
encoded segment) [51]. In an A2/ELA-specific TCR named MEL5 it was found that, 
unusually, the germline-encoded CDR1α loop (instead of the hypervariable CDR3 loop) 
plays a major role in recognizing the epitope, conferring an “innate-like” pattern of 
antigen recognition [128]. This possibly explains the observations on relatively high 
precursor frequencies of naïve A2/ELA-specific CD8 T cells and immunodominance of 
this epitope based on advantageous thymic output of germline-encoded TCR [127]–
[130]. 
 
At the beginning of my PhD thesis, I studied whether germline-encoded interactions 
operate in the recognition of the A2/LLW epitope of YF-17D by TCRs featuring the 
TRAV12-2 chain. I used structural and functional analyses to shed light on the high 
prevalence and immunodominance of the A2/LLW response, and to draw the parallel to 
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the CD8 T cell response to A2/ELA by the MEL5 TCR. We aimed at answering the 
following questions: 
 
- Is the TCR bias dependent on the epitope (only found for A2/LLW)? 
- Is the TCR bias already present before YF-17D vaccination? 
- Are A2/LLW-specific CD8 T cells expressing TRAV12-2 functionally superior to 
TRAV12-2-negative A2/LLW-specific counterparts? 
- Is there a structural basis explaining the TRAV12-2 bias in A2/LLW-specific CD8 
T cells (in the context of the TCR:pMHC interaction)? 
- Are A2/LLW-specific CD8 T cells biased for particular β –chains also? 
- What type of bias is the TRAV12-2 bias (TCR gene family, amino acid motif in 
the CDR3 sequence or exact same TCR sequence but different α – β pairing) 
 
This project resulted in a publication in the European Journal of Immunology in 2017 
and this article was selected for the front cover of the journal [126] (Appendix 1). In this 
Chapter, I will summarize the main findings and discussion points while the full-length 
manuscript can be found in Appendix 2. 
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3.1.1.2 Results 
A2/LLW-specific CD8 T cells are biased for the segment TRAV12-2, before and 
after vaccination 
 
As mentioned above, our group has previously revealed a high enrichment in TRAV12-
2 mRNA in A2/LLW-specific CD8 T SCM (Figure 11A). I confirmed this data using flow 
cytometry by analyzing TRAV12-2 protein levels on A2/LLW-specific CD8 T cells from 
eight YF-17D vaccines. Compared to total CD8 T cells (median 12.5%TRAV12-2+), the 
majority of A2/LLW-specific CD8 T cells expressed TRAV12-2, with a median of 55.5% 
TRAV12-2+ (Figure 11B). The TRAV12-2 bias reached a similar extent as in ELA-
specific CD8 T cells from healthy donors (median 57.7%) (Figure 11B). The bias was 
further corroborated studying A2/LLW-specific clones isolated from four YF-17D 
vaccine donors, where PCR analysis detected that 45/57 clones were TRAV12-2+ 
(78.9%) (Figure 11C). In contrast, the Vβ usage showed rather broad diversity, with a 
preferential usage of certain Vβ families such as TRBV9 (16/57) and TRBV2 (10/57) 
(Figure 11D). 
 
Taken together, I was able to confirm and quantify the bias towards TRAV12-2 in 
A2/LLW-specific CD8 T cells based on ex-vivo material and CD8 T cell clones from YF-
17D vaccinees. This raised several questions: Is the TCR bias dependent on the 
epitope? Is the TCR bias already present before YF-17D vaccination? Are CD8 T cells 
expressing TRAV12-2 functionally superior? 
 
	 45	
 
Figure 11 A2/LLW-specific CD8 T cells are strongly biased for TRAV12-2 similarly to A2/ELA-specific CD8 T 
cells. A, TRAV12-2 mRNA expression in A2/LLW-specific stem cell-like (SCM) CD8 T cells compared to reference 
differentiation subsets in total CD8 T cells (n = 8 YF-17D vaccines), including: Naïve, SCM, central memory (CM) 
and effectors (E). Samples were isolated from PBMCs by FACS and total RNA analyzed by microarray. B, Subject-
paired comparison of TRAV12-2 expression by flow cytometry using an TRAV12-2-specific antibody between 
various antigen-specific and total CD8 T cells from YF-17D vaccines (“vac.”, n = 8) and unvaccinated individuals 
(“unv.”, n = 5), A2/VML (n= 2) and B7/RPI (n= 2) in YF-17D vaccines, as well as A2/CMV (n= 8, stars represent 
CMV-seronegative donors= 5/8), A2/EBV (n= 8) and A2/ELA (n= 8). C and D, TCR repertoire analysis of A2/LLW-
specific CD8 T cell clones generated from 4 vaccinated donors. Total RNA was isolated from 57 A2/LLW-specific 
CD8 T cell clones, cDNA prepared, analyzed by PCR with primers specific for each TRAV (C) and TRBV (D) gene 
segment, and sequenced. 
 
Therefore, I used other HLA multimers to detect CD8 T cells specific to alternative YF-
17D epitopes. Only two other epitopes (the HLA-A*0201-restricted VMLFILAGL from 
NS4a protein, termed A2/VML, and HLA-B*07-restricted RPIDDRFGL from NS5 
protein, termed B7/RPI) could be analyzed with sufficient positive events in flow 
cytometry and in HLA-corresponding donors (illustrating again the practical advantage 
of studying HLA-A*02-resticted epitopes with HLA-A*02 being highly frequent in the 
Caucasian population, and the comparatively high prevalence and immunodominance 
of the A2/LLW epitope per se). I also included other reference viral HLA-A*0201-
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restricted specificities such as pp65 from cytomegalovirus (CMV) and BMFL1 from 
Epstein Barr Virus (EBV). TRAV12-2 analysis by flow cytometry revealed that, among 
the YFV epitopes, only the A2/LLW epitope response is biased for TRAV12-2 (Figure 
11B). 
 
Next, I analyzed the expression of TRAV12-2 in five unvaccinated HLA-A*0201+ 
donors. Interestingly, I found that the TRAV12-2 bias was already evident in naïve 
A2/LLW-specific CD8 T cells, prior to vaccination (median 69.2%) (Figure 11B). 
 
On a per cell basis, TRAV12-2 does not confer functional advantages to A2/LLW-
specific CD8 T cells 
 
To address whether TRAV12-2 expression could potentiate T cell function, I analyzed 
various functional properties of TRAV12-2+ and TRAV12-2- A2/LLW-specific CD8 T cell 
clones. First, I measured the functional sensitivity of 47 A2/LLW-specific CD8 T cell 
clones with a 51-chromium release assay (Figure 12A). Then, I measured the 
monomeric TCR:pMHC dissociation constant rates (koff) in 33 A2/LLW-specific CD8 T 
cell clones using NTAmers (Figure 12B). In parallel, I examined cytokine production 
and degranulation by flow cytometry in 17 A2/LLW-specific CD8 T cell clones after 4 
hours of stimulation with LLW-pulsed T2 cells (Figure 12C). These assays showed that 
TRAV12-2+ clones did not differ from TRAV12-2- clones. Altogether, expression of 
TRAV12-2 did not confer a particular functional advantage to A2/LLW-specific CD8 T 
cells on a per cell basis. 
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Figure 12 TRAV12-2 expression does not confer a functional advantage to A2/LLW-specific CD8 T cell 
clones. Functional properties of A2/LLW-specific CD8 T cells clones were assessed by various methods. A, Killing 
capacity (51-chromium release assay) of A2/LLW-specific CD8 T cell clones (TRAV12-2 positive n= 37, TRAV12-2 
negative n= 10) stimulated with peptide-pulsed T2 cells. Data are representative of two independent experiments 
(mean and SEM; t-test p value). B, Monomeric dissociation constant (Koff) rates measured in CD8 T cell clones 
(TRAV12-2 positive n= 25, TRAV12-2 negative n= 8) using NTAmers (mean and SD; t-test p value). C, Intracellular 
cytokine staining of CD8 T cell clones (TRAV12-2 positive n= 11, TRAV12-2 negative n= 6) stimulated with peptide-
pulsed T2 cells for 4h. Data are representative of two independent experiments. 
 
The germline-encoded CDR1α loop of TRAV12-2 contributes to pMHC binding 
 
To determine whether a structural basis could explain the TRAV12-2 bias in A2/LLW-
specific CD8 T cells, we initiated a collaboration with the group of Prof. Andrew Sewell 
at the University of Cardiff. Structural analysis can potentially reveal the critical and 
dominant contacts between the TCR chains, the LLW peptide and HLA-A*0201, 
determining differences and similarities to other TCRs, including whether this system 
has similar binding principles to the melanoma-specific MEL5 TCR. Thanks to a SNF 
Mobility grant, I had the opportunity to spend 9 months in the laboratory of Prof. Sewell 
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and to perform the experiments myself. The overall aims of my work in Cardiff were to: 
 
• Construct, express and produce soluble A2/LLW-specific TCRs. 
• Measure TCR affinity and binding kinetics using A2/LLW in real-time by surface 
plasmon resonance (SPR) on a BIAcore instrument. 
• Solve a high-resolution crystal structure of a TRAV12-2+ TCR-A2/LLW complex. 
• Detect potential cross-reactivity to other human epitopes and pathogens using in 
silico prediction and in vitro analyses. 
 
Unfortunately, despite several attempts with different TCRs, I did not obtain refolding of 
a functional A2/LLW-specific TRAV12-2+ TCR. The troubleshooting to produce a 
soluble TCR is described in detail in section 3.1.3. 
 
Nevertheless, I managed to solve the atomic structure of the A2/LLW pMHC complex 
at 1.59Å resolution. We could thus combine the data of this structure with the 
previously solved structure of the MEL5 TCR to perform in silico modeling of the 
A2/LLW-specific YF5048 TCR (TRAV12-2/TRBV9). This YF5048 TCR was chosen due 
to its closest similarity to the MEL5 TCR sequence for the α chain to facilitate the 
modeling (with only 3 amino acid differences in the CDR3 loop). 
 
In this model, most of the interactions between the TCR and the peptide originated 
from the α chain encoded by TRAV12-2 (Figure 13A, Table 1). Five peptide residues 
are pointing toward the TCR: Leu1, Asn4, Gly5, Met7 and Ala8. These predominantly 
contact the CDR1α loop. In particular, Asn4 extends into a polar pocket of TRAV12-2, 
where its side chain is making a network of hydrogen bonds with the side chains of 
CDR1α Ser32 and CDR3α Asp92, as well as non-polar interactions with the CDR1α 
Gln31. The functional importance of Asn4 was highlighted by an alanine substitution 
scan. Indeed, it revealed that it is essential for TCR recognition as this substitution 
(LLW-4A) completely abrogated the response (Figure 13B). In order to understand the 
structural basis underlying this perturbation in TCR recognition, we solved the TCR-
unbound structure of A2/LLW-4A. Comparison of the crystallographic structure of 
A2/LLW and A2/LLW-4A did not reveal major distortion in the overall peptide 
conformation. However, molecular modeling of the YF5048 TCR binding to the X-ray 
structure of the pMHC complex showed that the alanine at P4 is no longer in an optimal 
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position to be contacted by the TCR (Figure 14). Residue Asn4 of the peptide is 
making numerous favorable interactions with the TCR, including notably hydrogen 
bonds with Ser32 and Asp92 of TCRα. The lack of T cell response to A2/LLW-4A is 
therefore in line with the loss of critical TCR:pMHC interactions. 
 
In conclusion, the modeling and functional assays revealed the key elements mediating 
the TRAV12-2+ YF5048 TCR interaction with the A2/LLW complex and support the 
hypothesis that the germline-encoded CDR1α loop of TRAV12-2 makes critical 
contributions to cognate peptide recognition. 
 
Figure 13 Molecular modeling indicates that the germline-encoded CDR1 alpha loop in TRAV12-2 makes 
major contributions to the binding with the A2/LLW complex. A, Calculated 3D structure of the YF5048 
TRAV12-2/TRBV9 TCR bound to the HLA-A2/LLW peptide complex with ribbons representing a- and b- chains in 
dark and light orange, respectively; the MHC molecule in tan ribbon, and peptide in ball and stick representation. 
TCR and MHC side chains are shown in thick lines, with carbon atoms colored in orange and tan, respectively. 
Hydrogen bonds are displayed as magenta thin lines. B, Alanine-scan of the LLW peptide assessed by MIP-1β 
ELISA with graded concentrations of the peptides (mean and SEM). Data are representative of two independent 
experiments. 
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CDR loop TCR residue Peptide residue MHC residue Bond type 
     
CDR1α Arg28, Nϵ 
 
Glu166, Oϵ1/Oϵ2 Electrostatic 
 
Arg28, NH2 
 
Glu166, Oϵ1/Oϵ2 Electrostatic 
 
Arg28, O 
 
Trp167, Nϵ1 Electrostatic 
 
Gly29, Cα 
 
Trp167, CZ2 vdW 
 
Gly29, Cα Leu1, Cδ2 
 
vdW 
 
Gln31, Nϵ2 Leu2, O 
 
Electrostatic 
 
Gln31, Cβ Asn4, Cβ/Cγ 
 
vdW 
 
Gln31, Cγ Asn4, Cγ 
 
vdW 
 
Gln31, Oϵ1 Asn4, N 
 
Electrostatic 
 
Ser32, Oγ Asn4, Nδ2 
 
Electrostatic 
     CDR2α Tyr51, OH 
 
His151, O Electrostatic 
     CDR3α Asn92, Oδ2 Asn4, Nδ2 
 
Electrostatic 
 
Asn94, O 
 
Arg65, NH2 Electrostatic 
 
Ala95, O 
 
Arg65, Nϵ Electrostatic 
 
Ala95, Cβ 
 
Gly62, Cα/O vdW 
 
Ala95, Cβ 
 
Lys66, Cϵ vdW 
     CDR2β Asn48, Oϵ1 
 
Arg65, NH1 Electrostatic 
 
Tyr49, Cϵ1 
 
Arg65, Cδ vdW 
 
Arg55, NH2 
 
Glu19, Oϵ1 Electrostatic 
     CDR3β Gly97, Cα 
 
Thr73, Cγ2 vdW 
 
Ser98, N Gly5, O 
 
Electrostatic 
 
Ser98, N Pro6, O 
 
Electrostatic 
 
Ser98, Cβ Met7, Cϵ 
 
vdW 
Table 1 Molecular interactions between TCR and pMHC in the structural 3D model. (“vdW”= van der Waals) 
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Figure 14 Conformation comparison of A2/LLW and A2/LLW-4A and modeling of the interaction with the 
YF5048 TCR explains the abrogation of the T-cell response in the alanine scan. A. Calculated 3D structure of 
the YF5048 TRAV12-2/TRBV9 TCR bound to the HLA-A2/LLW peptide complex with ribbons representing the a- 
chain; the MHC molecule in tan ribbon, and peptide in grey ball and stick representation. Hydrogen bonds are 
displayed as green thin lines. B. Calculated 3D structure of the YF5048 TRAV12-2/TRBV9 TCR bound to the HLA-
A2/LLW-4A peptide complex with ribbons representing the a- chain; the MHC molecule in tan ribbon, and peptide in 
purple ball and stick representation. Hydrogen bonds are displayed as green thin lines. 
 
A2/LLW and A2/ELA TRAV12-2 positive TCRs preserve their respective 
specificity 
 
Given the germline nature of the CDR1α loop of TRAV12-2 that is critical to peptide 
recognition of both A2/LLW and A2/ELA specificities, we addressed whether there is 
any cross-reactivity between T cells with these TRAV12-2-dominated biased 
specificities (Figure 15). The TRAV12-2+ A2/LLW-specific clones did not respond to the 
ELA peptide and conversely TRAV12-2 positive A2/ELA-specific clones did not 
response to the LLW peptide. This indicates that there is no common, shared TRAV12-
2-mediated mode of determining antigen recognition specificity. In addition to the 
contribution of germline-encoded segments in TCR:pMHC binding, this observation of 
no cross-reactivity between TRAV12-2+ A2/ELA and A2/LLW specific TCRs highlights 
the importance that the β chain plays in the effective TCR specificity (although the β 
chain’s contribution to pMHC contact is minimal, it is determinant for specificity). 
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Figure 15 Absence of cross-reactivity between A2/LLW and A2/ELA epitopes. Recognition of the LLW and ELA 
peptides by A2/LLW-specific and A2/ELA-specific CD8 T cell clones was assessed by 51-chromium release assay 
using T2 cells as APCs. A, Cross-reactivity analysis of TRAV12-2 positive A2/LLW-specific CD8 T cell clones toward 
the LLWNGPMAV (LLW, black line) and ELAGIGILTV (ELA, red line) peptides (mean and SD). B, Cross-reactivity 
analysis of TRAV12-2 positive A2/ELA-specific CD8 T cell clones toward the LLWNGPMAV (LLW, black line) and 
ELAGIGILTV (ELA, red line) (mean and SD). 	
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3.1.1.3 Discussion 
 
In this study, we analyzed the TCR repertoire of CD8+ T cells specific for the 
immunodominant A2/LLW epitope in YF-17D vaccinees and controls. We revealed and 
quantified the TRAV12-2 bias in A2/LLW-specific CD8+ T cells. Various functional 
assays using T-cell clones demonstrated that TRAV12-2 does not provide a functional 
advantage on a per cell basis. Together with the fact that this strong TRAV12-2 bias 
was already present in naïve A2/LLW-specific CD8+ T cells before YF-17D vaccination, 
it rather suggests that TRAV12-2 might confer a selective advantage for high frequency 
and prevalence by favoring thymic output of naïve cells. We thus sought to investigate 
how TRAV12-2 may provide such advantage by investigating the mode of antigen 
binding and structural considerations of the TCR:pMHC complex. 
 
The A2/ELA epitope represents a well-known model antigen for which T cells are 
biased for TRAV12-2 usage [130]–[134]. A2/ELA-specific CD8+ T cells exhibit high 
frequency and prevalence in HLA-A*0201 healthy individuals as well as melanoma 
patients, showing naïve (in healthy individuals) and [130]–[133] differentiated (in 
melanoma patients) phenotypes [131] [134]. Intriguingly, the binding between the 
MEL5 TCR expressing TRAV12-2 and the ELA peptide in complex with HLA-A*0201 
occurs via dominant contacts with the CDR1 loop of TRAV12-2 [135]. The TRAV12-2 
gene is also expressed by the A6 TCR, which is specific for the A2/Tax epitope of the 
human T-cell leukemia virus type 1 (HTLV-1) [28]. The CDR1α and CDR2α loops of the 
A6 TCR utilize an antigen-binding mode virtually identical to that seen in the MEL5-
A2/ELA complex, making contacts between the CDR1α loop and the Tax peptide. A 
study in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) 
patients revealed that TRAV12-2 transcripts are predominant [136] and the frequency 
of naïve cells with this specificity is very high [137]. Therefore, A2/Tax-specific CD8+ T 
cells constitute another documented example of high naïve frequency associated with 
TRAV12-2 bias. 
 
Unfortunately, our extensive attempts to generate a TRAV12-2 TCR A2/LLW co-crystal 
structure failed. We resorted to molecular modeling of this interaction taking advantage 
of the high sequence similarity between the A2/LLW-specific TCR YF5048 and the 
A2/ELA-specific TCR MEL5. Conveniently, the LLW peptide in the free A2/LLW 
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structure we solved adopts a similar conformation to the ELA peptide in the 
A2/ELA/MEL5 TCR complex. Modeling showed that the YF5048 TCR α-chain 
positioned above the N-terminus of the peptide, making contacts predominantly with 
Asn4 in the middle of the peptide via the CDR1α loop of TRAV12-2. The importance of 
this interaction is further supported by our results from the mutagenesis scan across 
the LLW peptide. Our modeling data suggests that the germline-encoded TRAV12-2 
CDR1α loop of A2/LLW-specific CD8+ T cells makes critical contacts with both MHC 
and peptide in a comparable manner to the CDR1α loops in the MEL5 and A6 
TRAV12-2+ TCRs [28] [135]. These three paralleled examples of TRAV12-2-biased 
responses endorse the concept that the interactions between the TCR and the antigen 
can rely substantially on TCR segments that already pre-exist in the germline rather 
than on somatic CDR3 rearrangement. However, it is important to note that this 
observation does not apply to all immunodominant T cell responses, as many public 
TCRs or immunodominant epitope-specific TCRs bind their cognate peptide 
predominantly via residues encoded in the rearranged CDR3 loops [138] [139]. 
 
Importantly, we showed that TCRs sharing this heritable TRAV12-2 CDR1α component 
of antigen binding still preserve their respective antigen specificity. Indeed, we 
demonstrated that there is no cross-reactivity between the LLW and ELA specificities. 
Thus, even these examples of a TRAV germline-encoded antigen binding mode are 
still heavily relying on permissive sequences within the TRBV non-germline CDR3 loop 
to determine antigen specificity (beyond TCR:pMHC binding being largely contributed 
by germline TRAV segments). 
 
It is intriguing that these three examples of TCRs binding their epitope with a germline 
component all involve the CDR1α loop of TRAV12-2 and HLA*0201. It is conceivable 
that TCRs expressing the TRAV12-2 could have a selective advantage for binding to 
cognate antigen restricted by HLA-A*0201 or that other antigen specificities (not only 
restricted by HLA-A*0201) also harbor biases for certain germline-encoded TCR 
segments but that these have not yet been identified. In the HLA-A*0201 allele and its 
associated antigen specificities are the most studied because HLA-A*0201 is prevalent 
at 30-50% in Caucasian populations and is the most prevalent HLA subtype amongst 
the global human population, potentially inducing a research bias [140]. Indeed, the 
TCR:pMHC structural database is dominated by interactions with HLA A2. More 
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studies need to be conducted to appreciate the extent to which this phenomenon of 
germline-encoded TCR binding to pMHC applies to other specificities and TRAV/TRBV 
families. 
 
Despite the tremendous theoretical genetic diversity of the TCR repertoire, most 
studies showed that the adult TCR repertoire is a consequence of a process that is far 
from random and TCR bias is commonly found in immune responses [51]. A specificity 
and/or TCR bias could reflect an evolutionary advantage during infection and other 
diseases. Several lines of evidence indicate that the germline-encoded TCR segments 
have features that promote binding to MHC molecules, suggesting co-evolution 
between TCR and MHC molecules [141]–[143]. Our data suggests that there is also 
co-evolution between the TCR and the cognate peptide. Indeed, we observed that 
TRAV12-2 TCR bias is present before YF-17D vaccination. In agreement with our 
functional studies on A2/LLW-specific clones, it was reported that TRAV12-2 usage in 
A2/ELA-specific CD8+ T cells was independent from functional avidity [133]. In fact, the 
origin of the large naïve A2/ELA-specific CD8+ T cell population was attributed to 
preferential thymic selection. First, the unusual frequency of the A2/ELA-specific 
population was shown to be generated by thymic output of higher number of precursors 
[144]. In addition, this large naïve pool might also result from the lack of antigen 
presentation by AIRE in the thymus of the natural EAA epitope. Indeed, it has been 
shown that AIRE-expressing cells in the thymus only present a truncated version of the 
Melan-A epitope due to misinitiation of its transcription [145]. Therefore, this leaky 
central tolerance might explain the abundance of these cells. 
 
Given that antigen recognition features a germline-encoded component, there is 
presumably a genetic advantage that confers higher chances for thymic output of TCR 
constructions involving the CDR1α of TRAV12-2. Thus, although TRAV12-2 does not 
confer a functional advantage on a per cell basis, it may provide an advantage at the 
level of the organism by skewing the naïve CD8+ T cell compartment towards these 
specificities recognized by TRAV12-2 CDR1α. This possibly explains the high 
frequency and prevalence of specificities such as A2/LLW and A2/ELA. 
 
In summary, we discovered the TCR bias for TRAV12-2 in A2/LLW-specific CD8+ T 
cells and demonstrated that there is no functional advantage in featuring TRAV12-2 on 
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a per cell basis. Rather, our structural modeling suggests that the germline-encoded 
CDR1α loop centrally contributes to peptide binding similar to two other TRAV12-2 
positive TCR specificities. We also demonstrated that TCRs sharing this TRAV12-2 
CDR1α – mediated mode of antigen binding still preserve their own antigen specificity. 
 
3.1.1.4 Contributions 
 
I cultured (restimulated and maintained) the library of clones used in this study, 
performed and analyzed the flow cytometry stainings, killing assays, combinatorial 
peptide library screens, ELISA and TCR sequencing. I also produced the pMHC 
complex for further X-ray and circular dichroism (CD) analysis. I solved its crystal 
structure with the help of Dr. Pierre Rizkallah. Dr. Konrad Beck performed and 
analyzed the CD experiment. The in silico modeling were performed by Dr. Vincent 
Zoete. I wrote the manuscript entitled “T cell Receptor Alpha Variable 12-2 bias in the 
immunodominant response to Yellow Fever virus” with the essential contribution of Dr. 
Silvia Fuertes, Prof. Daniel Speiser, Dr. Vincent Zoete, Dr. Konrad Beck, Prof. Andrew 
Sewell and Dr. Garry Dolton. 
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3.1.2 Fishing out new A2/LLW-specific clonotypes using an optimized multimer 
staining procedure 
3.1.2.1 Background 
 
In the previous Chapter, I highlighted the presence of a strong bias for the TRAV12-2 
gene in A2/LLW-specific CD8 T cells before and after YF-17D vaccination. I also 
showed using A2/LLW-specific clones that most of the clonotypes were unique and that 
public clonotypes were infrequent. One major technical limitation in the study of 
antigen-specific CD8 T cells is their detection and discrimination from other 
specificities. In the present Chapter, I would like to further develop the clonotype 
analysis of A2/LLW-specific CD8 T cells and in particular show the experiments that we 
did to optimize the multimer staining procedure in the framework of my scientific visit in 
Cardiff. 
 
In 1996, the development of fluorochrome-conjugated Class I pMHC tetramers enabled 
for the first time the visualization and analysis of antigen-specific T cells by flow 
cytometry [146]. These complexes consisted of four biotinylated pMHC molecules 
bound to fluorochrome-conjugated streptavidin [146]: as opposed to single pMHC 
molecules, such a “multimeric” form favors TCR aggregation and enhances binding, 
thus detection of cognate TCRs. Improvements to the pMHC multimer technology led 
to the production of dextramers in 2005 [147]. This allowed the detection of far more 
antigen-specific T cells than with tetramers [148]. In addition, an optimized protocol of 
multimer staining in combination with a protein kinase inhibitor (PKI) treatment and the 
addition of an anti-fluorochrome antibody was developed in the group of Prof. Andrew 
Sewell. The PKI Dasatinib treatment prevents the TCR downregulation during the 
staining, while the antibody crosslinking the pMHC multimer reduces its cell surface 
removal during washes [149] [150]. These two optimization steps led to a substantial 
increase in the number of detectable antigen-specific T cells [151] [152] (Figure 16). It 
was recently demonstrated by this group that tumor-specific T cells in tumor-infiltrating 
lymphocytes failed to be stained with tetramers although this population was fully 
functional. However, such T cells could be detected with this optimized protocol 
combining PKI Dasatinib and crosslinking antibody [150]. 
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I tested this optimized multimer staining protocol in order to fish out new A2/LLW-
specific clonotypes that could potentially be missed by the conventional multimer 
staining procedure. This data was included in a manuscript published in the Journal of 
Immunology in 2018 [153]. 
 
 
Figure 16 Study approach. Cell samples were stained in parallel using standard and optimized pMHC 
multimer staining protocols. The standard approaches used pMHC tetramer or dextramer while the optimized 
protocol further included the protein kinase inhibitor (PKI) Dasatinib and an anti-fluorochrome antibody (Ab). 
Multimer+ T cells were sorted by flow cytometry for TCR sequencing or cell cloning. This figure was taken from [153]. 
 
3.1.2.2 Results 
 
First, a T cell line was generated from PBMCs of an HLA-A*02+ donor vaccinated with 
YF-17D. Briefly, PBMCs were cultured for 14 days in complete medium in presence of 
10-5 M LLW peptide, 10µg/ml anti-CD28 antibody and 20U/ml of IL-2 [153]. Then, this T 
cell line was stained with the A2/LLW multimer using either the standard or optimized 
staining protocols. The standard staining procedure was performed as following: 2-3 
x106 cells of a T cell line were stained with PE-conjugated dextramer on ice for 30 mins 
in dextramer buffer (0.05M Tris-HCL, 15mM sodium azide, 1% bovine serum albumin, 
pH 7.2). The optimized protocol involved two additional steps: 1) cells were pre-treated 
with 50 nM Dasatinib (PKI) at 37°C for 10-30 minutes and without washing prior to 
staining with dextramer; 2) following dextramer staining, a second staining with a 
mouse anti-PE monoclonal antibody (binding the PE-conjugated dextramer) and 
washing was used [153]. 
Using the standard staining, 0.08% of CD8 T cells were detected with cognate pMHC 
dextramer. This A2/LLW-specific frequency rose to 0.16% of cells when the PKI 
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Dasatinib was included along with anti-fluorochrome antibody in the optimized staining 
protocol (Figure 17A). 
In this vaccinated donor, TRAV chain usage was biased towards TRAV12-2 as 
expected from our own findings [126] (Figure 17B). The TRBV chain dominance was 
shared between TRBV20-1 and TRBV15 with similar distribution (Figure 17B). 
TRAV chain repertoire analyses of sorted cells by high throughput sequencing revealed 
9 CDR3s for the standard dextramer stained cells and 27 for the optimized staining, 
with 8 clonotypes shared between them (Figure 17C). Importantly, the optimized 
staining protocol revealed 19 sort-unique CDR3s compared to 1 from the standard 
protocol sort (Figure 17C and Table 2). Interestingly, a previously identified public 
TRAV sequence (CAVGDDKIIFG) was identified in this donor using both procedures 
(Table 2) [126]. Similar analyses of TRBV use gave 9 and 18 CDR3s for standard and 
optimized staining respectively with 6 shared sequences. Thus, TCR β-chain 
sequencing also showed more CDR3s for the optimized protocol (n=12) compared to 
the standard stained and sorted cells (n=3) (Figure 17C and Table 3). 
Taken together, the pMHC multimer staining procedure optimized using the 
combination of PKI Dasatinib and multimer-crossliking antibody revealed more and 
mainly unique A2/LLW-specific clonotypes compared to the standard multimer staining 
protocols. 
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Figure 17 Optimized pMHC multimer staining revealed many more TCRs than standard staining. (A) A T-cell 
line from a yellow fever vaccinated HLA-A2+ donor was sorted by flow cytometry in parallel using either HLA A2-
LLWNGPMAV dextramer alone (standard) or in combination with protein kinase inhibitor and anti-flurorochrome 
antibody (optimized). Percentage dextramer+ cells of CD8+ T cells is shown for each gate. Irrelevant dextramer 
made with HLA A2-ALWGPDPAAA) was used to set the gates for sorting. (B) Cumulative TRAV (upper panel) and 
TRBV (lower panel) gene usage for standard and optimized staining protocols, with all human genes listed on the x-
axis for completeness. (C) TCR sequencing and CDR3 analysis (Table 1 and 2) of alpha (left) and beta TCR chains 
(right) are displayed as sort-shared (grey) or sort-unique (blue) sections of a donut pie, with each section for each 
sort corresponding to a different CDR3. The number of shared (grey) and unique (blue) CDR3s for the respective 
sorts are shown in the center of each pie.  
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Alpha chain 
Protocol Frequency (%) V segment J segment CDR3𝛼 
 51.44 TRAV16 TRAJ37 CALSPSGNTGKLIF 
 17.81 TRAV12-2 TRAJ23 CAVGGGKLIF 
 14.26 TRAV12-2 TRAJ33 CAVSNYQLIW 
 6.27 TRAV12-2 TRAJ40 CVASGTYKYIF 
Standard 2.97 TRAV12-2 TRAJ30 CAVGNDKIIF 
 2.64 TRAV13-2 TRAJ13 CAENSGGYQKVTF 
 1.98 TRAV12-2 TRAJ16 CAVNSDGQKLLF 
 1.48 TRAV38-1 TRAJ48 CAFPESNFGNEKLTF 
 1.15 TRAV12-2 TRAJ30 CAVGDDKIIF 
 34.67 TRAV12-2 TRAJ33 CAVSNYQLIW 
 13.71 TRAV12-2 TRAJ23 CAVGGGKLIF 
 7.76 TRAV16 TRAJ37 CALSPSGNTGKLIF 
 5.95 TRAV12-2 TRAJ30 CAVGNDKIIF 
 3.10 TRAV12-2 TRAJ40 CVASGTYKYIF 
 2.98 TRAV25 TRAJ5 CASIGGGRRALTF 
 2.98 TRAV12-2 TRAJ30 CAVIGDKIIF 
 4.66 TRAV12-2 TRAJ30 CAVGDDKIIF 
 2.85 TRAV12-2 TRAJ30 CATGDDKIIF 
 2.72 TRAV12-2 TRAJ24 CAVNSGTDSWGKLQF 
 2.07 TRAV26-1 TRAJ24 CIVRGDSWGKLQF 
 1.81 TRAV12-2 TRAJ16 CAVNSDGQKLLF 
 1.55 TRAV14DV4 TRAJ16 CAMRETTASDGQKLLF 
Optimized 1.55 TRAV25 TRAJ16 CAADGQKLLF 
 1.42 TRAV1-2 TRAJ33 CASMDSNYQLIW 
 1.42 TRAV12-2 TRAJ34 CAVGTDKLIF 
 1.29 TRAV30 TRAJ11 CGTDISGYSTLTF 
 1.29 TRAV12-2 TRAJ27 CAVIAGKSTF 
 1.16 TRAV38-1 TRAJ48 CAFPESNFGNEKLTF 
 1.16 TRAV12-2 TRAJ50 CAVNAAGTSYDKVIF 
 0.91 TRAV12-1 TRAJ30 CVVADDKIIF 
 0.65 TRAV29DV5 TRAJ52 CAASDTNAGGTSYGKLTF 
 0.65 TRAV12-2 TRAJ57 CAPSQGGSEKLVF 
 0.39 TRAV8-6 TRAJ41 CAVRWENSGYALNF 
 0.39 TRAV35 TRAJ48 CAGRREKLTF 
 0.39 TRAV12-2 TRAJ31 CAVNNARLMF 
 0.26 TRAV12-2 TRAJ30 CAVSDDKIIF 
Key: Shared, Sort Unique 
Table 2 A greater number of unique (in blue) Yellow fever-specific TCR α-chain clonotypes are revealed with 
the optimized pMHC multimer staining protocol (n=19) when compared to standard protocol (n=1). 
Frequency (%) of clonotypes is calculated as Individual number of reads / Total number of reads x 100. TRAV/TRAJ 
annotation is displayed according to the IMTG database [154]. 
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Beta chain 
Protocol Frequency (%) V segment J segment CDR3β 
 51.46 TRBV20-1 TRBJ2-7 CSASHRAGNEQYF 
 33.62 TRBV15 TRBJ2-1 CATGLAGGNEQFF 
 5.21 TRBV15 TRBJ2-7 CATSRGQAYEQYF 
 2.84 TRBV27 TRBJ2-7 CASSPGTGTYEQYF 
Standard 2.29 TRBV3-1 TRBJ2-7 CASSPGQAYEQYF 
 2.13 TRBV5-1 TRBJ2-7 CASSLSDRVGEQYF 
 1.03 TRBV27 TRBJ1-5 CASSERGSNQPQHF 
 0.71 TRBV6-5 TRBJ1-1 CASRQQGGTEAFF 
 0.71 TRBV20-1 TRBJ2-3 CSASAADTDTQYF 
 34.50 TRBV15 TRBJ2-1 CATGLAGGNEQFF 
 33.29 TRBV20-1 TRBJ2-7 CSASHRAGNEQYF 
 10.41 TRBV15 TRBJ2-7 CATSRGQAYEQYF 
 4.54 TRBV27 TRBJ2-7 CASSPGTGTYEQYF 
 3.74 TRBV3-1 TRBJ2-7 CASSPGQAYEQYF 
 2.07 TRBV28 TRBJ2-3 CASSLSSSTGPTDTQYF 
 1.90 TRBV29-1 TRBJ2-7 CSVDVGAYEQYF 
 1.84 TRBV4-1 TRBJ2-7 CASSQGQAYEQYF 
Optimized 1.15 TRBV20-1 TRBJ2-7 CSAFRDFSYEQYF 
 1.09 TRBV27 TRBJ2-1 CASSQGLAGVHEQFF 
 0.92 TRBV5-1 TRBJ1-6 CASSLDWRGADSPLHF 
 0.92 TRBV20-1 TRBJ2-7 CSALAGAFYEQYF 
 0.86 TRBV7-3 TRBJ1-4 CASSVLRGRQGAWGEKLFF 
 0.75 TRBV27 TRBJ1-5 CASSRGGTGDQPQHF 
 0.75 TRBV29-1 TRBJ2-1 CSVDGRTGINEQFF 
 0.52 TRBV3-1 TRBJ2-3 CASSPGLAGGLASTDTQYF 
 0.40 TRBV6-5 TRBJ1-1 CASRQQGGTEAFF 
 0.35 TRBV4-1 TRBJ2-1 CASSQGERFGNEQFF 
Key: Shared, Sort Unique 
Table 3 A greater number of unique (in blue) Yellow fever virus-specific TCR β- chain clonotypes are 
revealed with the optimized pMHC multimer staining protocol (n=12) when compared to standard protocol 
(n=3). Frequency (%) of clonotypes is calculated as Individual number of reads / Total number of reads x 100. 
TRBV/TRBJ annotation is displayed according to the IMTG database 
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3.1.2.3 Discussion 
 
Several recent studies have suggested that the use of pMHC multimer staining may 
underestimate the size of antigen-specific T cell populations, in particular when low-
affinity (but functional) TCRs predominate such as in cancer. Importantly, recent 
studies also indicate that these populations that go undetected by standard stainings 
can make important contributions to immune responses [155]–[157]. 
 
Here, we used an optimized staining protocol including a PKI Dasatinib treatment to 
prevent TCR internalization due to multimer binding to TCR and the addition of an anti-
fluorochrome antibody to cross-link and thus stabilize the multimer. We compared 
standard and optimized staining protocols in combination with high-throughput TCR 
sequencing to characterize A2/LLW-specific CD8 T cells. 
 
Class I-restricted antiviral TCRs bind their cognate antigen with high affinity compared 
to self-antigens or to the binding between class II-restricted TCRs and class II pMHC 
complexes [47] [158]. Therefore, it has been assumed that the standard class I pMHC 
tetramer staining is the prototype successful protocol at detecting antigen-specific cells. 
Unexpectedly, we found that the optimized staining (combination of PKI Dasatinib and 
antibody cross-link) identified a much larger population of A2/LLW-specific CD8 T cells 
in a vaccinated donor. Of note, the situation was similar for the EBV BMLF1 epitope 
GLCTLVAML [153]. Although we showed that specific viral populations could be 
underestimated by standard staining, this was not the case for all viral epitopes. For 
instance, both protocols revealed similar specific populations from the influenza M1 
epitope GILGFVFTL, CMV pp65 epitope NLVPMVATV, and EBV LMP2A epitope 
CLGGLLTMV. Nevertheless, the optimization steps led to a brighter staining of the Ag-
specific T cells from these populations [153]. 
 
The present work was performed in the group of Prof. Andrew Sewell where the 
procedure was optimized starting from their own standard protocol of dextramer 
staining (“Cardiff”). The “Lausanne” protocol performed in the group of Prof. Daniel 
Speiser relies on the addition of sodium azide, a metabolic inhibitor, in the buffer to limit 
the internalization of the TCR/CD3 complex [159]. Direct comparison of the two 
standard protocols has not been performed. Table	 4 considers side-by-side the two 
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standard protocols. Sodium azide is also present in the “Cardiff” buffer so one can 
expect that the two additional steps would also improve the recovery of antigen-specific 
CD8 T cells compared to the standard “Lausanne” staining. Nevertheless, I have not 
tested whether the optimization would also improve the number of antigen-specific CD8 
T cells detected with the “Lausanne” standard staining protocol.  
 
Lausanne Cardiff 
Phosphate-buffered saline 
5mM EDTA 
0.2% BSA 
20mM sodium azide 
0.05M Tris-HCl 
pH 7.2 
1% BSA 
15mM sodium azide 
40min at 4°C 30min on ice 
PE-labeled multimer (TC Metrix) PE-labeled dextramer (in house) 
s Optimization: 
- PKI Dasatinib 
- Anti-fluorochrome Ab 
Table	4	Comparison	of	A2/LLE-specific	CD8	T	cells	standard	staining	procedure	from	Lausanne	and	Cardiff	
laboratories. 
 
It is important to mention that these stainings and TCR analysis were performed on T 
cell lines and not directly ex vivo on fresh PBMCs. This strategy was adopted because 
direct ex vivo analysis was close to detection limit. In my opinion, it is crucial to repeat 
this experiment ex vivo. Especially, it would be interesting to test these optimization 
steps on unvaccinated donors. The naïve pool of A2/LLW-specific CD8 T cells is 
surprisingly high and can be detected ex vivo directly in most of unvaccinated donors 
[97] [126]. However, the frequency of these naïve cells is very close to the detection 
limit of 0.01%. Therefore, such an improvement would be helpful to analyze and isolate 
the naïve population of unvaccinated donors. To ensure a correct gating of specific 
CD8 T cells and to phenotypically characterize these cells, markers of differentiation 
should be added to the FACS panel. 
 
As the yellow fever epitope was not the main specificity of interest for this publication, I 
regret that no time was dedicated to isolate specific clones for further functional 
analysis. Furthermore, I am convinced that the expertise in the group of Prof. Daniel 
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Speiser would have enabled to analyze ex vivo material and led to a successful 
cloning. 
 
In conclusion, this project highlights the importance of futher optimization of multimer 
staining protocols to avoid underestimating the size of functional Ag-specific T cell 
populations and to maximize the brightness of the staining for a better signal:noise 
ratio. This is not only true for rare populations and epitopes recognized by low-affinity 
TCRs but also for strong viral epitopes. It would be interesting to test whether these 
additional steps lead to an improvement in the detection of Ag-specific T cells using the 
“Lausanne” staining protocol. 
 
3.1.2.4 Contributions 
 
This work contributed to the thesis of Cristina Rius Raphael, a PhD student from the 
group of Prof. Andrew Sewell in Cardiff, UK. I contributed in her project by producing 
the PE-labeled A2/LLW-specific multimer, performing the first tests of the optimized 
protocol on my previously generated A2/LLW-specific clones and then proceeded with 
the sort of the specific population from T cell lines derived from a vaccinated donor and 
took care of the first steps of the RNA extraction. Cristina and her collaborators then 
sequenced the TCRs using the SMARTer technology and analyzed the data. I 
participated to the preparation of the manuscript entitled “Peptide-MHC class I multimer 
staining can fail to detect relevant functional T-cell clonotypes and underestimate 
antigen-specific T cell populations”. 
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3.1.3 Detailed description of the soluble TCR:pMHC production process 
3.1.3.1 Background 
As mentioned in 3.1.1, I attempted multiple times without success to solve the crystal 
structure of a TRAV12-2+ TCR in complex with A2/LLW. The critical step that failed 
was to produce a soluble TCR, which is necessary to then mix with pMHC in solution 
and make the TCR:pMHC complex crystals. In this Chapter, I would like to describe in 
detail the procedure of TCR production that I used [160]. This work is not part of a 
manuscript. The aim of this chapter is to highlight the issues that I encountered during 
this process in parallel to the detailed description of the methology – thus this 
methodological information is inserted here and not repeated in the Methods section for 
the purpose of clarity. 
 
Briefly, the procedure to produce a soluble TCR involves cloning of the protein 
sequences into an expression vector, expression of protein chains as inclusion bodies 
(IB) in E. Coli, purification of IB, refolding by dilution of denaturating agents, an anion 
exchange purification step and several gel filtration purification steps in order to obtain 
enough pure proteins to perform experiments such as SPR and X-ray crystallography 
(Figure 18). 
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Figure 18 An overview of the process of soluble TCR:pMHC manufacture 
 
3.1.3.2 Results 
Cloning of the α and β TCR chains into pGMT7 expression vector 
 
First, I chose five TRAV12-2+ TCR sequences from our library of A2/LLW-specific CD8 
T cell clones. It is important to mention that the original sequences were modified in 
order to introduce a non-native disulfide bond into the interface between the TCR 
constant domains (Table 5). The introduction of these cysteine substitutions, known as 
“Boulter-disufide”, improves the stability of the soluble TCR [161]. The selection of 
these clones was based on the functional assays and their fitness (expansion potential 
of the clones in culture upon restimulation). The sequences were then optimized for 
expression in E. Coli and restriction sites for cloning were added (Table 6). The 
sequences were synthetized by GeneWiz (USA) into the cloning plasmid pUC57. I 
processed all ten chains (α and β) in parallel but I will give only one example for each 
step. 
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YF1_alpha TRAV12-2 
MQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSA
TYLCAVTDDKIIFGKGTRLHILPIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAW
SNKSDFACANAFNNSIIPEDTFFPSPESS 
YF1_beta TRBV6-8 
MNAGVTQTPKFHILKTGQSMTLQCAQDMNHGYMSWYRQDPGMGLRLIYYSAAAGTTDKEVPNGYNVSRLNTEDFPLRLVSAAPS
QTSVYLCASSYSRTGSYEQYFGPGTRLTVTEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGV
CTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD 
YF3_alpha TRAV12-2 
MQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSA
TYLCAGGDDKIIFGKGTRLHILPIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAW
SNKSDFACANAFNNSIIPEDTFFPSPESS 
YF3__beta TRBV7-2 
MGAGVSQSPSNKVTEKGKDVELRCDPISGHTALYWYRQSLGQGLEFLIYFQGNSAPDKSGLPSDRFSAERTGGSVSTLTIQRTQQE
DSAVYLCASSQGLAYEQFFGPGTRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCT
DPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD 
YF4_alpha TRAV12-2 
MQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSA
TYLCAVKDARLMFGDGTQLVVKPIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAV
AWSNKSDFACANAFNNSIIPEDTFFPSPESS 
YF4_beta TRBV9 
MDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSELNLSSLELGD
SALYFCASSVEGPGELFFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTD
PQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD 
YF6_alpha TRAV12-2 
MQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSA
TYLCAVGSDKIIFGKGTRLHILPIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAW
SNKSDFACANAFNNSIIPEDTFFPSPESS 
YF6_beta TRBV2 
MEPEVTQTPSHQVTQMGQEVILRCVPISNHLYFYWYRQILGQKVEFLVSFYNNEISEKSEIFDDQFSVERPDGSNFTLKIRSTKLEDS
AMYFCASSEATGASYEQYFGPGTRLTVTEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVC
TDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD 
YF15_alpha TRAV12-2 
MQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSA
TYLCAVDTNAGKSTFGDGTTLTVKPIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSA
VAWSNKSDFACANAFNNSIIPEDTFFPSPESS 
YF15_beta TRBV9 
MDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSELNLSSLELGD
SALYFCASSVSGSSYEQYFGPGTRLTVTEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCT
DPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD 
Table 5 Original amino acid sequences containing the Boulter-disulfide mutation. CDR3 sequences are 
highlighted in red. 
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YF1_alpha TRAV12-2 
GGATCCATGCAGAAAGAGGTGGAACAGAATAGCGGCCCGCTGAGTGTGCCTGAAGGTGCCATTGCCAGCCTGAACTGCACCT
ATAGCGATCGCGGCAGCCAGAGCTTTTTCTGGTACCGCCAGTATAGCGGCAAGAGCCCGGAACTGATTATGTTCATCTATAGT
AATGGCGATAAAGAGGACGGCCGCTTTACCGCCCAGCTGAATAAGGCCAGCCAGTACGTTAGTCTGCTGATTCGCGATAGCC
AGCCGAGCGATAGCGCCACCTATTTATGCGCCGTGACCGACGACAAGATCATCTTTGGCAAGGGTACCCGCCTGCATATTCT
GCCGATCCAGAATCCTGATCCTGCCGTTTATCAGCTGCGCGATAGCAAAAGCAGCGACAAGAGCGTGTGTCTGTTTACCGACT
TCGACAGCCAGACCAACGTGAGCCAGAGCAAAGACAGCGACGTGTACATCACCGACAAATGCGTGCTGGACATGCGCAGCAT
GGACTTCAAAAGCAACAGCGCCGTGGCCTGGAGCAACAAAAGCGATTTTGCCTGCGCCAACGCATTCAACAACAGCATCATC
CCGGAAGACACCTTCTTTCCGAGTCCGGAAAGCAGCTAATAAGAATTC 
YF1_beta TRBV6-8 
GGATCCATGAATGCCGGTGTGACCCAGACACCGAAGTTCCACATTCTGAAGACCGGCCAGAGCATGACCCTGCAGTGCGCCC
AGGATATGAACCATGGCTATATGAGCTGGTACCGCCAAGATCCGGGTATGGGCCTGCGTCTGATCTACTATTCTGCAGCCGC
CGGTACCACCGATAAAGAAGTGCCGAACGGCTACAACGTTAGCCGCCTGAACACCGAGGATTTTCCGCTGCGCCTGGTGAGT
GCCGCACCGAGTCAGACCAGCGTGTATCTGTGCGCCAGCAGCTATAGCCGCACCGGCAGCTATGAGCAGTATTTTGGCCCG
GGTACCCGCTTAACCGTGACCGAGGATCTGAAGAATGTGTTTCCGCCGGAAGTGGCCGTGTTTGAACCTAGCGAAGCCGAGA
TCAGCCACACCCAGAAAGCCACACTGGTGTGTCTGGCCACCGGCTTTTACCCGGATCATGTGGAGCTGAGTTGGTGGGTGAA
TGGTAAAGAGGTGCACAGCGGTGTGTGTACCGATCCGCAGCCGCTGAAAGAACAGCCGGCACTGAATGATAGCCGTTATGCC
CTGAGCAGTCGCCTGCGTGTGAGTGCCACCTTTTGGCAAGATCCTCGTAACCATTTCCGCTGCCAGGTGCAGTTCTACGGCC
TGAGTGAAAACGACGAATGGACCCAGGATCGCGCCAAACCGGTGACCCAGATTGTGAGCGCAGAAGCATGGGGTCGCGCAG
ATTAATAAGAATTC 
YF3_alpha TRAV12-2 
GGATCCATGCAGAAAGAGGTGGAACAGAATAGCGGCCCGCTGAGTGTGCCTGAAGGTGCCATTGCCAGCCTGAACTGCACCT
ATAGCGATCGCGGCAGCCAGAGCTTTTTCTGGTACCGCCAGTATAGCGGCAAGAGCCCGGAACTGATTATGTTCATCTATAGT
AATGGCGATAAAGAGGACGGCCGCTTTACCGCCCAGCTGAATAAGGCCAGCCAGTACGTTAGTCTGCTGATTCGCGATAGCC
AGCCGAGCGATAGCGCCACCTATTTATGCGCCGGTGGTGACGACAAGATCATCTTTGGCAAGGGTACCCGCCTGCATATTCT
GCCGATCCAGAATCCTGATCCTGCCGTTTATCAGCTGCGCGATAGCAAAAGCAGCGACAAGAGCGTGTGTCTGTTTACCGACT
TCGACAGCCAGACCAACGTGAGCCAGAGCAAAGACAGCGACGTGTACATCACCGACAAATGCGTGCTGGACATGCGCAGCAT
GGACTTCAAAAGCAACAGCGCCGTGGCCTGGAGCAACAAAAGCGATTTTGCCTGCGCCAACGCATTCAACAACAGCATCATC
CCGGAAGACACCTTCTTTCCGAGTCCGGAAAGCAGCTAATAAGAATTC 
YF3_beta TRBV7-2 
GGATCCATGGGCGCCGGCGTTAGTCAGAGCCCGAGCAATAAAGTGACCGAGAAGGGCAAAGACGTGGAACTGCGCTGCGAT
CCGATTAGCGGCCATACCGCCCTGTATTGGTATCGCCAGAGTCTGGGCCAAGGCCTGGAGTTTCTGATCTACTTCCAGGGCA
ACAGCGCCCCGGATAAAAGCGGTCTGCCGAGCGATCGCTTTAGTGCCGAACGTACCGGTGGTAGCGTGAGCACCCTGACCA
TTCAGCGCACCCAGCAGGAAGACAGTGCCGTGTATTTATGCGCCAGCAGCCAGGGCCTGGCATATGAGCAGTTCTTTGGTCC
GGGCACACGCCTGACCGTGCTGGAAGACCTGAAAAACGTGTTCCCGCCGGAAGTGGCCGTGTTTGAACCGAGCGAGGCAGA
GATTAGCCATACACAGAAAGCCACCCTGGTGTGCCTGGCCACCGGCTTTTACCCGGATCATGTGGAACTGAGCTGGTGGGTG
AACGGCAAAGAGGTTCATAGCGGCGTGTGTACCGATCCGCAGCCGCTGAAGGAACAACCGGCCCTGAATGATAGCCGCTATG
CACTGAGTAGCCGCCTGCGCGTTAGTGCAACCTTCTGGCAAGATCCTCGTAACCATTTTCGCTGTCAGGTGCAGTTCTACGGC
CTGAGCGAAAACGATGAATGGACCCAGGACCGTGCCAAACCGGTGACCCAGATTGTGAGTGCAGAAGCCTGGGGCCGTGCC
GACTAATAAGAATTC 
YF4_alpha TRAV12-2 
GGATCCATGCAGAAGGAAGTGGAACAGAATAGTGGTCCGCTGAGCGTTCCGGAGGGTGCCATCGCCAGCCTGAATTGCACCT
ATAGCGATCGCGGCAGCCAGAGTTTCTTCTGGTATCGCCAGTACAGCGGCAAAAGCCCGGAGCTGATCATGTTCATCTACAG
CAATGGTGACAAAGAAGATGGCCGCTTTACCGCCCAGCTGAACAAGGCAAGCCAGTATGTGAGCCTGCTGATTCGTGATAGC
CAGCCGAGCGATAGCGCCACCTACCTGTGCGCCGTTAAAGATGCCCGCCTGATGTTCGGCGATGGTACCCAGCTGGTGGTG
AAACCGATTCAGAACCCTGATCCGGCCGTGTATCAGCTGCGCGATAGCAAAAGCAGCGACAAAAGCGTGTGCCTGTTCACCG
ACTTTGATAGCCAGACCAACGTGAGCCAGAGCAAGGATAGCGACGTGTATATCACCGACAAGTGCGTGCTGGACATGCGCAG
CATGGACTTCAAAAGTAACAGCGCCGTTGCCTGGAGCAATAAGAGCGACTTCGCCTGCGCCAATGCCTTCAACAACAGCATCA
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TCCCGGAGGACACCTTCTTTCCGAGTCCGGAAAGCAGCTAATAAGAATTC 
YF4_beta TRBV9 
GGATCCATGGATAGTGGTGTTACCCAGACCCCGAAACACCTGATCACCGCAACCGGTCAGCGCGTTACCCTGCGTTGCAGTC
CGCGCAGCGGTGATCTGAGCGTGTACTGGTATCAGCAGAGCCTGGATCAGGGTCTGCAGTTTCTGATCCAGTACTATAACGG
TGAAGAGCGCGCCAAAGGCAACATTCTGGAGCGCTTTAGCGCCCAGCAGTTCCCGGATCTGCATAGCGAGCTGAACCTGAGC
AGCCTGGAACTGGGCGATAGCGCCCTGTATTTTTGCGCAAGTAGCGTGGAGGGTCCGGGTGAACTGTTTTTTGGCGAAGGTA
GCCGCCTGACCGTGCTGGAAGACCTGAAGAACGTGTTTCCTCCGGAAGTTGCCGTGTTTGAACCGAGCGAGGCCGAGATTAG
CCATACCCAGAAAGCCACCCTGGTGTGTCTGGCCACCGGTTTCTATCCGGATCATGTGGAACTGAGCTGGTGGGTGAACGGC
AAGGAAGTGCACAGCGGCGTGTGTACAGATCCGCAGCCGCTGAAAGAACAGCCGGCACTGAATGATAGCCGCTATGCACTGA
GCAGCCGCCTGCGCGTTAGTGCCACCTTTTGGCAAGATCCTCGCAACCATTTTCGCTGTCAGGTGCAGTTCTACGGCCTGAG
CGAAAATGATGAGTGGACCCAAGACCGCGCAAAACCGGTGACCCAGATTGTTAGCGCCGAAGCATGGGGTCGCGCCGATTAA
TAAGAATTC 
YF6_alpha TRAV12-2 
GGATCCATGCAGAAAGAGGTGGAACAGAATAGCGGCCCGCTGAGTGTGCCTGAAGGTGCCATTGCCAGCCTGAACTGCACCT
ATAGCGATCGCGGCAGCCAGAGCTTTTTCTGGTACCGCCAGTATAGCGGCAAGAGCCCGGAACTGATTATGTTCATCTATAGT
AATGGCGATAAAGAGGACGGCCGCTTTACCGCCCAGCTGAATAAGGCCAGCCAGTACGTTAGTCTGCTGATTCGCGATAGCC
AGCCGAGCGATAGCGCCACCTATTTATGCGCCGTGGGTAGCGACAAGATCATCTTTGGCAAGGGTACCCGCCTGCATATTCT
GCCGATCCAGAATCCTGATCCTGCCGTTTATCAGCTGCGCGATAGCAAAAGCAGCGACAAGAGCGTGTGTCTGTTTACCGACT
TCGACAGCCAGACCAACGTGAGCCAGAGCAAAGACAGCGACGTGTACATCACCGACAAATGCGTGCTGGACATGCGCAGCAT
GGACTTCAAAAGCAACAGCGCCGTGGCCTGGAGCAACAAAAGCGATTTTGCCTGCGCCAACGCATTCAACAACAGCATCATC
CCGGAAGACACCTTCTTTCCGAGTCCGGAAAGCAGCTAATAAGAATTC 
YF6_beta TRBV2 
GGATCCATGGAACCGGAAGTGACACAGACCCCGAGCCATCAAGTGACCCAGATGGGCCAGGAAGTGATTCTGCGCTGCGTT
CCGATCAGCAACCACCTGTACTTCTACTGGTATCGCCAGATCCTGGGCCAGAAAGTGGAATTTCTGGTGAGCTTCTATAACAA
TGAAATCAGCGAAAAGAGCGAGATCTTCGACGACCAGTTTAGCGTGGAACGCCCGGACGGCAGTAATTTCACACTGAAAATCC
GCAGCACCAAACTGGAGGATAGCGCCATGTATTTTTGCGCCAGCAGCGAGGCAACAGGTGCCAGCTACGAACAGTATTTCGG
TCCGGGTACCCGTCTGACCGTGACCGAAGACCTGAAGAACGTGTTTCCGCCGGAAGTGGCCGTTTTCGAACCGAGTGAAGCC
GAGATTAGCCACACCCAGAAAGCCACCCTGGTGTGCCTGGCAACCGGTTTTTACCCGGATCATGTGGAACTGAGCTGGTGGG
TTAACGGCAAAGAAGTTCACAGCGGCGTGTGCACCGACCCGCAGCCGCTGAAAGAACAGCCGGCCCTGAATGACAGTCGTTA
TGCCCTGAGCAGCCGTCTGCGCGTTAGCGCCACCTTTTGGCAAGATCCTCGCAACCACTTTCGCTGCCAGGTGCAGTTCTAT
GGCCTGAGCGAGAACGACGAATGGACCCAGGATCGCGCAAAACCGGTGACCCAAATTGTGAGTGCCGAAGCCTGGGGTCGT
GCCGATTAATAAGAATTC 
YF15_alpha TRAV12-2 
GGATCCATGCAGAAAGAAGTGGAACAGAATAGCGGCCCGCTGAGCGTTCCGGAAGGTGCAATTGCCAGCCTGAATTGCACCT
ACAGCGATCGCGGCAGCCAGAGCTTTTTCTGGTACCGCCAGTATAGCGGCAAAAGCCCGGAACTGATTATGTTTATTTATAGC
AACGGCGATAAAGAGGATGGCCGCTTTACCGCCCAGCTGAATAAGGCCAGCCAGTACGTGAGCTTACTGATTCGCGATAGCC
AGCCGAGCGATAGCGCCACCTATCTGTGCGCCGTGGATACCAATGCCGGTAAGAGCACCTTCGGCGATGGTACCACCCTGAC
CGTGAAGCCGATCCAGAATCCTGATCCTGCCGTGTATCAGCTGCGCGACAGCAAAAGCAGCGATAAGAGCGTGTGCCTGTTT
ACCGACTTCGACAGCCAGACCAATGTGAGCCAGAGCAAGGATAGCGACGTGTACATTACCGACAAGTGCGTGCTGGACATGC
GCAGCATGGACTTCAAGAGCAATAGCGCCGTGGCCTGGAGCAACAAAAGCGATTTCGCATGTGCCAACGCCTTCAACAACAG
CATCATCCCGGAGGATACCTTCTTTCCGAGCCCGGAGAGCAGTTAATAAGAATTC 
YF15_beta TRBV9 
GGATCCATGGATAGCGGCGTGACCCAGACCCCGAAACACCTGATCACCGCCACCGGTCAGCGTGTTACCCTGCGTTGTAGCC
CGCGTAGCGGTGACCTGAGCGTGTATTGGTACCAGCAGAGCCTGGATCAGGGTCTGCAGTTCCTGATCCAGTACTACAACGG
CGAAGAACGTGCCAAAGGCAACATCCTGGAACGCTTTAGCGCCCAGCAGTTTCCGGATCTGCACAGTGAGCTGAATCTGAGT
AGCCTGGAGCTGGGTGATAGCGCCCTGTATTTTTGCGCCAGCAGCGTTAGCGGCAGCAGCTACGAACAGTATTTTGGTCCGG
GTACCCGCCTGACCGTGACCGAAGACCTGAAGAATGTGTTTCCGCCGGAGGTGGCCGTGTTTGAACCGAGCGAAGCCGAGA
TCAGTCATACCCAGAAAGCCACCCTGGTGTGCCTGGCAACCGGCTTCTATCCGGATCATGTGGAACTGAGCTGGTGGGTGAA
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CGGCAAAGAAGTGCATAGCGGTGTGTGCACCGATCCGCAGCCGCTGAAAGAACAGCCGGCCCTGAACGATAGCCGCTATGC
CCTGAGCAGCCGTCTGCGTGTTAGTGCCACCTTTTGGCAAGATCCTCGCAATCATTTCCGCTGCCAGGTGCAGTTTTACGGCC
TGAGCGAAAATGACGAGTGGACCCAGGATCGCGCCAAACCGGTTACCCAGATTGTTAGCGCCGAGGCATGGGGTCGCGCCG
ATTAATAAGAATTC 
Table 6 Optimized nucleotide sequences for E.Coli. 5’BamHI restriction sites are highlighted in yellow, 
3’EcoRI restriction sites in pink and 3’UTR in green. BamHI and EcoRI restriction sites are absent from all 
optimized sequences. 
 
The TCR α and β chains were cloned into the expression vector pGMT7 (Figure 19). 
First, I digested the pUC57 plasmid containing our sequences and the pGMT7 plasmid 
using the enzymes BamHI and EcoRI for 2h at 37°C. I ran the digestion products on an 
agarose gel and cut the band of interest according to their lengths (Figure 20). DNA 
was purified from the agarose gel using the Wizard® SV Gel and PCR Clean-Up 
system (Promega). 
 
 
Figure 19 Overview of the cloning process of a TCR chain into the pGMT7 expression vector. 
 
  
Figure 20 Example of plasmid digestion. Hyperladder™ 1kb Bioline. On the left panel, the inserts are released 
from the pUC57 plasmid after digestion by the restriction enzymes EcoRI and BamHI (black rectangle). On the right 
panel, the pGMT7 plasmid is opened up after digestion by the restriction enzymes EcoRI and BamHI (black 
rectangle). 
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Next, the digested TCR sequences were ligated to the digested pGMT7 plasmid 
following this equation: 
 𝐹𝑜𝑟 100𝑛𝑔 𝑝𝐺𝑀𝑇7: 
 100𝑛𝑔 × 500 (𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡)3000 (𝑠𝑖𝑧𝑒 𝑜𝑓 𝑝𝐺𝑀𝑇7)  × 3 =  50𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 
 
After 2h at room temperature, we transformed the ligation products into One Shot™ 
chemically competent TOP10 bacteria (ThermoFisher) and plated the bacteria on 
CARB+ agar plates. Plates were left at 37°C overnight until colonies grew. I picked five 
colonies per chain and grew them in CARB+ LB medium overnight. DNA was isolated 
from bacteria using the PureLink® Quick Plasmid miniprep kit (Life Technologies). I 
sent two products per chain for sequencing (Central Biotechnology Services, Cardiff 
University, Wales). I confirmed that no mutation was introduced in the ligation products. 
The α and β TCR chains were then inserted into a vector that allows protein expression 
in E. coli. 
 
Expression of TCR chains as inclusion bodies in E. Coli, purification and protein 
refolding 
 
The DNA products were then transformed into BL21 star or Rosetta™ (DE3)pLysS 
competent bacteria (Promega or Novagen) and plated on CARB+ agar plates. The next 
day, three colonies were picked into 40 ml CARB+ TYP medium and shaken at 37°C 
until the optical density (OD) reached 0.5. These small cultures were transferred to 1L 
CARB+ TYP medium shaken at 37°C. At OD = 0.5, the protein expression as IB was 
induced by the addition of 1mM IPTG for 3 hours. An aliquot was taken to check the 
protein expression and purity of the IB (Figure 21). It is important to note that all α 
chains took longer to reach the expected OD compared to the β chain, suggesting that 
these constructs were somehow toxic to the bacterial cells. The cultures were then 
centrifuged for 20min at 4’000rpm and pellets were kept for IB purification. The 
Rosetta™ bacteria were growing very slowly compared to BL21 bacteria (data not 
shown). Furthermore, they led to sticky IB. Therefore, we decided to transform only 
BL21 star (DE3)pLysS competent bacteria (Promega) for the next experiments. 
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Purified IB of α and β chains were opened up with 20mM DTT at 37°C for 15min. The α 
and β chains were then added sequentially with a ratio 1:1 to the refold buffer (2.5M 
Urea) at 4°C. The next day, the refold buffer containing both chains were transferred to 
a dialysis tube into 20L of cold water for 10 hours and again into a fresh 20L of cold 
water overnight. 
 
 
Figure 21 Example of inclusion bodies purity. YF6 α and β chains were produced as inclusion bodies in E.Coli. 
Although the protein of interest was overexpressed (arrow), several contaminants remained in the preparation, 
hence the need to purify the inclusion bodies before refolding the TCR. 
 
Protein purification by anion exchange chromatography 
 
The first step of protein purification involves anion exchange chromatography. It 
consists in the attraction of negatively charged molecules such as proteins to a 
positively charged ion exchange resin. The mobile phase has a low conductivity (10mM 
Tris), which favors the binding of the proteins to the column. The proteins are then 
eluted from the column by applying a linear salt gradient (NaCl). 
 
I ran the various refolds on the anion exchange chromatography column (7.9ml 
POROS® 10/100 HQ 50µm). Figure 22 shows an example of the YF6_5001 TCR 
(YF6) as well as the α11β6 TCR which serves as a positive control. The fractions 
eluted in the main peak were analyzed by SDS-PAGE followed by Coomassie staining. 
Under non-reducing conditions, this staining revealed that some fractions contained a 
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potential refolded TCR at a high molecular weight (55kb). However, under reducing 
conditions, only a band at the size of the β chain was visible. This suggests that the 
band of high molecular weight might be a homodimer of β chains (35kb). On the 
contrary, the positive control that was performed side-by-side with the YF6 TCR refold 
worked as expected: under non-reducing conditions, I observed a band at the size of 
the refolded α11β6 TCR (55kb), whereas both α and β chains are visible under 
reducing conditions (28kb and 35kb, respectively). None of the other YF TCR refolds 
led to the production of a soluble refolded TCR. The results of the analysis of the 
Coomassie gel after anion exchange purification are summarized in Table 7. 
 
 
Figure 22 Example of anion exchange chromatography purification step. A, Trace of an anion exchange 
purification after refolding of the YF6 TCR shows a main peak between the two dotted lines. The TCR and potential 
contaminants from the IB preparation are eluted by gradually increasing the NaCl gradient (green line) form 0mM to 
500mM and all the proteins bound on the column are eventually eluted into the waste fraction with 1M NaCl to 
regenerate the column. Analysis of the fractions comprised in the main peak of elution by SDS-PAGE under non-
reducing and reducing conditions followed by Coomassie staining allows the discrimination of the fractions 
containing the protein of interest. The YF6 TCR is shown in B, whereas the α11β6 TCR is shown in C as a positive 
control. 
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beta chain
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TCR Reducing conditions Non-reducing conditions 
YF1 Aggregation 
(smear on the gel) 
α and β chains visible 
YF3 no visible band 
at the expected size 
only β chain visible 
YF4 no visible band 
at the expected size 
only β chain visible 
YF6 β chains homodimer only β chain visible 
YF15 Aggregation 
(smear on the gel) 
only β chain visible 
Table 7 Summary of anion exchange chromatography purification. 	
Troubleshooting 
 
To minimizing the aggregation, I added arginine to the refold buffer (2.5M Urea + 
400mM arginine). Arginine is one of the most commonly used folding helps for the 
recovery of soluble proteins from IBs [162] [163]. However, I did not observe any 
improvement in terms of aggregation upon addition of arginine in the buffer. 
Nevertheless, to maximize chances, I still decided to use the arginine-containing buffer 
for all refolding experiments (data not shown). 
 
As it seemed that the issue comes mainly from the α chain, I increased the ratio of α 
and β chains (Figure 23): 
 - For the YF1, YF3, YF4, and YF15 TCRs, increasing the α: β ratio allowed to 
observe two visible bands (α and β chains) on the Coomassie gel under reducing 
conditions. However, only a smear could be detected under non-reducing conditions, 
suggesting aggregation of the TCR. - For the YF6 TCR, increasing the α: β ratio allowed to see a faint band 
corresponding to the α chain in addition to the β chain under reducing conditions. It 
prevented the formation of the β chains homodimer but rather led to aggregation. 
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Figure 23 Analysis of the fractions comprised in the main peak of elution after anion exchange 
chromatography by SDS-PAGE under non-reducing and reducing conditions followed by Coomassie 
staining. TCR identities and α: β chains ratios are indicated on the figure. “R” stands for “reducing conditions” and 
“non-R” for “non-reducing conditions. 
 
To confirm that the trouble came from the α chain, we attempted to refold the β chains 
of our YF TCRs together with the α chain of the MEL5 TCR, which is very similar to 
ours (all of them are TRAV12-2 positive). The refold of chimeric TCRs worked for the β 
chain of the YF3, YF4 and YF15 TCRs. On example is shown in Figure 24A. The β 
chain of the YF6 TCR only aggregated with the α chain of the MEL5 TCR (data not 
shown). We did not test the β chain of the YF1 TCR. 
 
After anion exchange chromatography, fractions containing the chimeric TCRs were 
pooled, concentrated and purified by several steps of gel filtration (24ml Superdex 200 
10/300 GL column) (Figure 24B). Gel filtration chromatography columns separate 
proteins on the basis of their size. Proteins move through a stationary phase composed 
of porous beads. Molecules that are too large to enter the pores stay in the mobile 
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phase move through the column more quickly and elute first, while smaller molecules 
diffuse further into the pores and therefore move more slowly. Several steps of gel 
filtration purification allow having a pure product of refolded TCR that could be further 
used to solve the crystal structure and perform binding affinity assays and 
thermodynamics by SPR. 
 
 
Figure 24 Example of a chimeric TCR containing the α chain of the MEL5 TCR and the β chain of the YF4 
TCR. A, Trace of an anion exchange purification after refolding and analysis of the fractions comprised in the main 
peak of elution highlighted by the dotted rectangle by SDS-PAGE under non-reducing (“non-R”) and reducing (“R”) 
conditions followed by Coomassie staining. B, Trace of the second step of gel filtration and analysis of the fractions 
comprised in the dotted rectangle by SDS-PAGE under non-reducing (“non-R”) and reducing (“R”) conditions 
followed by Coomassie staining. The third analyzed fraction contains pure refolded TCR as no contaminants were 
detectable. 
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IBs are the results of cytoplasmic accumulation of recombinant proteins in E. Coli. They 
offer a high level of protein expression. However, they are often present as insoluble 
aggregates devoid of biological activity [164]. As the conventional method of refolding 
insoluble IBs by dialysis did not work, I tried to extract the insoluble proteins from E. 
Coli. This involves a purification step on a HiTrap Q HP anion exchange 
chromatography column (GE Healthcare). Regrettably, the starting material was not 
sufficient enough to recover any protein from the purification as revealed by the SDS-
PAGE (data not shown). 
 
3.1.3.3 Discussion 
 
Before 1987, it was not imagined that pMHC could be successfully produced starting 
from empty MHC molecules produced in the laboratory (bypassing the restriction of 
isolating from the naturally bound pMHC) because of the failure of empty MHC to 
refold, until it was discovered that the MHC heavy chain and the b2m actually pair quite 
easily when refolded in presence of the cognate peptide [165]. Unlike pMHC 
complexes, α and β TCR chains hardly refold correctly in vitro and are therefore rather 
insoluble when obtained from expression in E. Coli. The first structures of a human and 
mouse αβ TCRs were solved in 1996 [28] [29]. Since then, the recovered yield of 
stable TCR chains has been improved by the introduction of the Boulter disulfide bond 
as it was used in our experiments [166]. To date, E. Coli still makes up for the main 
system for TCR production as it has the advantages of low cost, higher protein yield 
and greater procedure speed. Here, I would like to discuss the alternative systems that 
we could have tested for the production of our YF TCRs. 
 
Eukaryote expression platforms have also been extensively explored. Insect cells have 
the machinery for folding of mammalian proteins, increasing the chances to obtain a 
soluble protein. However, these systems are also able to carry out complex post-
translational modifications such as glycosylation, which might be then challenging for 
further crystallization [167]. 
 
Human cells can be used for the generation of proteins. It allows transfecting bicistronic 
vectors encoding both TCR chains separated by a 2A sequence making the ribosome 
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skip the synthesis [168]. When the 2A sequence is fused in frame between two 
cistrons, it triggers co-translational “ribosomal skipping”. This contributes to the 
equimolar expression of the α and β chains and more efficient folding [169]. As for 
insect cells, human cells induce post-translational modifications to the protein of 
interest, yet in this case (the human expression context for a human protein) this might 
provide a proper refolding as the proteins are in their species context. TCRs possess 
up to seven N-linked glycosylation sites [170]. However, post-translational 
modifications are often considered as a nuisance in protein crystallography. Especially, 
glycans, a larger chemical modification, increase surface entropy and reduce favorable 
crystal contacts [167]. A way to overcome the issue of N-glycosylation is to use an 
expression system with intact folding and initial glycosylation, but restricted processing 
of the N-glycans in order to permit subsequent removal by the endogylcosidase H [167] 
[171]. The development of this strategy was initiated in the lab at a time close before I 
left, so I did not have the change to test it, knowing that the establishment of such 
method can take several months (it is still ongoing). 
 
I spent already several months on troubleshooting and alternative methods were not 
available directly in the lab, thus we decided not to pursue our attempts to refold a YF 
TCR. Meanwhile, we decided to perform an in silico modeling of the YF TCR that had 
the closest sequence to MEL5 together with the X-ray structure of the cognate pMHC 
complex as described in the previous Chapter [126]. 
 
3.1.3.4 Contributions 
 
I performed all the work presented in the “Results” section after being introduced to the 
various techniques by Dr. Anna Bulek. Conclusions and troubleshooting were 
discussed with both Dr. Anna Bulek and Dr. David Cole. 
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3.1.4 in vivo analysis of the TRAV12-2 bias using the transgenic ABabDII mouse 
model 
3.1.4.1 Background 
 
In order to overcome the limitations of working with human material, we sought whether 
an appropriate mouse model could be used for YF-17D vaccination. In particular, we 
considered the importance of recapitulating our observations in the mouse, and sought 
the model that would allow us to study A2/LLW-specific CD8 T cells, including the 
TRAV12-2+ TCR bias of A2/LLW-specific CD8 T cells and the impact of this bias on the 
immune response to YF-17D. The group of Prof. Thomas Blankenstein from the Max-
Delbrück-Center for Molecular Medicine in Berlin (Germany) has a unique mouse 
model, the ABabDII transgenic mice, which carry human αβ TCRs and a single human 
MHC-I gene: HLA-A*0201 [172]. It was shown that A2/ELA-specific CD8 T cells in 
ABabDII mice use uniquely TRAV12-2 and have a limited Vβ repertoire, validating the 
TRAV12-2 bias observed in human A2/ELA-specific CD8 T cells [172]. Therefore, we 
could likely use ABabDII to model the TRAV12-2 bias in A2/LLW responses during YF-
17D vaccination. 
 
In a collaborative agreement with us, this group performed pilot immunizations with the 
LLWNGPMAV peptide in their animal facility and shipped to us frozen blood, spleen 
and thymus. We first needed to address whether the observations in humans after YF-
17D vaccination can be validated in the ABabDII mouse model. The initial questions 
were : 
 
- Do ABabDII mice mount an A2/LLW-specific CD8 T cell response? 
- Is the A2/LLW epitope already detectable in the naïve population? 
- Is this epitope immunodominant in these mice? 
- Is the TCR usage in these mice similar to that in humans? 
- Does an SCM CD8 T cell subset also develop in A2/LLW-specific cells in these mice? 
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3.1.4.2 Results 
A2/LLW-specific CD8 T cell response in ABabDII mice 
 
ABabDII mice received subcutaneous injections of 100ug of LLWNGPMAV peptide + 
50ug CpG + IFA (Incomplete Freund’s adjuvant). Blood samples from 6 naïve and 6 
immunized mice were collected and analyzed by flow cytometry at day 7. One part of 
each sample was used for tetramer staining using a PE-labeled chimeric A2/LLW-
specific tetramer enabling mouse CD8 binding (H2-Kb/ LLW). The other part was used 
for in vitro LLW peptide stimulation and subsequent intracellular staining for IFNγ. 
Immunization with peptide did not induce a response that could be detected by 
tetramer staining (Figure 25). It is important to note that we deplore a positive control 
for this experiment. 
 
 
Figure 25 Lack of peripheral A2/LLW-specific CD8 T cell response in ABabDII mice after first in vivo 
injection of the LLW peptide. Staining of CD8 T cells with PE-labeled H2/Kb/LLW chimeric tetramer and anti-
mouse CD8 after gating on CD3-positive lymphocytes from either immunized or naïve mice. 
 
However, 4 out of 6 immunized mice showed a moderate and close to be significant (p 
= 0.0545) specific response to peptide restimulation as demonstrated by the production 
of IFNγ (Figure 26). This suggests that the peptide is indeed immunogenic in these 
mice. 
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Figure 26 Peripheral IFNγ production after first in vivo injection of the LLW peptide in ABabDII mice followed 
by in vitro peptide stimulation. Intracellular staining of CD8 T cells after gating on CD3-positive lymphocytes from 
either immunized or naïve mice (n = 6 per group). A, Individual dot plots. B, Quantification of IFNγ-positive cells and 
statistical analysis (paired t-est, “n.s” = not significant). 
 
We then sacrificed one responding mouse (#31684) and one naïve mouse (#31677) at 
day 11 in order to analyze the splenocytes for tetramer and IFNγ staining after in vitro 
expansion with low peptide concentration for 7 days. Peptide-specific CD8 T cells could 
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expand in splenocytes from the immunized mouse, as shown by the IFNγ production 
(Figure 27). Detectable tetramer staining was also achieved, however, this tetramer 
staining intensity was not prominent (Figure 27). 
 
 
Figure 27 IFNγ production and tetramer staining were monitored in CD8 T cells from splenocytes at day 11 
after injection followed by in vitro expansion with the LLW peptide for 7 days. Two concentrations were used 
for expansion: 1nM, 10nM, and a “no peptide” control. 
 
We therefore decided to inject the remaining mice with a booster dose of the peptide 
(or vehicle for naïve mice) 3 weeks after the first injection (Figure 28). Blood samples 
were analyzed 7 days after the booster injection. A2/LLW-specific CD8 T cells were 
detected in all immunized mice (Figure 29). 
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Figure 28 Schematic representing the experimental timeline of LLW peptide injection and samples collection 
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Figure 29 Peripheral A2/LLW-specific CD8 T cell response in ABabDII mice after the second in vivo injection 
of the LLW peptide. Staining of CD8 T cells with PE-labeled H2/Kb/LLW chimeric tetramer after gating on CD3-
positive lymphocytes from either immunized or naïve mice. (n = 5 per group). A, Individual dot plots. B, 
Quantification of tetramer-positive cells and statistical analysis (t-est, p-value is indicated on the graph). 
 
It seems that the intracellular staining for IFNγ after peptide stimulation was not very 
strong this time (Figure 30). However, the IFNγ production reflects the tetramer 
response to the peptide. 
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Figure 30 Peripheral IFNγ production after second in vivo injection of the LLW peptide in ABabDII mice 
followed by in vitro peptide stimulation. Intracellular staining of CD8 T cells after gating on CD3-positive 
lymphocytes from either immunized or naïve mice (n = 5 per group). A, Individual dot plots. B, Quantification of 
IFNγ-positive cells and statistical analysis (paired t-est, “n.s” = not significant). 
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Altogether, we concluded that two injections of the LLW peptide are required to induce 
a detectable A2/LLW-specific CD8 T cell response ex vivo in ABabDII mice. Of note, 
this epitope could not be detected in naïve mice. 
 
TRAV12-2 usage of A2/LLW-specific CD8 T cells in ABabDII mice 
 
We next wondered whether A2/LLW-specific CD8 T cells in ABabDII mice would show 
a TRAV12-2 bias, similarly to human A2/LLW-specific CD8 T cells [126]. The analysis 
was carried out directly on frozen splenocytes from immunized mice (in 10%DSMO- 
90% FCS). We quantified by flow cytometry the TRAV12-2 usage in A2/LLW-specific 
CD8 T cells compared to total CD8 T cells (Table 8 and Figure 31). The gate of 
TRAV12-2- positive cells was set according to the staining of the “primary antibody 
only” sample. The TRAV12-2 segment was already highly expressed by the majority of 
total CD8 T cells. We did not observe any further enrichment in TRAV12-2 usage in 
A2/LLW-specific CD8 T cells (median 48.0%) compared to total CD8 T cells (median 
54.8%). Actually, the percentage of TRAV12-2- positive cells was even lower in 
A2/LLW-specific CD8 T cells compared to total CD8 T cells (Figure 31B). This result 
does not reflect the human TCR bias of A2/LLW-specific CD8 T cells which express 
TRAV12-2 with a median of 55.5% compared to 12.5% in total CD8 T cells [126]. 
Alternatively, the fact that ABabDII mice already express high levels of TRAV12-2 
might reflect a global bias for TRAV12-2 in this model and mask TRAV12-2 biases in 
given antigen-specificities. 
 
Marker Fluorochrome Company 
CD8 Alexa Fluor 700 “in house” LICR 
CD44 FITC “in house” LICR 
CD62L PE-Cy7 eBioscience 
CD122 eFluor450 eBioscience 
Sca-1 PerCP-Cy5.5 eBioscience 
H2-Kb/LLW PE TC Metrix 
Va2.1 - Beckman Coulter 
Secondary goat anti-rat APC BD Bioscience 
Live/dead VIVID-AQUA Life Technologies 
Table 8 Flow cytometry panel used for TRAV12-2 usage and SCM phenotype 
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Figure 31 TRAV12-2 usage in splenocytes from immunized ABabDII mice at day 11 after the second injection 
of the LLW peptide. A, Tetramer staining (left panel) was monitored in total CD8 T cells. TRAV12-2 usage was 
monitored either in total CD8 T cells (middle panel) or in H2-Lb/LLW-specific CD8 T cells (right panel). (n = 6). B, 
Quantification of TRAV12-2 expression (paired t-test, p-value is indicated on the graph). 
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SCM subset in A2/LLW-specific CD8 T cells in ABabDII mice 
 
The SCM subset was previously described in mice as a CD44low CD62Lhigh population 
expressing high cell surface levels of stem cell antigen-1 (Sca-1), B cell lymphoma 
protein-2 (Bcl-2) and common IL-2 and IL-15 receptor β chain (CD122) [173] [174]. 
Mouse SCM cells were phenotypically defined in vivo following allogeneic 
transplantation [173] or following in vitro manipulation with drugs [174] [175]. However, 
there is no evidence of antigen-specific SCM responses to viral or bacterial antigens in 
mice. Here we characterized by flow cytometry the surface expression of Sca-1 and 
CD122 in the naïve compartment (CD44low CD62Lhigh) of A2/LLW-specific CD8 T cells 
compared to total CD8 T cells (Figure 32). There was no difference in terms of 
expression levels for both markers, suggesting that immunized mice do not develop an 
SCM subset in A2/LLW-specific CD8 T cells. This phenotype does not align with the 
one seen in human studies: A2/LLW-specific CD8 T cells in humans expressed high 
levels of the SCM markers CD95 and CXCR3 compared to total CD8 T cells in 
vaccinated individuals [97]. 
 
 
Figure 32 SCM phenotype of splenocytes from immunized ABabDII mice at day 11 after the second injection 
of the LLW peptide. Histograms of Sca-1 and CD122 expression after gating on CD44low CD62Lhigh CD8 T cells. 
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3.1.4.3 Discussion 
 
Compared to mouse models, questions about mechanisms of protection, ontogeny and 
development of the immune response after YF-17D vaccination and after wild-type 
YFV infection cannot be readily addressed in humans. We therefore sought of an 
appropriate mouse model and investigated the CD8 T cell responses specific to YF-
17D in ABabDII mice. 
 
Unfortunately, this mouse model turned out to be unsuitable. First, the mice needed 2 
doses in order to develop a response that could be detected using a chimeric A2/LLW-
specific tetramer enabling mouse CD8 binding. The tetramer positive population could 
not be detected in unvaccinated (naïve) mice as opposed to the achievable direct ex 
vivo detection of naïve A2/LLW-specific CD8 T cells in humans. Then, we could not 
observe a TRAV12-2 bias in these mouse A2/LLW-specific CD8 T cells, as opposed to 
human counterparts. In addition, we could not observe a murine SCM phenotype in of 
A2/LLW-specific CD8 T cells with the immunization protocol used in these mice. 
Finally, the mice could not be physically shared with us (only tissue was shipped), 
making experiments and logistics difficult. 
 
To date, the most relevant animal models to study the YFV are non-human primates 
(NHP) due to their close relationship to humans and their natural susceptibility to 
infection. They develop a disease very similar to (yet more severe than) the disease in 
humans [176]. However, NHP are logistically, costly and ethically challenging to work 
with. In addition, NHP are outbred leading to a large variability of MHC haplotypes. 
Therefore, only a few YF-17D studies have been conducted using these models [177]–
[180]. 
Mice are naturally resilient to YFV infection: when the virus is introduced 
subcutaneously to mimic vaccination, little or no replication is detected [181]. This is 
mainly due to restriction by type-I interferon [182] [183]. YFV can replicate after SC 
injection in type-I interferon receptor knockout mice (IFNAR-/-), which lack all type-I 
interferon responses. However, the IFNAR-/- model is not ideal for the study of T cell 
responses as the innate immunity is compromised in these mice and this could 
potentially lead to an impaired activation and proliferation of T cells [184] [185]. 
Furthermore, type-I interferon is produced by human cells when infected with YF-17D 
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in vitro [115] [186] [187]. Nevertheless, the effector phenotypes of the YFV-specific T 
cells induced in these mice appear to be similar to those effectors seen in human 
studies [181]. More recently, the Syrian golden hamster appeared to model the disease 
well, although it requires an adapted virus strain [188] [189]. The main disadvantage is 
the current lack of reagents available for this species. 
 
Thus, there is still an obvious need for an optimal animal model in order to study the 
mechanisms of protection and the development of the immune response after YF-17D 
vaccination and after wild-type YFV infection. 
 
3.1.4.4 Contributions 
 
As the ABabDII mice could not be shared with us, Dr. Ioannis Gavvovidis from the 
group of Prof. Thomas Blankenstein injected the mice at the Max-Delbrücke Center or 
Molecular Medicine in Berlin. He also performed the initial tetramer and intracellular 
stainings. He also carried out the freezing of the spleen samples for shipment to 
Switzerland. A previous PhD student from our lab, Dr. Tim Murray, compared the 
viability of mouse CD8 T cells after direct or overnight rest staining (data not shown). I 
optimized and performed the TRAV12-2 and SCM panels stainings. 
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3.1.5 Characterization of potential superagonist variants of the A2/LLW epitope 
3.1.5.1 Background 
 
As presented in 3.1.1, we aimed to examine the TCR:pMHC interface and T-cell 
functionality using CPL screens to determine the relative TCR-binding strength of the 
LLW epitope, whether stronger altered versions of the epitope exist. The CPL screen 
involves the creation of synthetic peptides libraries featuring all possible combinations 
of amino acids in the nonamer, which are divided into peptide mixtures where one 
amino acid residue is always fixed at a given position – this pools and greatly 
diminishes the numbers of tests needed, avoiding to screen all possible peptide 
combinations individually. Deconvolution allows then discovering individual agonist 
peptides from the mixture. Usually, a reduced number of candidate peptides are 
pinpointed from this analysis, which can then be individually tested in further peptide 
stimulations [190]–[192]. 
This technique enables the identification of peptide preferences of A2/LLW-specific 
TCRs and optimal peptide derivatives. In addition, during our attempts to solve a 
TCR:pMHC complex, super-agonist peptides potentially identified would have been 
particularly helpful in determining the optimal conditions for crystallization as it is known 
that crystallization is favored by the use of the strongest TCR-binding peptide. 
CPL screens were performed on several A2/LLW-specific TCRs, as reported in our 
publication on the TRAV12-2 [126]. We decided to focus on and further investigate the 
YF5048 TCR in the context of the master project of the student that I supervised in 
2017/2018, Philippe Delbreil. The aim of his work was to characterize the properties of 
the agonist variants identified from the CPL screening, focusing on the impact in 
functionality of the A2/LLW specific CD8 T cell clone LAU5048 NN4 carrying the 
YF5048 TCR. We wanted to determine whether it is possible to enhance the response 
to an already potent viral antigen and what are the aspects of the TCR:pMHC 
interaction that could allow to achieve a better functionality. For this, we studied the 
influence of the different mutations based on various assays to measure functional 
avidity, TCR:pMHC molecular interaction, and pMHC stability (Figure 33). 
 
In contrast to tumor antigens, the A2/LLW epitope was shown to be highly potent in 
terms of functional and magnitude of response [97] [117] [118] [120] [126]. 
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Nevertheless, our work attests that altered peptides improving T cell function exist even 
for a strongly immunogenic viral epitope. Interestingly, this enhancement was not due 
to a higher TCR avidity (longer off-rates of binding) but rather to a more rigid pMHC 
complex relating to lower entropy loss upon TCR:pMHC binding. 
 
 
Figure 33 Overview of the parameters analyzed in this section. Influence of the different peptide variants on 
overall CD8 T cell functionality was examined through an intracellular cytokine staining (ICS) and a flow cytometry 
analysis measuring CD8 T cell cytokine production, a 51Cr release assay measuring killing capacity, as well as an 
ELISA measuring the production of the MIP-1b cytokine. The avidity of the TCR-pMHC complex was determined by 
the monomeric dissociation for each peptide with NTAmer staining. In addition, an in silico analysis of the TCR-
pMHC interaction was performed to shed some light on the molecular interactions of the complex. Finally, various 
aspects of pMHC complex stability were examined by circular dichroism and in silico analysis of molecular 
dynamics. 
  
	 94	
3.1.5.2 Results 
Identification of superagonist peptides for the A2/LLW-specific CD8 T cell clone 
YF5048  
 
The initial phase was to identify candidate superagonist peptides for the A2/LLW 
epitope binding to YF5048 TCR by performing a CPL screen on the YF5048 clone 
[126]. 
 
Figure 34 Peptide recognition signature of an individual TCR derived from clone YF5048. A, Peptide length 
preference is determined by examining functional recognition of a sizing scan comprising random peptide mixtures 
of different lengths. Values are expressed as the concentration of MIP-1β secreted in the supernatant measured by 
ELISA in duplicate (mean and SD). B, Nonamer CPL scan for clone YF5048 assayed by MIP-1β activation in 
duplicate (mean and SD). Index peptide residues are represented as red bars. Data are representative of 3 
independent experiments. C, Recognition of 3 individual peptides chosen from the CPL assessed by MIP-1β 
activation in duplicate with graded concentrations of the peptides (mean and SD). 
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First, we assessed the peptide length preference of the YF5048 clone by the functional 
recognition of a custom-built “sizing scan” comprising random peptide libraries of 
different lengths (8 to 13-mer) [193]. Previous data suggest that CD8 T cell clones 
exhibit preference for the length of the index peptide [193]: as expected, we validated 
that the YF5048 clone exhibited a preference for the length of the index peptide (i.e. a 
9-mer) (Figure 34A). We thus performed a nonamer CPL screening to assess potential 
superagonists. Only a few non-index residues at positions 7 and 8 could increase the 
response compared to the index peptide (Figure 34B). In particular, the CPL results 
suggested that LLW-7I (LLWNGPIAV), LLW-8H (LLWNGPMHV) and LLW-8Q 
(LLWNGPMQV) are optimal peptides (Figure 34B). As previously reported, LLW-4R 
(LLWRGPMAV) failed to activate the TCR [126]. 
Next, we tested the peptide sequences revealed by the nonamer CPL screening by 
stimulating with peptides individually (Figure 34C). Indeed, the ELISA confirmed that all 
three mutant peptides (LLW-7I, -8H and -8Q) induced the expression of the cytokine 
MIP-1β at superior levels than stimulation with LLW-WT. The LLW-4A (LLWAGPMAV) 
peptide served as a negative control (according to our previous report [126]). 
 
We further investigated the functional sensitivity to the mutant peptides revealed by the 
CPL screening. First, we assessed the killing capacity of the YF5048 clone using a 
chromium release assay after stimulation with these peptides (Figure 35A and B). 
Upon titration, the LLW-7I peptide led to an approximately 1-log higher functional 
sensitivity than LLW-WT (Figure 35A), although only a tendency decrease was 
observed in EC50 (Figure 2B, data from three independent experiments) (unpaired t-
test LLW-WT vs LLW-7I: p = 0.0384). The response to the LLW-8H and -8Q peptides 
were comparable to the LLW-WT peptide (unpaired t-test: p = 0.0735 and p= 0.1700, 
respectively). 
Second, we compared the degranulation and secretion of cytokines upon stimulation 
with the various peptides by flow cytometry. Stimulation with titrating amounts of the 
LLW-7I peptide led to an approximate 1-log increased secretion of all measured 
cytokines compared to LLW-WT titration (Figure 35C and Figure 36). The calculated 
EC50 of the LLW-7I peptide titration was approximately 10-fold better than LLW-WT for 
IFNγ, TNFα and IL-2 (unpaired t-test: p = 0.0211, p = 0.0543, p = 0.2186, respectively) 
(Figure 35D). Similar effects were observed for the degranulation marker CD107a 
(unpaired t-test: p = 0.131) (Figure 35C and D). The peptides LLW-8H and LLW-8Q did 
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not improve substantially the functional sensitivity compared to LLW-WT. Also, the 
LLW-7I peptide induced a higher polyfunctionality at low peptide concentrations 
compared to the LLW-WT (Figure 37). 
 
Altogether, we showed that the substitution to an isoleucine at P7 in the LLWNGPMAV 
nonamer results in improved sensitivity (functional avidity) in the YF5048 clone. 
 
 
Figure 35 Functional properties of the YF5048 clone following stimulation with mutant peptides identified by 
the CPL. A, Killing capacity (51-chromium release assay) with titration of the different peptides as indicated. Data 
are the combination of 3 independent experiments (mean and SEM). B, The EC50 values of the 3 independent 51-
chromium release assays shown in A (mean and SEM). Statistical values were obtained from a t-test, * = p < 0.05, 
n.s. = not significant. C, Intracellular cytokine staining following peptides stimulation for 4 hours. Data are the 
combination of 3 independent experiments (mean and SEM). IL-2 expression was assessed in only 2 independent 
experiments. D, Values of the 3 independent intracellular cytokine staining are expressed as EC50 (mean and 
SEM). Statistical values were obtained from a t-test, * = p < 0.05, n.s. = not significant. 
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Figure 36 Gating strategy for the intracellular cytokine staining. Staining was performed on the YF5048 NN4 
clone following stimulation with T2 cells pulsed with the inidicated peptides at concentrations ranging between 10-11 
and 10-6M. Unpulsed T cell clone is used as negative control. A representative flow cytometry experiment is shown. 
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Figure 37 SPICE analysis of a representative intracellular cytokine staining. Pie charts showing frequencies of 
the combinatorial expression of the indicated cytokines and degranulation marker following stimulation of the 
YF5048 clone with various peptides at concentrations ranging between 10-11 and 10-6M. Color graduation 
corresponds to the number of simultaneous functions. 
 
The 7I mutation in LLW does not impact the TCR:pMHC off-rate, in contrast to 
the 8Q and 8H mutations 
 
We hypothesized that the enhanced functional sensitivity of the LLW-7I mutant could 
be a consequence of a stronger TCR:pMHC interaction. In order to characterize the 
interaction between the TCR and the agonist pMHC complexes, we first used 
fluorescently-labeled pMHC multimers at equivalent concentrations and calculated the 
fluorescence intensity upon staining of the YF5048 clone (Figure 38A) [151] [194]. The 
A2/LLW-8H and -8Q multimers stained the YF5048 NN4 clone with a slightly stronger 
intensity (Figure 38A). 
Previous reports have linked higher functional avidity specifically to longer TCR:pMHC 
off-rates [43]–[45] [195] [196]). We next measured the monomeric dissociation constant 
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rates (koff) using dually labeled pMHC multimers built on NTA-Ni2+-His-tag interactions 
called NTAmers (Figure 39 and Figure 40) [197] [198]. We found that the off-rate koff 
was highly decreased for A2/LLW-8H and -8Q compared to A2/LLL-WT (unpaired t-
test: p < 0.0001 and p < 0.0001, respectively) (Figure 38B). Rather unexpectedly, no 
significant difference was observed for the t1/2 of A2/LLW-7I compared to A2/LLW-WT 
(unpaired t-test: p = 0.1274), such that changes in off-rates would not explain 
increased sensitivity of the LLW-7I peptide. 
 
We did not observe changes in PD1 expression (a potential regulator of TCR:pMHC 
signaling) but we did not examine the expression of other inhibitory receptors or the 
phosphatase SHP-1 [199] (Figure 41). We think that the relatively short (4h) stimulation 
used in this experiment does not allow to detect effect on the expression of these 
regulatory markers.  
 
 
Figure 38 TCR affinity of the YF5048 clone towards mutant peptides. A, Wild-type and mutant pMHC multimer 
staining intensities (Y axis labels) of the YF5048 clone. B, TCR dissociation rates (koff) of the NTAmer Cy5 decay 
normalized to PE background, calculated from the data of the 3 independent experiments (mean and SEM; t-test). 
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Figure 39 PE-NTA fluorescence decay. Dot plot from a representative flow cytometry experiment is shown. Half 
lives were analyzed in Prism with a first-order monomeric decay function after substraction of non-specific 
background from an irrelevant clone.  
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Figure 40 Cy5- pMHC fluorescence decay. Dot plot from a representative flow cytometry experiment is shown. 
Half lives were analyzed in Prism with a first-order monomeric decay function after substraction of non-specific 
background from an irrelevant clone.  
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Figure 41 PD1 expression in the YF5048 clone after stimulation with T2 cells pulsed with the indicated 
peptides at concentrations ranging between 10-11 and 10-6M. Unpulsed T2 cells were used as a negative control 
(not shown) and treatment with PMA-ionomycin (“PMA-iono”) was used as a positive control and. A representative 
flow cytometry experiment is shown 
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In silico modeling shows no particular structural advantage in the 7I mutation of 
LLW, while the 8Q and 8H mutations show favorable contacts with the TCR 
 
In order to address structural determinants of the TCR:pMHC interaction, we solved the 
atomic structure of the A2/LLW-7I, A2/LLW-8H and A2/LLW-8Q pMHC complexes 
(Figure 42).  
Unfortunately, we could not determine the structural parameters that govern the TCR 
binding to the pMHC complex due to the failure to obtain a crystal of the YF5048 TCR 
[126]. Instead, we performed in silico modeling based on our crystal structures of the 
three mutant pMHC complexes and the previously solved structure of the MEL5 TCR 
[128], which has a TCR α chain that is very close in sequence to the TCR α chain of 
YF5048 [126]. In these modeled structures, the LLW-8H and -8Q mutant peptides 
made favorable contacts with the TCR (Figure 43A and B), which would explain the 
higher TCR avidity measured by NTAmer. In contrast, the 7I substitution (isoleucine at 
P7) did not introduce additional favorable contact with the TCR (Fig 4C). This is in line 
with the lack of a particular advantage in TCR:pMHC koff as measured by NTAmer for 
the 7I mutation (Figure 38), but still did not explain the increased functional avidity 
based on immunoassays upon titration with the 7I peptide (Figure 35). 
 
In conclusion, our data shows that a substitution to an isoleucine at P7 does not 
change the TCR koff. This was further supported by our in silico model which shows 
that the 7I mutant peptide does not make more favorable contacts with the TCR 
compared to the WT peptide. The superior T cell function induced by the LLW-7I 
mutant peptide is therefore not due to increased structural TCR:pMHC interactions.  
In contrast, our data suggest that the LLW-8H and -8Q mutant peptides make favorable 
contacts with the TCR, supporting the significantly longer off-rates and higher TCR 
avidity compared to the WT peptide. 
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Figure 42 Observed electron density around the peptide copies in complex with HLA-A2 showing the overall 
conformation of the peptides. A, LLW-7I (LLWNGPIAV), B, LLW-8H (LLWNGPMHV), C, LLW-8Q 
(LLWNGPMQV). 
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Figure 43 Molecular modeling of the YF5048 TCR bound to the various mutant peptides in complex with 
HLA-A2. Ribbons represent TCR β –chain in grey; the MHC molecule in tan ribbon, and peptides in ball and stick 
representation. A) WT peptide on left (in grey) and 8H peptide on the right (in orange). B) WT peptide on left (in 
grey) and 8Q peptide on the right (in green), C) WT peptide on left (in grey) and 7I peptide on the right (in light blue). 
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The 7I mutant peptide shows higher entropy loss and rigidity in complex with 
HLA-A*02 
 
Another potential mechanism by which the 7I mutant peptide could lead to an 
enhanced T cell function is that the peptide binds the MHC molecule with higher 
affinity. To assess this, we expressed, refolded and purified HLA-A*0201 in complex 
with the mutant and WT peptides. To assay the peptide binding affinity to the MHC 
molecule, we performed circular dichroism (CD) temperature melting experiments 
(Figure 44A). The A2/LLW-7I, A2/LLW-8H and A2/LLW-8Q complexes showed a 
melting temperature Tm of 66.2, 65.2, 65.3 °C, respectively. Thus, the stability of the 
mutant complexes is not significantly different from the A2/LLW-WT complex (Tm of 
66.5 °C, ΔHvH of -488 kJ/mol).  
The values of transition enthalpies ΔHvH were also calculated in the same experiment 
(Figure 44B). The binding of the LLW-7I peptide to the MHC shows a lower (favorable) 
ΔHvH than the other peptides, suggesting that the entropy loss upon binding is greater 
and that the resultant LLW-7I mutant pMHC complex is more rigid than the LLW-WT 
pMHC complex. 
 
 
Figure 44 Stability of the mutant peptides binding to HLA-A*0201. A, Apparent melting temperature Tm 
assayed by circular dichroism spectroscopy (mean and SD). B, van’t Hoff’s enthalpy of unfolding ΔHvH 
assayed by circular dichroism spectroscopy (mean and SD). 
 
In order to investigate pMHC rigidity further, we performed molecular dynamics (MD) 
simulations of the A2/LLW pMHC complex variants starting from the crystal structures 
of the A2/LLW-7I, A2/LLW-8H and A2/LLW-8Q complexes. The Root Mean Square 
Fluctuations (RMSF) of the different peptide and MHC residues were calculated. The 
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latter constitute a measure of the vibration intensity of the residues around their 
average position: a residue is more flexible if its RMSF value is higher. In the A2/LLW-
WT complex, the peptide residues Leu1, Asn4 and Met7, which are facing the solvent 
in the absence of TCR, are the most flexible residues, while the peptide residues Leu2, 
Trp3 and Val9, which are buried into the MHC pockets, are less flexible (Figure 45A). 
Interestingly, the isoleucine substitution at P7 of the LLW-7I mutant peptide in the 
pMHC complex shows a significantly decreased flexibility compared to Met7 in the 
LLW-WT pMHC complex (Figure 45A, p = 0.0006).  
Of note, the difference between the RMSF of the other peptide residues between the 
LLW-WT and -7I mutant are not significant (Figure 45A). Also, the flexibility of Met7 in 
the LLW-8H and LLW-8Q mutants is similar to that of the WT peptide.  
His8 and Gln8 contain more dihedral angles than the Ala8 residue in the WT system, 
and can be expected to display more flexibility when they face the solvent, in absence 
of TCR. This is indeed what is observed in the MD simulations for residues His8 and 
Gln8, in the MD simulations of the A2/LLW-8H and -8Q complexes, compared to Ala8 
of the WT complex. However, this increase in flexibility compared to Ala8 is limited and 
not statistically significant (Figure 45A, p=0.03 and 0.2 for LLW-8H and -8Q, 
respectively). The corresponding small entropy penalty upon binding for the mutated 
systems is compensated by the additional interactions made between the His8 or Gln8 
side chains and TCR, compared to Ala8 in the WT system as suggested by our in silico 
model (Figure 43B and C). 
 
The peptide substitutions could potentially modify the MHC flexibility. To control for this, 
the RMSF of the MHC residues were calculated from the same MD simulations (Figure 
45B). No significant difference could be observed in the flexibility of the MHC residues 
upon peptide mutation. Glu154 shows a higher flexibility in the A2/LLW-7I complex 
compared to the WT pMHC. However, this residue is not in contact with the mutation 
site, and the difference in the RMSF is not statistically significant (p=0.07). The only 
exception is the higher flexibility of Thr73, in the A2/LLW-7I and -8H complexes, which 
is statistically significant with p values of 0.01 and 0.009, respectively. This MHC 
residue is close to residues 7 and 8 of the peptide, explaining that its flexibility could be 
a function of mutations at these positions of the peptide. However, the absolute values 
and the differences in the RMSF remain small. 
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The larger binding avidity of the A2/LLW-7I complex for the TCR compared to the 
A2/LLW-WT complex can be explained by the more limited flexibility of the isoleucine 
side chain before binding the TCR (i.e. in absence of the TCR) which translates into a 
lower entropy penalty upon TCR binding [200]. The A2/LLW-7I complex seems to be 
enthalpically favorable and more rigid than the A2/LLW-WT complex. This is supporting 
a better recognition of the interface by the TCR as less induced fit is required. 
In conclusion, the superior functional sensitivity of the LLW-7I mutant peptide is not 
provided by an optimal interaction with the TCR but rather by an increased pMHC 
complex rigidity. 
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Figure 45 Flexibility of the peptide and MHC residues. Root Mean Square Fluctuations (RMSF in Å) calculated 
for the peptide (A) and MHC (B) residues, averaged over 3 independent MD simulations of the LLW-WT, -7I, -8H 
and -8Q complexes, each 140 ns in length. Standard deviations are reported. Of note, the MD simulations were 
performed for the pMHC complex, in absence of the TCR. 
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3.1.5.3 Discussion 
 
Using a CPL screening, we identified 3 superagonist peptides: the LLW-7I mutant 
peptide confers a higher functionality sensitivity compared to the natural WT sequence, 
whereas the LLW-8H and LLW-8Q mutant peptides moderately increase functional 
sensitivity. The data presented in this chapter are summarized in Figure 46. 
 
 
Figure 46 Table summarizing the data sets of the various mutant peptides 
 
The LLW-8H and LLW-8Q substitutions showed modest enhancement of the functional 
sensitivity compared to LLW-WT. In that case, the mechanism explaining this slight 
improvement is relatively clear as we found that the TCR dissociation rate (koff 
measured by NTAmer) was significantly lower compared to A2/LLW-WT. This was 
further supported by our in silico modeling suggesting that the TCR makes favorable 
interactions with the mutated residues. This is in agreement with several reports that 
have positively correlated functional avidity specifically to longer TCR:pMHC off-rates 
[43]–[45] [195] [196]. 
 
 
However, our data shows that a substitution to an isoleucine at P7 does not change the 
TCR:pMHC off-rates. This was further supported by our in silico model which shows 
that the 7I mutant and wild type peptides make similar interactions with the TCR. The 
superior T cell function induced by the LLW-7I mutant peptide is therefore not due to an 
increased interface with the TCR. In contrast, the LLW-8H and -8Q mutant peptides 
display longer TCR:pMHC off-rates and the in silico modeling suggests these peptides 
assay WT 7I 8H 8Q
ELISA MIP-1b EC50 6.4E-09 3.4E-10 5.9E-10 4.6E-10
51Cr lysis EC50 2.1E+09 4.7E+10 7.9E+09 8.3E+09
INFg EC50 6E-10 9.8E-11 2.4E-10 3.8E-10
TNFa EC50 1.6E-09 2.4E-10 8E-10 1E-09
CD107a EC50 1.5E-10 1.5E-11 4.9E-11 9.9E-11
IL-2 EC50 2.5E-09 2.5E-10 1.5E-09 1.8E-09
TCR avidity NTAmer dissociation rate t1/2 12.1333 17.9667 141 113.633
stability Tm 66.5 66.2 65.2 65.3
rigidity dHvH -511 -592 -514 -537
MD flexibility at P7 RMSF 1.4503 0.9656 1.4167 1.3961
read-out
peptides
ICS
CD
fuctional 
sensitivity
pMHC 
binding
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make more favorable contacts with the TCR, supporting the significantly higher TCR 
avidity compared to the WT peptide. 
 
Position 7 of a nonamer peptide is not usually considered as a primary MHC anchor 
residue, we indeed did not find any significant change in thermal stability for A2/LLW-7I 
compared to the WT complex. However, supported by experimental ΔHvH values and in 
silico molecular dynamics simulations, our results suggest that the LLW-7I mutant 
peptide binds the MHC molecule with higher rigidity. It has been shown that peptide 
motion, which also impacts MHC motion, affects recognition by the TCR [200]. Along 
these lines, the LLW-7I mutant peptide may therefore be presented by the MHC to the 
TCR more efficiently compared to the WT peptide – a phenomenon related to kon - 
given that the more rigid isoleucine side-chain in the A2/LLW-7I pMHC complex might 
require less induced fit and might lead to lower entropy penalty upon TCR binding. We 
may hypothesize that this 7I substitution leads to a more favorable pMHC-TCR binding, 
decreasing the related binding constant (KD, which is described as KD = koff/ kon), which 
translates into a higher affinity of the TCR:pMHC complex [201]. 
 
While our experimental data shows that the 7I mutation does not alter the TCR 
dissociation rate (koff) measured using the NTAmer technology, we hypothesize it 
improves the TCR association rate (kon) of the TCR:pMHC complex, consequently 
explaining the 1-log higher functional avidity observed with immunoassays (killing and 
cytokine secretion) on the YF5048 clone. To answer this question, we will perform an 
on and off-rate analysis with tetramers [202]. Briefly, tetramer binding kinetics is 
measured by flow cytometry at different time-points during tetramer staining until 
equilibrium is reached (kon). Addition of an HLA-blocking antibody leads to the tetramer 
dissociation (koff). These measurements will be performed at 4°C to inhibit tetramer 
internalization. For this experiment, it is useful to use a tetramer consisting of CD8 null 
binding monomers to ensure that we consider effects from the TCR only. 
 
Another technical pitfall relates to the assessment of the pMHC rigidity. Indeed, our 
conclusions are mainly based on in silico data from the molecular dynamics analysis. 
We also have some experimental data regarding the values of transition enthalpies 
ΔHvH measured by CD but it would have been important to investigate the 
peptide:MHC interaction in more detail. Isothermal titration calorimetry (ITC) allows to 
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determine the thermodynamics parameters of binding interactions by measuring 
changes in enthalpy when two molecules interact. However, such technique requires 
the molecules to interact in solution. This is not possible for pMHC complexes as they 
do not dynamically interact in solution. 
However, we could assess pMHC stability by measuring the on- and off-rates using a 
cellular peptide-binding assay. This involves pulsing HLA-A2-carrying T2 cells with the 
peptide followed by anti-HLA-A2 staining and fixation. For peptide on-rates, T2 cells 
are monitored by flow cytometry at several time points for 22 hours. For peptide off-
rates, T2 cells are pulsed overnight. Part of the cells are stained with anti-HLA-A2 and 
fixed, while the remaining cells being washed and incubated at 37°C and 5% CO2 for 
peptide dissociation, then stained with anti-HLA-A2 and fixed. Dissociation is measured 
by flow cytometry at several time points to calculate the off-rate [203]. 
 
One hypothesis would be that the LLW-7I peptide is better presented to the T cell. It is 
complex to assess experimentally the extent of the peptide presentation at the cell 
surface of APCs but we could monitor HLA-A2 levels in presence of the different 
peptides by flow cytometry. In addition, we could pulse APCs with the LLW-7I peptide 
and perform functional experiments at different time-points to determine whether this 
mutant peptide has a longer half-life at the cell surface and whether the antigen density 
would consequently be higher [203]. 
 
Another scenario could be that the TCR signal transduction is improved after 
stimulation with the LLW-7I peptide compared to the WT peptide. To test this 
hypothesis, T cell activation could be measured with a calcium (Ca2+) flux experiment, 
and the phosphorylation of the key players in the signal transduction pathways could 
be examined by phospho-flow cytometry. 
 
It is important to note that the mutant peptides identified by CPL are specific to the TCR 
carried by the clone tested (i.e. YF5048). Therefore, we do not necessarily expect that 
the mutant peptides would generally improve functional sensitivity at the polyclonal, 
population level. To confirm this, we will stimulate PBMCs from the donor LAU5048 
that was used for the cloning with the different peptides and monitor the cytokine 
response by flow cytometry in the total A2/LLW-specific CD8 T cell population 
(including TRAV12-2+ and TRAV12-2- cells). 
	 113	
 
We are also interested in assessing the functional sensitivity (killing assay and cytokine 
production) of the double-mutant peptides LLWNGPIHV (LLW-7I8H) and LLWNGPIQV 
(LLW-7I8Q). 
 
In conclusion, in contrast to tumor antigens, the A2/LLW epitope was showed to be 
highly potent [97] [117] [118] [120] [126]. Nevertheless, our work attests that altered 
peptides improving T cell function exist even for a strong viral epitope. Interestingly, the 
enhancement induced by the LLW-7I substitution was not due to a higher TCR avidity 
but rather to a more rigid pMHC complex. 
 
3.1.5.4 Contributions 
 
I performed and analyzed the killing assays, ELISA and NTAmer stainings. The ICS 
data were produced by Philippe Delbreil and analyzed by myself. The in silico 
TCR:pMHC modeling and molecular dynamics were performed by Dr. Vincent Zoete. 
Dr. Konrad Beck performed and analyzed the CD experiment. From this project, I am 
currently preparing a manuscript entitled “Functionally optimized peptide rigidity in a 
novel superagonist mutant of the immunodominant Yellow Fever Virus epitope 
NS4b214-222” with the essential contribution of Dr. Silvia Fuertes and Dr. David Cole. 
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3.1.6 CONCLUDING REMARKS 
 
In this chapter, I addressed several aspects of the TRAV12-2 bias in A2/LLW-specific 
CD8 T cells, including the functional and structural analysis of the TCR:pMHC 
interaction and finding a suitable mouse model.  
 
Several questions remain open. However, we could not find appropriate and/or 
immediately available models to answer them: 
- We attempted to use the ABabDII transgenic mice as a mouse model to study the YF-
17D vaccination, including the TCR bias of A2/LLW-specific CD8 T cells. Unfortunately, 
this mouse model turned out unsuitable for the biological and logistic reasons 
mentioned in section 3.1.4.3.  
- In order to test our hypothesis that TRAV12-2 would favor thymic output, we could 
have used a fetal thymus organ culture (FTOC). This is a culture system that allows 
intrathymic T cell development in vitro. However, we cannot do this because we do not 
have the ABabDII transgenic mice. 
- In the absence of a crystal structure of an A2/LLW-specific TRAV12-2 positive TCR in 
complex with A2/LLW, mutational analysis of the TCR would be required to support our 
in silico model and determine which residues are critical for antigen binding. We could 
measure functional avidity of TCR mutants with transfection into the TCRαβ- J76/CD8 
T cell line. T cell signaling responses following stimulation with LLW-pulsed targets 
would provide a functional map of the TCR binding site, in particular the contribution of 
the germline-encoded CDR1 loop of TRAV12-2 compared to the somatically 
recombined CDR3 loops. However, these experiments are technically challenging: it is 
possible that some of the mutants would not express well at the cell surface, requiring 
careful validation that the expression level is similar for wild-type and mutant TCRs.  
- Given the immunodominance and prevalence of A2/LLW-specific CD8 T cells, 
another interesting question is whether there is any advantage in having the HLA*02 
type. We could establish a new clinical protocol to assess whether HLA-A*02 positive 
individuals are better protected and/or raise better innate/adaptive responses than non-
HLA-A*02 individuals. However, it would not be feasible during the time of my PhD. An 
alternative is to seek for published reports of clinical studies on YF-17D vaccination 
with large numbers of volunteers or cases that may have HLA data – at first sight, we 
did not find such studies. 
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3.2 AXIS 2: Longitudinal analysis of the human immune responses to YF-
17D vaccination 
 
When I joined the laboratory of Prof. Speiser, the recruitment of a clinical study (“YF2 
study”) was ongoing, in which we collected blood samples longitudinally before and 
several time-points after YF-17D vaccination (Figure 47). The study involved healthy 
volunteers receiving a dose either for the first time (“priming” group, n= 10) or after at 
least 10 years of previous vaccination (“boost” group, n= 6). By the time I concluded 
the major experiments in Axis 1, the “YF2” study cohort biobank was ready for analysis. 
 
The main aims of my work on the YF2 study were (Figure 47): 
a) Characterize the dynamics, proportions and profiles of all major immune cell 
populations following primary and booster YF-17D vaccination. 
b) Interrogate correlations and identify the key determinants of immunogenicity 
using bioinformatics analyses (based on the parameters in a). 
c) Uncover the activation and differentiation of A2/LLW-specific effector and long-
lasting memory CD8 T cells. 
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Figure 47 Overview of the longitudinal YF2 study. Blood samples were collected at several time-points before 
vaccination (“BL”) and after vaccination (days “D”, weeks “W”, months “M”) with various purposes (as depicted by 
specific experimental methods).  
 
We have designed multiple, complementary and parallel analyses using 
comprehensive and cutting-edge technology, sustained by a solid and collaborative 
network of world-leading experts that have agreed to participate in this project. 
 
I characterized the proportion, number and activation state of all major immune cell 
populations by flow cytometry. Only these data alongside nAbs and viral titers will be 
shown in my PhD thesis. 
 
In a preliminary phase, I made major efforts to establish quality-controlled and 
optimized flow cytometry panels with at least 14 colors using an LSR-II SORP 
cytometer (Figure 48). Next, I investigated the PBMCs from all 16 donors and time-
points of the YF2 study (112 samples per panel) for: 
 
 
	 117	
• Adaptive immune cell types: CD8 T cells (including YFV-specific T cells with 
tetramers), CD4 T cells, B cells. 
• Innate immune cell types: monocytes and dendritic cells (DC), Innate Lymphoid 
Cells (ILC), Natural killer (NK) cells. 
 
Of note, PBMCs were isolated by Ficoll gradient for freezing and subsequent grouped 
analysis of multiple sample dates per volunteer in the same experiment. Therefore, 
erythrocytes, platelets and granulocytes (neutrophils, basophils, and eosinophils) could 
not be analyzed as these cell types are excluded by Ficoll gradient isolation. All 
samples were cryopreserved during the longitudinal collection from donors and while 
awaiting experimental use, thus certain cell types such as DC are also likely more 
negatively affected by this experimental design. 
 
All these cell types bulleted listed above were studied for their composition of 
differentiation subsets and activation status. I obtained frequencies as well absolute 
numbers based on the information that we obtain from complete blood cell counts also 
performed at each blood sample collection from the donors.  
 
 
Figure 48 Flow cytometry panels used for the YF2 study. 
 
Obviously, I could not run all 112 samples per panel (with multiple panels) on the same 
day. Therefore, I paid special attention to use the same lot of antibodies throughout the 
experiments. Importantly, I performed Cytometer Set-up and Tracking (CSnT) settings 
LSRII - SORP
T1 T2 Tet TCF1
FITC HLA-DR CD58 CD19 Dump: CD3, CD19, CD20, CD56, FcER1
Dump: CD3, 
CD14, CD15, 
CD19, CD20, 
CD33, CD34, 
CD203c, FcER1
CD58 TCF1
PerCP-Cy5.5 PD1 	PerCPef710 CD38 CD38 CD123 CD38 CXCR3 PD1 	PerCPef710
PE CD58 Ki67 IgD peIF2S1	(aRab) ckit tetramer tetramer
ECD CD45RA CD15S PE-CF594 HLA-DR CD16 HLA-DR HLA-DR HLA-DR
PE-Cy7 CD95 CD95 BCMA HLA-DR CD56 CD95 CD95
APC CCR10 Foxp3 CD83 CD83 Nkp44 (CD336) Ki67 A647 CD58
A700 CD38 CD3 CD86 CD86 CD137 CD38 CD38
APC-A750 CD8 CD8 CD40 APC-H7 CD1c AC7 - CD8 CD8
BrV421 CCR7 CCR7 CD20	PaB CD141 VioBlue CRTH2 CCR7 CCR7
Krome	Orange CD3 CD45RA BV510 CD3 CD14 CD16 CD45RA	BV510 CD45RA BV510
BV605 CXCR5 CD25 CD27 - CD127 CD127 CXCR5
BV650 CD69 CXCR3 CD69 CD40 CD69 CD69 CD69
BV785 CD4 CD4 CD138	BV711 CD303 PD1 BV711 PD1 BV711 CD127
DAPI	/	UV FVD-eF455 FVD-eF455 FVD-eF455 FVD-eF455 FVD-eF455 FVD-eF455 FVD-eF455
FcR	Block	20%	without	
pre-incubation
All samples were fixed overnight with the Foxp3 kit (eBioscience)
Whole PBMCs CD8+ fraction
T B Mono/DC ILC/NK Yellow Fever-specific
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before each flow cytometry acquisition in order to quality control the performance of the 
machine and to calibrate the voltages such that we normalize the sensitivity of the 
machine across experiments [204]. Thus, inter-experimental variability is minimized. 
 
In this chapter, I will describe the data in two parallel ways: one conventional analysis 
and one functional data analysis, for reasons that will be outlined. 
 
For the conventional analysis of our flow cytometry data, we applied the traditional 
method involving visual inspection and manual gating using serial 2D dot plots with 
FlowJo software, to then generate tabulated counts and frequencies of the populations 
of interest. 
In parallel, functional data analysis (FDA) was applied to analyze and interpret our 
longitudinal study. Although time course studies hold great potential in deciphering the 
temporal dynamic of continuous immunological processes, analyzing the resulting time-
series data remains challenging in part due to small sample sizes, uneven time-points, 
natural heterogeneity and multi-dimensionality of immunological data. In addition, the 
temporal order and dependence of repeated measures from the same individual 
introduce complex correlation structure in the data, which if ignored can lead to loss of 
information and reduced statistical power. 
 
In order to make the results description succinct, in this section, I jointly address aims a 
and b, which interrogate the same data series.  
 
3.2.1 Characterization of all major immune cell populations following primary and 
booster YF-17D vaccination (aims a and b) 
3.2.1.1 Background 
 
Despite the accumulating knowledge about the highly effective YF-17D vaccine, it is 
clear that a better comprehension of the immune correlates of protection is needed in 
order to gain insight into the mechanisms by which the vaccine induces such optimal 
immune responses. There is an inadequacy in the global characterization of all arms of 
the immune response (Table 9). Most studies focused on the primary adaptive 
response of YF-17D vaccination. Especially, these studies pinpoint only on few aspects 
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at the time. In addition, studying the immune response to YF-17D vaccination should 
include the early phase shortly after vaccination, and also the comparison to baseline. 
 
 Prime Boost 
CD8 T cells Dos Santos et al 2005 
Martins et al 2007 
Miller et al 2008 
Querec et al 2009 
Luiza et al 2011 
Kohler et al 2012 
Muyaja et al 2014 
Akondy et al 2015 
Campi et al 2015 
De Witt et al 2015 
Fuertes et al 2015 
Konsgaard et al 2017 
Dos Santos et al 2005 
Konsgaard et al 2017 
 
CD4 T cells Dos Santos et al 2005 
Martins et al 2007 
Kohler et al 2012 
Blom et al 2013 
Muyaja et al 2014 
Campi et al 2015 
De Wolf et al 2017 
Konsgaard et al 2017 
Dos Santos et al 2005 
Konsgaard et al 2017 
 
Ag-specific CD8 T 
cells 
Co et al 2002 
Miller et al 2008 
Akondy et al 2009 
Co et al 2009 
Querec et al 2009 
Blom et al 2013 
Melo et al 2013 
Muyaja et al 2014 
Akondy et al 2015 
Fuertes et al 2015 
Wieten et al 2016 
Akondy et al 2017 
Konsgaard et al 2017 
Muyaja et al 2014 
Wieten et al 2016 
Konsgaard et al 2017 
 
Ag-specific CD4 T 
cells 
Kohler et al 2012 
De Melo et al 2013 
James et al 2013 
Koblitschke et al 2017 
no report 
B cells Martins et al 2007 
Silva et al 2011 
Kohler et al 2012 
Muyaja et al 2014 
Campi et al 2015 
 
 
 
no report 
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nAbs Rosenzweig et al 1963 
Poland et al 1981 
Niedrig et al 1999 
Dos Santos et al 2005 
Hepburn et al 2006 
Querec et al 2009 
Luiza et al 2011 
Collaborative group 2014 
Muyaja et al 2014 
Campi et al 2015 
Wieten et al 2016 
Konsgaard et al 2017 
Dos Santos et al 2005 
Hepburn et al 2006 
Muyaja et al 2014 
Wieten et al 2016 
Konsgaard et al 2017 
Miyaji et al 2017 
 
virus Miller et al 2008 
Akondy et al 2009 
Muyaja et al 2014 
Akondy et al 2015 
Akondy et al 2017 
Muyanja et al 2014 
monocytes Martins et al 2008 
Luiza et al 2011 
Kohler et al 2012 
Hou et al 2017 
no report 
NK cells Martins et al 2008 
Da Costa Neves et al 2009 
Luiza et al 2011 
Muyanja et al 2014 
Marquardt et al 2015 
Hou et al 2017 
no report 
DCs Kohler et al 2012 
Hou et al 2017 
no report 
ILCs no report no report 
Neutrophils/ 
eosinophils 
Martins et al 2008 
Luiza et al 2011 
no report 
Table 9. Reports of immune responses to vaccination with YF-17D in humans 
 
The comparison between primary and booster vaccination will determine how the 
presence of pre-existing antibodies influence the reactivity to YF-17D. Furthermore, our 
study provides more insights of the importance of re-vaccination for the duration of 
immunity as it is still debated. 
 
To our knowledge, it is the first study that compares in details primary and booster 
vaccinations side-by-side, including the global and specific adaptive and innate 
parameters in parallel to antibodies and viral load after priming and booster YF-17D 
vaccination. Therefore we can expect that our approach provides a more 
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comprehensive insight into the various immune parameters involved in the YF-17D 
vaccination. 
 
3.2.1.2 Results 
 
Of note, apart from nAbs and virus, I have added the fitted population means 
(popMean) derived from the FDA to the classical raw data and average. Data was first 
normalized by log- and logit-transformation of raw counts and frequency measures, 
respectively. Having treated measurements prior to vaccination as baseline (day 0), we 
next fit a linear spline model with 4 internal knots located at days 3, 7, 14, and 28 
(Figure 49A). Visually, fitting a linear spline with 4 internal knots is equivalent to fitting a 
piecewise linear regression with 4 breakpoints and 5 segments. We chose the location 
of internal knots based on the observation that most features showed temporal 
fluctuations up to 4 weeks post vaccination, and reached a steady state from 28 days 
onward. Broadly speaking, the heterogeneity of individual profiles can be explained by 
either variability at the baseline (random intercepts) or variability in the slopes (random 
slopes). Given our sample size, we could not afford the most flexible model (by 
incorporating both random intercepts and random slopes). Instead, we opted for a 
random intercept model. Intuitively, our random intercept model assumes that 
individual profiles exhibit a consistent temporal dynamic, and that differences among 
individual profiles can be explained by variability at the baseline. Once the model was 
fit and unknown parameters were estimated/predicted for each feature, individual 
profiles were extracted for visualization and downstream analyses. It is important to 
note that popMean did not differ much from the average of raw data but were used for 
the global network analysis (Figure 49B, aim b). 
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Figure 49 Example of the functional data analysis. A, Total CD8 absolute numbers fitted into linear spline model 
with 4 nodes at days 3, 7, 14, and 28 (dotted blue bars). Grey lines represent the fitted individual profiles and the 
red line is the fitted population mean. B, Comparison of the fitted population mean (red line, left panel) and the 
mean of raw data (black line, right panel) of total CD8 absolute numbers. 
 
Higher titers of neutralizing antibodies after primary than booster vaccination 
The level of nAbs is generally considered as the main correlate of protection to assess 
the protective efficacy of the YF-17D vaccine [177] [205] [206]. In 6/6 individuals that 
had previously been vaccinated (booster group), nAbs could be detected already at 
baseline at levels > 1:20 titer (the titer considered protective [177] [207]) (Figure 50A 
and B). Following study vaccination, all the donors from the boost group showed a 
modest increase in nAbs titer with a peak at day 14 after booster vaccination (Figure 
50A and B). The nAbs increase upon booster was below 4-fold in 5/6 donors, which is 
commonly considered as significant [99]. Upon priming, 10/10 individuals generated 
nAbs peaking at 28 days after vaccination (Figure 50A and B). The peak in nAbs titer 
was statistically significantly higher after primary vaccination compared to the peak in 
the booster vaccination (Figure 50B). This confirms the observations in previous 
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studies showing that YF-17D booster vaccination induces a limited increase in nAbs 
compared to primary vaccination [98] [99] [208] [209]. 
Interestingly, there was a trend towards an increase between the pre-booster nAbs 
titers and the levels of nAbs after 6 months (Figure 50C). 
 
 
Figure 50 Neutralizing antibody titers in the plasma in response to primary and booster YF-17D vaccination. 
A, Dynamics of YFV-specific neutralizing antibody (“nAbs”) titers during the course of primary YF-17D vaccination 
(right panel, n = 10) and booster vaccination (left panel, n = 6). The average of individuals within each group is 
shown in red and blue, respectively. B, YFV-specific neutralizing antibodies in sera of healthy volunteers before 
(“BL”) and after primary vaccination (“Priming”, n = 10) or booster vaccination (“Boost”, n = 6); “D28” = 28 days after 
primary vaccination, “D14” = 14 days after revaccination. Paired or unpaired t-tests. C, Linear correlation between 
the pre-existing neutralizing antibodies and long-term neutralizing antibodies level in sera of healthy volunteers after 
booster vaccination (n = 6). 
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The B cell activation upon booster vaccination is reduced compared to primary 
vaccination 
 
Next, we studied the detailed B cell response during the course of primary and booster 
YF-17D vaccinations (Figure 51A, Figure 52A). As expected from the seroconversion 
period, the number and frequency of total B cells is transiently reduced at day 7 after 
primary YF-17D vaccination [88]. This observation has been hypothesized to be a 
consequence of the compartmentalization of B cell activation, which precedes plasma 
cell differentiation and antibody production [122] [125]. In contrast to primary 
vaccination, booster vaccination did not induce a reduction in B cell numbers (Figure 
52A). The same opposing trends of total B cells was observed in terms of frequency 
(data not shown). 
 
 
Figure 51 Representative FlowJo gating strategy for the B cells analysis A, Total B cells (CD19+ CD3-) were 
gated on live lymphocytes using forward/sideward scatter properties. Singlets were selected using forward/side ward 
scatter width/height characteristics. B cell subsets distribution was based on IgD and CD27 expression to determine 
naïve (IgD+ CD27-), negative memory (IgD-CD27-), non-switched memory (IgD+ CD27+), switched memory (IgD- 
CD27+), and plasmablasts (IgD- CD27++ CD38+ CD138+). B, The indicated activation markers were analyzed in 
total B cells (CD19+ CD3-) at baseline (BL) and day 14 after YF-17D vaccination (D14). They are represented in off-
set overlay histograms. C, The indicated activation markers were analyzed in various B cell subsets. The expression 
at baseline (BL) and at day 14 after YF-17D vaccination (D14) are represented in off-set overlay histograms. 
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Figure 52 Kinetics of total B cells and plasmablasts in response to primary and booster YF-17D vaccination. 
A, Absolute number of total B cells (CD19+CD3-) in healthy volunteers after primary vaccination (left panel, n = 10) 
and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group 
and in blue for the booster group (right panel). B, Absolute number of plasmablasts (CD19+IgD-
CD27++CD38+CD138+) in healthy volunteers after primary vaccination (left panel, n = 10) and booster vaccination 
(middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue for the 
booster group (right panel). C, Heat map showing the absolute number of plasmablasts among healthy volunteers 
after primary vaccination for each time point (n = 10). D, Linear correlation between the neutralizing antibody titers 
(“nAbs”) at D28 and the absolute number of plasmablasts at D14 after primary vaccination (n = 10) 
 
The dynamics of B cell subset numbers followed the one of total B cells, except for 
plasmablasts (IgD- CD27++ CD38+ CD138+) (Figure 51A). In contrast to other B cell 
subsets, which also transiently decreased, the number and percentage of plasmablasts 
increased after primary YF-17D vaccination, reaching a maximum at day 14 and 
subsequently returned to baseline level (Figure 52B). Booster dose of YF-17D vaccine 
induced a slight increase of plasmablasts but the peak occurred very early on at day 3 
(Figure 52B). 
 
B cell maturation antigen (BCMA), also known as TNFRSF17, is a receptor for the B 
cell growth factor BLyS-BAFF [210] [211]. It is essential for the maintenance of long-
live plasma cells [212]–[214]. BCMA was therefore highly expressed only by 
plasmablasts and not by other B cell subsets (Figure 53A). BCMA maximal expression 
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was observed at day 14 after primary YF-17D vaccination, whereas it took place at day 
3 after booster vaccination (Figure 53B). 
A systems biology approach revealed that BCMA mRNA level in PBMCs collected at 
day 7 after primary YF-17D vaccination predicted the magnitude of nAb titers. [113]. 
However, we did not find that the percentage of B cells expressing BCMA at day 7 after 
primary vaccination correlated with the nAbs titers after 28 days (p = 0.1137) (Figure 
53E). 
 
 
Figure 53 Kinetics of activation in B cells in response to primary and booster YF-17D vaccination. A, 
Percentages of cells positive for BCMA within the various B cell subsets in healthy volunteers after primary 
vaccination (n = 10). B, Percentages of cells positive for BCMA within total B cells subsets in healthy volunteers after 
primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). C, Percentages of cells 
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positive for CD83 within total B cells subsets in healthy volunteers after primary vaccination (left panel, n = 10) and 
booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and 
in blue for the booster group (right panel). D, Percentages of cells positive for CD86 within total B cells subsets in 
healthy volunteers after primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The 
fitted population mean is represented in red for the priming group and in blue for the booster group (right panel). E, 
Linear correlation between the percentage of B cells positive for BCMA and the level of neutralizing antibodies at 
D28 after primary vaccination (n = 10). 
 
In order to analyze activation of B cells in response to YF-17D vaccination, we studied 
the expression of CD83 and CD86 [215]–[217] (Figure 51B and C). Analysis of B cell 
activation status revealed an increase in the percentage of CD83+ and CD86+ cells 
within total B cells at day 14 after primary YF-17D vaccination (Figure 53C and D). In 
contrast, up-regulation of CD83+ and CD86+ B cells after booster vaccination precedes 
the one after primary vaccination and occurred at day 3 (Figure 53C and D). Mainly the 
plasmablast subset among total B cells showed an activated status (Figure 51C). 
 
Altogether, the plasmablast population increases and gets activated in both vaccination 
groups. The peak of these events occurs at day 14 after primary vaccination, while a 
booster vaccination induces a much earlier response peaking at day 3. 
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Figure	54	Changes	of	B	cell-related	parameters	after	primary	or	boost	vaccination.	Changes	are	calculated	from	baseline	“BL”	to	the	peak	at	either	day	3	“D3”,	day	7	“D7”	or	day	14	“D14”	after	vaccination.	P-values	of	Wilcoxon	test	are	indicated	in	the	graphs. 
 
YF-17D viral replication is detectable after primary but not after booster 
vaccination 
 
The live-attenuated YFV-17D virus can be detected in blood circulation within the first 
week after vaccination [118]. We assessed viral replication after primary and booster 
YF-17D vaccination, for two reasons: first, because this viral load is positively 
correlated with a stronger immune response and in particular with the magnitude of the 
CD8 T cell activation [119]; second, if a subject is immune to Yellow Fever, we 
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hypothesized that virus would be rapidly neutralized and less capable to replicate. Viral 
load would thus be a measure of pre-existing immunity as well as predictive of 
subsequent T cell activation. 
We found that most individuals of the priming group showed detectable viremia, with a 
peak at day 3 (n = 4/10) or day 7 (n = 2/10), after which it dropped rapidly (Figure 55A). 
In 4/10 individuals of the priming group there was no detectable virus (n= 4/10) (Figure 
55A). None of the individuals in the booster group (n=0/6) showed detectable viremia 
(Figure 55B). 
By directly comparing the nAbs titers versus viremia, we found a positive correlation 
between the absence of detectable viral copies after booster vaccination and pre-
existing positive nAbs titers (Figure 55D). These observations provide supporting 
evidence to the hypothesis that pre-existing humoral immunity to the virus precludes 
replication of the YF-17D vaccine virus [99]. 
 
 
Figure 55 Viral load in the plasma in response to primary and booster YF-17D vaccination. A, Dynamics of 
viral load during the course of primary YF-17D vaccination (left panel, n = 10) and booster vaccination (right panel, n 
= 6). The average of individuals within each group is shown in red and blue, respectively. B, Comparison of maximal 
copies of viral RNA per ml assessed in sera of healthy volunteers after primary vaccination (“priming”, n = 10) and 
booster vaccination (“boost”, n = 6); “n.d.” = not detectable. Mann-Whitney test, p = 0.0395. C, Relationship between 
maximal copies of viral RNA per ml and the neutralizing antibodies titers before primary or booster vaccination. 
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Booster YF-17D vaccination induces minor T cell activation compared to primary 
vaccination 
In order to assess T cell activation, we measured modulations of the activation markers 
CD69, CD38 and HLA-DR as well as the proliferation marker ki67, in CD8 and CD4 T 
cells (Figure 56). In analogy to previous studies, CD38 and HLA-DR expression 
reached their maximal up-regulation in CD8 T cells at day 14 after primary YF-17D 
vaccination and decreases back to baseline level around day 28 (Figure 57A and B) 
[99] [120] [122]. The expression of the early activation marker CD69 increased before 
the peak of the response, at day 7 after primary YF-17D vaccination (Figure 57C). 
However, we did not observe an up-regulation of these activation markers in CD8 T 
cells after a booster dose of YF-17D (Figure 57, Figure 58). 
Within the priming group, we expected a link between viral load and T cell activation 
[119]. When the maximal viral load is comprised between 0 and 60 copies / ml, we 
found a positive linear correlation between the maximal viral load and the frequencies 
of activated CD8 T cells (defined as HLA-DR+ CD38+) at day 14 after YF-17D 
vaccination (p = 0.0152) (Figure 59). Above this range, the correlation was not linear 
any more. This is in accordance with previously published data [119]. 
 
 
Figure 56 Representative FlowJo gating strategy for the total T cells analysis. CD8 versus CD4 distinction 
were gated on live CD3+ CD16- lymphocytes. Subsets distribution in CD8 and CD4 T cells was based on the 
conventional differentiation markers CCR7 and CD45RA to determine naïve (CCR7+ CD45RA+), CM (CCR7+ 
CD45RA-), EM (CCR7- CD45RA-), and EMRA (CCR7- CD45RA+). The indicated activation markers were analyzed 
in total CD4 and CD8 T cells. The expression at baseline (BL) and at day 14 after vaccination (D14) are represented 
in off-set overlay histogram 
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Figure 57 Kinetics of activation and proliferation in total CD8 T cells in response to primary and booster YF-
17D vaccination. A, Percentages of cells positive for CD38 within total CD8 T cells in healthy volunteers after 
primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). B, Percentages of cells 
positive for HLA-DR within total CD8 T cells in healthy volunteers after primary vaccination (left panel, n = 10) and 
booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and 
in blue for the booster group (right panel). 
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Figure 58 Expression changes of the activation and proliferation markers in CD8 T cells after primary or 
boost vaccination. P-values of Wilcoxon test are indicated in the graphs. 
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Figure 59 Linear correlation between the percentage of activated CD8 T cells at day 14 after primary YF-17D 
vaccination and maximal viral load. “activated CD8 T cells at D14” defined as CD38+ HLADR+ CD8 T cells at day 
14 (n=9). 
 
Concerning CD4 T cells, the overall activation induced by the YF-17D vaccine was 
more modest (significant increase in HLA-DR and Ki67), even after primary vaccination 
(Figure 60, Figure 61). The CD4 T cell responses that could be detected in the priming 
group preceded the CD8 T cell response, peaking at day 7 after vaccination (Figure 
60). 
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Figure 60 Kinetics of activation and proliferation in total CD4 T cells in response to primary and booster YF-
17D vaccination. A, Percentages of cells positive for CD38 within total CD4 T cells in healthy volunteers after 
primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). B, Percentages of cells 
positive for HLA-DR within total CD4 T cells in healthy volunteers after primary vaccination (left panel, n = 10) and 
booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and 
in blue for the booster group (right panel). C, Percentages of cells positive for CD69 within total CD4 T cells in 
healthy volunteers after primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The 
fitted population mean is represented in red for the priming group and in blue for the booster group (right panel). D, 
Percentages of cells positive for Ki-67 within total CD4 T cells in healthy volunteers after primary vaccination (left 
panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the 
priming group and in blue for the booster group (right panel). 
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Figure 61 Expression changes of the activation and proliferation markers in CD4 T cells after primary or 
boost vaccination. P-values of Wilcoxon test are indicated in the graphs. 
 
The absence of detectable virus in the plasma of booster vaccinees suggests that the 
low degree of T cell activation was due to the neutralization of antigen when there is 
pre-existing humoral immunity. This dichotomy between primary and secondary 
vaccination regarding T cell activation is consistent with a recent report [99]. 
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The magnitude of the re-call response of antigen-specific T cells is reduced 
compared to primary YF-17D vaccination 
 
To further investigate the CD8 T cell response, we focused on the magnitude and 
kinetics of the antigen-specific response to the YF-17D vaccine. Using an A2/LLW-
specific fluorescent multimer, we analyzed by flow cytometry the CD8-enriched fraction 
of PBMCs during the course of primary and booster vaccination (Figure 62). Following 
the peak of the viral replication at day 3/7 after primary vaccination, the A2/LLW-
specific response culminated at day 14, which is in line with previous studies (Fig 8A) 
[98] [99] [118] [120]. A2/LLW-specific CD8 T cells showed an activated phenotype 
indicated by the up-regulation of the activation markers CD38 and HLA-DR at day 14 
after primary vaccination (Figure 63A and B). The expression of the proliferation 
marker Ki67 was also increased at the peak of the primary response (Figure 63D). 
 
 
Figure 62 Representative FlowJo gating strategy for the analysis of A2/LLW-specific CD8 T cells. A, 
Frequency of tetramer positive CD8 T cells (A2/LLW) is represented in dot plots at baseline (BL) and several time 
points after YF-17D vaccination (D = days, M = months). B, The indicated markers were analyzed in tetramer 
positive CD8 T cells. The expression at baseline (BL) and at day 14 after vaccination (D14) are represented in off-
set overlay histograms.  
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Figure 63 Kinetics of A2/LLW-specific CD8 T cells in response to primary and booster YF-17D vaccination. 
A, Percentage of tetramer positive CD8 T cells (A2/LLW) expressed as percentage in total CD8 T cells in healthy 
volunteers after primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted 
population mean is represented in red for the priming group and in blue for the booster group (right panel). B, 
Percentages of cells positive for CD38 within total tetramer positive CD8 T cells in healthy volunteers after primary 
vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). C, Percentages of cells 
positive for HLA-DR within total tetramer positive CD8 T cells in healthy volunteers after primary vaccination (left 
panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the 
priming group and in blue for the booster group (right panel). D, Percentages of cells positive for Ki67 within total 
tetramer positive CD8 T cells in healthy volunteers after primary vaccination (left panel, n = 10) and booster 
vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue 
for the booster group (right panel). 
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Booster vaccinees showed higher detectable frequencies of A2/LLW-specific CD8 T 
cells at baseline compared to pre-boost frequencies (Mann-Withney test, p = 0.0312) 
(Figure 64). Following booster vaccination, a modest increase of the antigen-specific 
population frequency was observed (Figure 63A). Supporting this observation, booster 
vaccinees showed similar up-regulation of activation marker but decreased Ki67 
expression compared to the priming group (Figure 63D). 
 
	  
Figure 64 Changes of A2/LLW-related parameters. A, Comparison of the frequencies of tetramer positive CD8 T 
cells (A2/LLW) at baseline (BL) in healthy volunteers from the priming (n = 10) and boost (n = 6) groups. P-value of 
Mann-Whitney test is indicated on the graph. B, P-values of Wilcoxon test are indicated on the graphs. 
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Taken together, a booster dose of the YF-17D vaccine does not substantially induce 
the proliferation of A2/LLW-specific CD8 T cells found in blood. 
 
T cells transiently drop immediately after YF-17D primary vaccination 
 
Given the established correlation between viral load and the magnitude of the CD8 T 
cell response [119], we analyzed the number of total CD8 and CD4 T cells based on 
flow cytometry analyses and the complete blood counts (Figure 56). Intriguingly, the 
numbers of both CD8 and CD4 T cells in the blood transiently declined immediately 
after primary YF-17D vaccination and expanded back to baseline level after 14 days 
(Figure 65A and B). The same was true in terms of frequencies (data not shown). This 
observation had already been made by Kohler et al [122]. Notably, the drop of total 
CD8 T cells in the peripheral blood preceded this increase in A2/LLW-specific CD8 T 
cells. In contrast, we did not observe such a decrease of CD8 or CD4 T cell numbers in 
individuals of the booster group (Figure 65A and B). 
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Figure 65 Kinetics of total CD8 and CD4 T cells in response to primary and booster YF-17D vaccination. A, 
Absolute number of total CD8 T cells in healthy volunteers after primary vaccination (left panel, n = 10) and booster 
vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue 
for the booster group (right panel). B, Absolute number of total CD4 T cells in healthy volunteers after primary 
vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). C, Percentages of various 
CD8 (right panel) and CD4 (left panel) T cell subsets in healthy volunteers after primary vaccination (n = 10). 
 
Interestingly, the reduction of CD8 and CD4 T cells after primary vaccination was 
restricted to the central memory (CM; CCR7+ CD45RA-) and naïve (CCR7+ CD45RA+) 
subsets (Figure 65C). Both these subsets express the chemokine receptor CCR7. This 
molecule is critical for naïve CD8 T cell migration to lymph nodes and splenic white 
pulp, and memory CD8 T cell localization into secondary lymphoid organs. The CM 
population that expresses CCR7 is able to enter lymph nodes, whereas effector 
memory cells (EM; CCR7- CD45RA- and EMRA; CCR7- CD45RA+) that lack expression 
of this receptor cannot enter lymph nodes and therefore localize preferentially in the 
periphery [218]–[220]. 
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In addition to chemotaxis, another important aspect of T cell homing and subsequent 
priming is the retention in the lymph nodes. Upon peptide-MHC encounter on dendritic 
cells, T cells get activated and up-regulate the early activation marker CD69 on their 
surface. CD69 binds to the egress mediator Sphingosine 1-Phosphate Receptor 1 
(S1PR1), which leads to the internalization of the receptor and consequently to T cell 
retention in the lymph node [221]–[227]. Along these lines, we found a positive 
correlation between CD69 expression level in T cells at baseline and the fold change in 
CD8 and CD4 T cell numbers (p= 0.036 and p < 0.0001, respectively) (Figure 66A). 
Curiously, we did not find a significant correlation between the fold change in CD8 T 
cell numbers and the peak frequency of CD69 at day 7 (p = 0.3177) (Figure 66B). This 
correlation was significant for CD4 T cell though (p = 0.0162). This would suggest that 
individuals with high CD69 expression before vaccination might have a pre-disposition 
to a better recruitment of CD8 T cells. 
 
 
Figure 66 Correlation of the T cell drop with retention in the lymph node. A, Linear correlation between the fold 
change of total CD8 (left) and CD4 (right) T cell numbers in the blood after primary vaccination and the percentage 
of CD69+ CD8 T cells at baseline (n = 10). B, Linear correlation between the fold change of CD8 (left) and CD4 
(right) T cell numbers after primary vaccination and the percentage of CD69+ CD4 T cells at day 7 (n = 10). 
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We next wondered whether T cells migrate to the skin after subcutaneous injection of 
the YF-17D vaccine. We therefore analyzed in some individuals the chemokine 
receptor CCR10, which is conventionally known as a skin homing marker (n = 6) [228]–
[230]. Only a small proportion of CD8 and CD4 T cells in the periphery expressed this 
marker at baseline (Figure 67A). However, we noted that the increase of CCR10+ cells 
after primary vaccination correlated with the drop of CD8 T cells but not the drop of 
CD4 T cells (raw data: p = 0.0506 and p = 0.8851) (Figure 67B). 
 
 
Figure 67 Correlation of the T cell drop with migration. A, Frequency of CCR10-positive CD8 and CD4 T cells 
following YF-17D primary vaccination. B, Linear correlation between the fold change of CD8 (left) and CD4 (right) T 
cell numbers after primary vaccination and the increase of CCR10 expression at day 7 (n = 7). 
 
These findings indicate that the T cell drop observed after primary YF-17D vaccination 
results from the migration and trapping of T cells from the periphery into secondary 
lymphoid organs. 
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Innate immune activation is detectable in primary and not in booster vaccination 
 
In agreement with recent findings, we hypothesized that the reduction in T cell 
responses observed in the booster versus the priming group is linked to pre-existing 
immunity (nAbs at baseline), which eliminates the vaccine virus, precludes viral 
replication and precludes antigen availability for T cell activation. This would also 
suggest that the innate response in the booster vaccination is not substantially 
triggered. To address innate activation, we studied NK cells, Innate-lymphoid cells 
(ILCs) and monocytes.  
 
In our study, the number of total monocytes were slightly increased after primary 
vaccination, yet not significantly (Figure 69, Figure 69 and Figure 71). Previous work 
did not show much changes in monocytes number neither [122]. The same was 
observed in terms of frequencies (data not shown). The “classical” (CD14++ CD16-) and 
“inflammatory” (CD14++ CD16+) subsets were increased in terms of numbers and 
frequencies after primary vaccination (Figure 69 and Figure 71). In addition, activation 
of monocytes occurred at day 7 after primary vaccination, as shown by the up-
regulation of the activation markers CD40, CD83 and CD86 (Figure 70). This was true 
for all monocyte subsets (Figure 72). In contrast, booster vaccination did not induce 
any significant change of any monocyte populations at day 3 and failed to activate 
these cells (Figure 69, Figure 70 and Figure 71). 
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Figure 68 Representative FlowJo gating strategy for the monocytes analysis. A, Total monocytes (lineage- 
HLA-DR+) were gated on live leukocytes using forward/sideward scatter properties. Singlets were selected using 
forward/side ward scatter width/height characteristics. Monocyte subsets distribution was based on CD14 and CD16 
expression to determine classical (CD14++ CD16-), non- classical (CD14+ CD16++), and intermediate (CD14++ 
CD16+) monocytes. Lineage: CD3, CD19, CD20, CD56, FcER1. B, The indicated activation markers were analyzed 
in all monocytes subsets at baseline (BL) and day 7 after YF-17D vaccination (D7). They are represented in off-set 
overlay histograms. 
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Figure 69 Kinetics of the monocytes response to primary and booster YF-17D vaccination. A, Absolute 
number of total monocytes in healthy volunteers after primary vaccination (left panel, n = 7) and booster vaccination 
(middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue for the 
booster group (right panel). B, Absolute number of the CD16+ monocyte subset in healthy volunteers after primary 
vaccination (left panel, n = 7) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). C, Absolute number of the 
CD14+ monocyte subset in healthy volunteers after primary vaccination (left panel, n = 7) and booster vaccination 
(middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue for the 
booster group (right panel). D, Absolute number of the inflammatory CD14+CD16+ monocyte subset in healthy 
volunteers after primary vaccination (left panel, n = 7) and booster vaccination (middle panel, n = 6). The fitted 
population mean is represented in red for the priming group and in blue for the booster group (right panel). 
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Figure 70 Kinetics of activation in total monocytes in response to primary and booster YF-17D vaccination. 
A, Percentages of cells positive for CD40 within total monocytes in healthy volunteers after primary vaccination (left 
panel, n = 7) and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the 
priming group and in blue for the booster group (right panel). B, Percentages of cells positive for CD83 within total 
monocytes in healthy volunteers after primary vaccination (left panel, n = 7) and booster vaccination (middle panel, n 
= 6). The fitted population mean is represented in red for the priming group and in blue for the booster group (right 
panel). C, Percentages of cells positive for CD86 within total monocytes in healthy volunteers after primary 
vaccination (left panel, n = 7) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). 
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Figure 71 Changes of total monocytes and monocyte subsets number after primary or boost vaccination. P-
values of Wilcoxon test are indicated in the graphs. 	
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Figure 72 Kinetics of activation in monocyte subsets in response to primary and booster YF-17D 
vaccination. A, Frequencies of cells positive for the indicated markers within CD16+ monocytes in healthy 
volunteers after primary vaccination (left panel, n = 7) and booster vaccination (middle panel, n = 6). B, Frequencies 
of cells positive for the indicated markers within CD14+ monocytes in healthy volunteers after primary vaccination 
(left panel, n = 7) and booster vaccination (middle panel, n = 6). C, Frequencies of cells positive for the indicated 
markers within inflammatory CD14+ CD16+ monocytes in healthy volunteers after primary vaccination (left panel, n 
= 7) and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming 
group and in blue for the booster group. 
 
We also investigated the dynamics of dendritic cells (DCs) in the course of YF-17D 
vaccination. Total DCs did not show much changes in cell numbers both after priming 
and booster vaccination (Figure 73). The various myeloid and plasmacytoid DC 
subsets (mDC and pDC, respectively) did not show remarkable changes in terms of 
numbers but we observed a reduced number of cells at day 7 compared to baseline in 
both priming and booster groups (Figure 73). 
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Figure 73 Kinetics of the dendritic cells response to primary and booster YF-17D vaccination. A, Absolute 
number of total dendritic cells (DC) in healthy volunteers after primary vaccination (left panel, n = 7) and booster 
vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue 
for the booster group (right panel). B, Fitted population mean of absolute numbers of Cd1c mDC (left panel), 
CD141mDC (middle panel) and CD123 pDC (right panel) in healthy volunteers after primary vaccination (red line, n 
= 7) and booster vaccination (blue line, n = 6). 
 
We next analyzed natural killer cells (NK; CD56+ CD3- CD14- CD15- CD19- CD20-
FcER1-) (Figure 74). It was previously shown that YF-17D induced a robust NK cell 
response with increased expression of Ki-67 and CD69 [124]. There was no substantial 
change in NK cell numbers after primary or booster vaccination but we observed an 
opposite trend between the two groups with a slight decrease and increase, 
respectively (Figure 75A). The analysis of NK subsets also revealed opposite dynamics 
between donors from the priming and boost groups (Figure 75B and C). On one hand, 
the number of NK dim cells (CD56+ CD16+), referred to as cytotoxic NK cells, was 
moderately decreased after primary vaccination, whereas it was slightly increased after 
booster vaccination (Figure 75B). On the other hand, the number of NK bright cells 
(CD56++ CD16-), known as cytokine-secreting NK cells, was decreased after primary 
vaccination, whereas it was increased after booster vaccination (Figure 75C). As 
reported in a past study, the expression of several activation markers (4-1BB, CD69, 
Nkp44, PD-1) was increased at day 7 after primary vaccination (Figure 77) [123]. No 
increased expression of these markers was observed after booster vaccination (Figure 
77). 
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Figure 74 Representative FlowJo gating strategy for the NK cells analysis (A) Total monocytes (lineage- 
HLA-DR+) were gated on live lymphocytes using forward/sideward scatter properties. Singlets were 
selected using forward/side ward scatter width/height characteristics. Monocyte subsets distribution was 
based on CD14 and CD16 expression to determine classical (CD14++ CD16-), non- classical (CD14+ 
CD16++), and intermediate (CD14++ CD16+) monocytes. Lineage: CD3, CD19, CD20, CD56, FcER1. (B) The 
indicated activation markers were analyzed in all monocytes subsets at baseline (BL) and day 7 after YF-17D 
vaccination (D7). They are represented in off-set overlay histograms. 
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Figure 75 Kinetics of NK cells response to primary and booster YF-17D vaccination. A, Absolute number of 
total natural killer cells (NK) in healthy volunteers after primary vaccination (left panel, n = 10) and booster 
vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue 
for the booster group (right panel). B, Absolute number of bright NK cells (CD56++ CD16-) in healthy volunteers 
after primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population 
mean is represented in red for the priming group and in blue for the booster group (right panel). C, Absolute number 
of dim NK cells (CD56+ CD16+) in healthy volunteers after primary vaccination (left panel, n = 10) and booster 
vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue 
for the booster group (right panel). 
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Figure	76	Changes of total Natural killer (NK) cells and their subsets number after primary or boost 
vaccination. P-values of Wilcoxon test are indicated in the graphs. 
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Figure 77 Kinetics of activation in total NK cells in response to primary and booster YF-17D vaccination. A, 
Percentages of cells positive for 4-1BB within total NK cells in healthy volunteers after primary vaccination (left 
panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the 
priming group and in blue for the booster group (right panel). B, Percentages of cells positive for CD38 within total 
NK cells in healthy volunteers after primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n 
= 6). The fitted population mean is represented in red for the priming group and in blue for the booster group (right 
panel). C, Percentages of cells positive for Nkp44 within total NK cells in healthy volunteers after primary vaccination 
(left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red 
for the priming group and in blue for the booster group (right panel). D, Percentages of cells positive for PD1 within 
total NK cells in healthy volunteers after primary vaccination (left panel, n = 10) and booster vaccination (middle 
panel, n = 6). The fitted population mean is represented in red for the priming group and in blue for the booster 
group (right panel). 
 
	 154	
 
Figure	78	Changes in expression of the indicated activation markers in total Natural killer cells after primary 
or boost vaccination. P-values of Wilcoxon test are indicated in the graphs. 
 
The innate lymphoid cell (ILC) response has not yet been described in the context of 
YF-17D vaccination. Therefore, we looked into the dynamics of total ILCs (CD127+ 
CD3- CD14- CD15- CD19- CD20- CD33- CD34- CD203c- FcER1-, CD16-) after primary 
and booster vaccination (Figure 79). On one hand our analysis revealed that the 
number of total ILCs transiently decreased 7 days after primary vaccination (Figure 
80A). On the other hand, the number of total ILCs modestly increased after booster 
vaccination (Figure 80A, Figure 81). The dynamics of the ILC subsets also showed an 
opposite trend depending on the vaccination group. Immediately after primary 
vaccination, the number of ILC3 (c-kit+ CRTH2-) decreased transiently whereas the 
number of ILC2 (c-kit+/- CRTH2+) transiently increased (Figure 80C and D). On the 
contrary, the number of ILC3 increased shortly after booster vaccination, whereas the 
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ILC2 subset modestly decreased (Figure 80C and D). The number of ILC1 (c-kit- 
CRTH2-) did not show any particular trend neither after primary nor booster vaccination 
(Figure 80B). Despite the lack of known conventional ILC activation receptor, we 
attempted to analyze the expression of CD69 in total ILCs after primary and booster 
vaccination (Figure 79). Interestingly, we observed a sharp increase in CD69-positive 
ILCs after primary vaccination but not after a boost dose of the vaccine (Figure 82). 
 
 
Figure 79 Representative FlowJo gating strategy for the ILCs analysis. Total ILCs (lineage- CD127+ CD16-) 
were gated on live lymphocytes using forward/sideward scatter properties. Singlets were selected using forward/side 
ward scatter width/height characteristics. ILC subsets distribution was based on c-kit and CRTH2 expression to 
determine ILC1 (c-kit- CRTH2-), ILC2 (c-kit-/+ CRTH2+), and ILC3 (c-kit+ CRTH2-). Lineage: CD3, CD14, CD15, 
CD19, CD20, CD33, CD34, CD203c, FcER1. The early activation marker CD69 was analyzed in total ILCs at 
baseline (BL) and day 7 after YF-17D vaccination (D7). They are represented in off-set overlay histograms. 
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Figure 80 Kinetics of the ILC response to primary and booster YF-17D vaccination. A, Absolute number of total 
ILCs (CD127+ CD3- CD14- CD15- CD19- CD20- CD33- CD34- CD203c- FcER1-, CD16-) in healthy volunteers after 
primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population mean is 
represented in red for the priming group and in blue for the booster group (right panel). B, Absolute number of the 
ILC1 subset (c-kit- CRTH2-) in healthy volunteers after primary vaccination (left panel, n = 10) and booster 
vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue 
for the booster group (right panel). C, Absolute number of the ILC2 subset (c-kit+/- CRTH2+) in healthy volunteers 
after primary vaccination (left panel, n = 10) and booster vaccination (middle panel, n = 6). The fitted population 
mean is represented in red for the priming group and in blue for the booster group (right panel). D, Absolute number 
of the ILC3 subset (c-kit+ CRTH2-) in healthy volunteers after primary vaccination (left panel, n = 10) and booster 
vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming group and in blue 
for the booster group (right panel). 
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Figure 81 Changes of total ILCs and ILC subsets number after primary or boost vaccination. P-values of 
Wilcoxon test are indicated in the graphs. 
 
 
Figure 82 Kinetics of activation in total ILCs in response to primary and booster YF-17D vaccination. 
Percentages of cells positive for CD69 within total ILCs in healthy volunteers after primary vaccination (left panel, n 
= 10) and booster vaccination (middle panel, n = 6). The fitted population mean is represented in red for the priming 
group and in blue for the booster group (right panel). 
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The global immune response pattern is substantially reduced in booster 
compared to primary YF-17D vaccination 
 
We aimed to assess and compare the global pattern of response to primary versus 
booster YF-17D vaccination by applying principal component analysis (PCA) and 
hierarchical clustering based on the immune observations detailed above. First, we 
controlled for potential age and gender bias due to study volunteer recruitment: while 
age was not significantly different between the two groups, the gender distribution was 
biased for females (5/6) in the booster group (Figure 83). 
Comparing each immune feature between males and females at baseline, we found no 
significant gender-related bias (including no difference for the nAbs which are known to 
differ at baseline comparing priming or booster groups) (Figure 84). To further control 
for potential age-effects, we plotted each immune feature versus age and found that 
the frequency of CD38+ CD8 T cells significantly increased with age, while no other 
parameter showed age correlation (Figure 85). Since the age distribution in the two 
groups is not different we did not expect any age bias in the study either. Finally, we 
controlled each immune feature at baseline comparing the two groups and found that a 
few parameters significantly differed (Figure 86). As expected, nAbs titers were 
significantly higher at baseline in the booster group (p = 0.006). Significant differences 
were also found for the frequencies of CD38-positive CD4 T cells and CD86-positive 
monocytes (p = 0.049 and p = 0.042, respectively), which are not due to age (Figure 
84) nor gender (Figure 85) effects. 
 
 
Figure 83 Age and gender composition of individuals from the priming and booster groups. P values (Chi 
square test and Mann-Whitney test, respectively), n = 16. 
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Figure 84 Correlation between age and the various immune parameters. Pearson r and p-values are indicated 
for significant correlation, n = 16. 
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Figure 85 Comparison of the various immune parameters at baseline between male and female. None of the 
p-values (Mann-Whitey test) showed significance, n =16. 
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Figure 86 Comparison of the various immune parameters at baseline between priming and boost groups. P-
values (Mann-Whitney test) are indicated for each comparison, n = 16. 
 
Using a hierarchical clustering algorithm, we interrogated the relatedness of 37 immune 
features. This analysis was based on the frequencies and absolute counts from the 
flow cytometry data, the viral load, and the neutralizing antibody titers. We found 4 
main clusters that reflected varying kinetics (Figure 87A) particularly in the priming 
group: i) early events peaking at day 7 such as monocyte, NK and CD4 T cell 
activation, together with CD69 in CD8 T cells (early clusters 1 and 2), followed by ii) 
events peaking at day 14 to 28 (cluster 3: adaptive activation in B and CD8 T cells and 
nAbs), and iii) events that drop at day 7 (B, CD4 and CD8 T cells in cluster 4). The 
resulting heatmap clearly illustrates that the pattern of immune reactivity is globally 
distinct in priming versus the booster vaccination, with the large majority of immune 
features peaking or dropping in priming but not in booster vaccination. We further 
performed a multidimensional scaling of all parameters to underline the differences 
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between the two vaccination groups and observed that i) the two groups cluster 
separately, and ii) it is particularly the day 7 and day 14 time-points upon priming which 
are isolated from each other and all the remaining samples (Figure 87B).  
 
Altogether, the global pattern of immune responses is clearly distinct following primary 
and booster vaccination. While the innate and adaptive responses are robustly 
mobilized at day 7 and/or 14 after primary vaccination, the magnitude of the response 
is minor after booster vaccination. 
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Figure 87 Global comparison of the flow cytometry data, viral load, and neutralizing antibody titers between 
primary and booster vaccination. A, heatmap based on median expression of the indicated markers. B. PCA 
analysis based on the expression of the same markers. 
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3.2.1.3 Discussion 
Characterization of all major immune cell populations following primary and 
booster YF-17D vaccination 
 
To our knowledge, our YF2 study is the first to compare longitudinally and side-by-side 
the innate and adaptive parameters (including viral load and neutralizing antibodies) 
after primary and booster YF-17D vaccination. As stated throughout the results, our 
work generally confirmed previous data revealed by several individual studies. 
For instance, we validated a reduced antibody response to revaccination compared to 
primary vaccination [98] [99] [208] [209]. Furthermore, our study allowed us to reveal 
that the maximal nAbs titers is reached faster after booster than priming (day 14 vs. 
day 28) (Figure 50A and B). This is corroborated by the timing of B cell activation 
(Figure 53). However, we could not reproduce the correlation between BCMA 
expression at day 7 and the magnitude of nAbs titers after YF-17D priming [113]. This 
could be explained by the type of sample analyzed. Querec and colleagues analyzed 
the genomic signature of the TNFRSF17 gene (encoding BCMA) by RT-PCR, whereas 
we measured the surface expression of BCMA protein level by flow cytometry. 
 
No previous study assessed the viral load after booster vaccination with YF-17D. We 
found no detectable virus in re-vaccinees (Figure 55B). However, it is questionable 
whether the virus could not replicate or the load was simply below our detection limit. 
For instance, it is surprising that 4 out of 10 individuals from the priming group showed 
no viral copies (Figure 55A). Nevertheless, these donors showed a diminished 
activation as quantified by the frequency of CD38-positive CD8 T cells. This 
relationship was highlighted by the positive correlation between viral load and the 
frequency of activated CD8 T cells (Figure 59). 
 
The magnitude and timing of the total CD4 and CD8 T cell responses are in 
accordance with previous studies [112] [120] [122]. The T cell drop was already 
mentioned by Kohler and colleagues but has not been further investigated [122]. We 
found a correlation between the T cell drop and CD69 expression at baseline (Figure 
66). Studies on CD4 T cells in mice suggested that CD69 expression promotes T cell 
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retention in the lymph nodes by downregulating the migratory response to S1P1 and 
that the modulation of CD69 expression is important for the migration of naïve CD4 T 
cells [231]. In addition, we showed that the T cell drop precedes the activation of T cells 
and the increase of antigen-specific CD8 T cells. Therefore, we hypothesize that these 
cells disappear from the periphery to migrate to lymph nodes for activation. However, 
antigen-specific CD8 T cells still increased significantly in the booster group although 
no T cell drop is observed. It would be interesting to further investigate into this 
mechanism. In addition to the retention marker CD69, we could analyze the adhesion 
markers CD62L and LFA-1, which allow to bind and enter the lymph node [232]. 
 
We analyzed the antigen-specific CD8 T cell response using the epitope A2/LLW 
because it is an immunodominant epitope and HLA-A*0201 is a prevalent allele in the 
Caucasian population [118] [140]. Other CD8 epitopes were described in the literature 
with other HLA-restriction [99] [117] [118] [233]. The kinetics and activation of A2/LLW-
specific CD8 T cells are consistent across other YFV specificities. We did not address 
antigen-specific CD4 responses during my PhD thesis but we are planning to monitor 
the antigen-specific CD4 response following YF-17D vaccination in the near future. 
Two screenings identified CD4 epitopes [117] [234] [235]. Based on these and on the 
HLA typing of our donors, we selected some epitopes to be tested for immunogenicity. 
The epitopes giving the strongest response will be used for tetramer production. Of 
note, MHC Class II tetramers are more difficult to produce but scientists on site are 
experienced and already produced successfully such molecules. We intend to 
investigate the kinetics, subset distribution and activation of these cells. In particular, 
we would like to find out whether a population of antigen-specific SCM CD4 T cells is 
induced upon YF-17D vaccination. 
 
In contrast to total CD8 T cells, we found that A2/LLW-specific CD8 T cells are 
activated at the same level by both primary and booster vaccination. However, we 
observed that the proliferation of these cells was lower after booster compared to 
primary vaccination, resulting in a lower magnitude of the A2/LLW-specific response. 
 
Concerning the innate response, we did not find an overall decrease in the frequency 
of NK cells as previously published [123]. This could be explained by the variability 
among the donors of NK cells at baseline and their dynamics. We confirmed the 
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expansion and activation of monocytes at day 7 after primary vaccination [123]. We did 
not observe the increase of mDC numbers at day 7 as determined by Kohler and 
colleagues [122]. In this study however, mDCs are defined as CD11c+ HLA-DR+ CD45+ 
CD19- CD14- CD56- BDCA-2-. CD16+ cells are not excluded from these cells. 
Therefore, it may be possible that the increase in mDCs that is described in this study 
can be imputed to the increase of monocytes. Indeed, we observed an increase in total 
monocytes and in particular in CD16+ monocytes. 
For the first time, ILCs were investigated in the context of YF-17D vaccination. As the 
ILC3 was the only subset to show a drop after primary vaccination, it indicates that they 
are implicated in the response to the vaccine. We used CD69 as a potential activation 
marker although activation of ILCs is conventionally monitored by cytokine production. 
 
Overall, our longitudinal study revealed the systemic and detailed dynamics of the 
immune response following YF-17D vaccination in humans.  
 
Comparison between primary and booster YF-17D vaccination 
 
The YF2 study allowed us to compare side-by side and in detail the innate and 
adaptive parameters after priming and boosting with YF-17D. We addressed the 
underlying questions: 
 
i) What is the difference in the dynamics, proportions and profiles of the major cellular 
populations upon priming versus booster vaccination? To what extent are the innate 
and adaptive components mobilized upon boosting and can we observe and study 
prominent recall responses? 
Our YF2 longitudinal study of primary and booster responses to YF-17D vaccination 
offers a unique opportunity to analyze human immune responses during an acute viral 
infection in a controlled experimental system (knowing the exact time of antigen 
exposure). To our knowledge, the study we report is the first to globally compare 
primary and booster vaccinations side-by-side, including specific adaptive and innate 
features in parallel to nAb titers and viral load. 
As expected, at baseline, all the booster individuals showed detectable levels of nAbs 
(induced by their first vaccination 10 years prior), while primary vaccinees had no 
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detectable nAbs. We confirmed the observations in previous studies showing that YF-
17D booster vaccination induces a limited further increase in nAbs, compared to the 
strong induction of nAbs upon primary vaccination [98] [99] [208] [209]. 
Following primary vaccine injection, the live-attenuated virus replicated with a peak of 
viremia detectable in circulating blood within the first 10 days for most of the donors. In 
contrast, no viral copy could be detected upon revaccination. 
Regarding the cellular responses, our work and prior studies have shown that booster 
dose of YF-17D does not substantially re-activate the immune system [98] [99] [236]. 
We observed a modest adaptive response (CD8, CD4, B cells). Only the A2/NS4b-
specific CD8 T cells showed high reactivation frequencies, while showing no profound 
amplification in terms of relative or absolute total A2/NS4b-specific CD8 T cells counts. 
The innate response in the booster vaccination was not substantially triggered neither. 
We faced some limitations that are inherent to human studies. For instance, accessible 
biomaterial is primarily limited to blood samples and to the secondary lymphoid organs 
or the skin. Another drawback is that we were limited in terms of frequency and amount 
of blood sampling in our volunteers (based on the volumes per period of time that are 
allowed for standard blood donations). Therefore, we analyzed few and specific time-
points, providing snapshots of the response. 
 
ii) What is the impact of pre-existing antibodies on the recall responses? 
Titers of neutralizing antibodies (nAbs) are commonly examined as the most 
appropriate surrogate marker of protection. In mice, it is now clear that the presence of 
nAbs correlate with efficient protection against viral reinfection. Numerous studies on 
mouse models established that the residual titers of antibodies present at time of 
secondary infection and the amount of antigen expressed influence the strength of the 
immune response [237] [238]. Whether this relationship holds true in humans remains 
an essential question. 
 
By comparing the nAbs titers versus viremia, we found direct relationship between the 
absence of detectable viral copies after booster vaccination and pre-existing positive 
nAbs titers, as we could not detect any viral copies in the sera of booster vaccinees. 
These observations provide supporting evidence to the hypothesis that pre-existing 
humoral immunity to the virus limits replication of the YF-17D vaccine virus. Therefore, 
the dichotomy between primary and secondary vaccination can be explained by the 
	 168	
presence of pre-existing nAbs, which rapidly shield the virus. Consequently, the virus 
fails to massively replicate and cellular responses are weakly primed. 
In conclusion, our data indicate that the presence of pre-existing nAbs curtails viral 
replication and therefore might diminish the subsequent reactivity and magnitude of 
innate and adaptive immune responses after revaccination. 
 
iii) Is there a need for a booster dose after 10 years? 
Until recently, the World Health Organization (WHO) recommended a booster dose of 
the YF-17D vaccine. However, in 2013, the Strategic Advisory Group of Experts 
(SAGE) workgroup of the WHO proposed that revaccination every 10 years is not 
necessary and considered that a single dose of YF-17D provides life-long protection in 
healthy individuals [239]. 
 
The change in vaccination strategy stipulated by the WHO has elicited debate because 
there is limited clinical evidence on the incidence of YFV infections in vaccinated 
individuals, as it is not ethically possible to study YFV vaccine efficacy in humans. 
Antibodies are conventionally examined as the most appropriate surrogate correlate of 
protection, although innate and cellular adaptive immunity may contribute to sustaining 
the immune memory to YF-17D vaccination [240]. 
 
The humoral immunological response to a booster dose of the YF-17D vaccine has 
been addressed by several studies. Early studies from the ‘60s suggested that the 
magnitude of nAbs titers induced by booster vaccination was reduced compared to 
primary vaccination [208] [241]. Several studies highlighted the importance of the pre-
booster serology, indicating that booster vaccination did not provide additional benefit if 
the primary vaccination was effective [98] [99] [209]. The impact of pre-vaccination 
serology on the outcome of YF-17D booster vaccination has been shown in that 
individuals with low titers had a strong humoral response to booster vaccination, 
whereas donors with high pre-vaccination titers did not increase their nAbs titers [96]. 
This latter observation has also been reported for vaccination with attenuated measles 
[242].  
Regarding the cellular responses, our work and prior studies have shown that booster 
dose of YF-17D does not substantially re-activate the immune system [98] [99] [236]. 
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We observed a modest response for CD8, CD4, B cells as well as the innate 
compartment at selected time-points in the blood. 
 
In addition to the response to boost, it is important to consider the duration of immunity 
after primary immunization. Several studies assessed the long-term protection induced 
by primary YF-17D vaccination. Although the nAbs titers decrease with time, these 
studies showed that nAbs titers persist at protective level in most individuals (74.5-
100%) [92] [94] [95] [121] [208] [209] [243]–[245]. 
Our YF2 study examined the response only until 6 months after vaccination. However, 
a previous study conducted by our laboratory showed that LLW-specific SCM CD8 T 
cells are detected several decades after primary vaccination with YF-17D [97]. These 
cells were fully functional and showed IL-15-driven homeostatic proliferation [97]. 
 
Despite the accumulating amount of evidence in favor of the WHO’s decision, endemic 
countries do not follow this recommendation. For instance, the Brazilian national 
immunization policy guidelines still recommend a booster dose 10 years after primary 
YF-17D vaccination. The different conclusions drawn by the Brazilian authorities 
cannot be imputed to the different vaccine strains used (YF-17DD instead of YF-17D-
204) as it presents only subtle nucleotide differences and similar immunogenicity [246].  
Critically, Brazil has suffered recent massive outbreaks of Yellow Fever [247] [248]. 
The YFV has been extending from the previously known endemic area (Amazon 
region) into Southern and Southeastern regions in Brazil. Between December 2016 
and July 2017, 777 cases of YF disease were confirmed leading to 261 deaths [248]. 
The Brazilian authorities rely on a study conducted in Brazil concluding that a booster 
dose is recommended as they found that nAbs titers decrease with time [101]. In 
addition, this decision is supported by a study on the duration of immunity in individuals 
living in endemic (Africa) or non-endemic areas (Switzerland) suggesting that endemic 
African populations might need a booster dose to achieve efficient immunity [249].  
 
Here we report that a booster dose of the YF-17D vaccine in 6 healthy volunteers living 
in a non-endemic area (Switzerland) induces only modest increase in nAbs titers. In 
addition, compared to the robust global immune reaction upon priming, only few of the 
37 innate or adaptive features (36 features in parallel to viremia) studied were slightly 
activated after booster vaccination. In spite of the limited number of individuals in our 
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study, our readouts provide evidence in support of the reduced magnitude and strength 
of the response conferred by booster YF-17D vaccination for already seropositive 
adults living in non-endemic areas. Our YF2 study spans up to 6 months after re-
vaccination, but it would be interesting to have more long-term samples to monitor the 
duration of the secondary response in terms of persistence of neutralizing antibodies. 
Also, as already mentioned above, we cannot assess the protective efficacy of the 
vaccine. 
 
It is important to emphasize the fact that our report only provides immunological data 
for the discussion as to whether a booster dose is needed after 10 years. Furthermore, 
one major limitation of our study is the small size of our cohort (n= 6 in boost group), 
especially given the heterogeneity observed in humans. Other perspectives need to be 
taken into consideration: epidemiology, public health (including risk/benefit), financial, 
and operational aspects.  
 
Identification of key determinants of immunogenicity 
 
The correlations that I presented above are based on conventional analytical 
strategies. This approach is not only labor intensive but also highly subjective. Given 
the large number of possible pairs of parameters to analyze, we might neglect 
information present in the data that is not visible at first sight and clearly give a 
direction to the analysis. This obstacle could be overcome by unsupervised learning 
algorithms enabling the identification of patterns that have not been previously 
considered [250]. An additional bias in our study comes from the limitation of the 
number of markers and their selection based on the literature. Nevertheless, flow 
cytometry remains a powerful tool for singe-cell analysis at the cellular level.  
 
Given the tremendous high number of parameters to consider in the YF2 study (several 
markers in various cell types and their subsets at 7 time-points, both frequencies and 
absolute numbers), it is not advisable to analyze their correlation “by hand”. We 
therefore received assistance from a bioinformatician to perform a global network 
analysis comprising all the analyzed parameters. Dr. Sina Nassiri performed the FDA 
and global network correlation analysis. In FDA, discrete observations are viewed as 
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noisy realizations of an underlying function over time. By treating the entire sequence 
of observations as a single functional entity, FDA directly utilizes the temporal structure 
and potential dependence of measurements to borrow information across observations.  
My main contribution was to explain and translate our biological questions so that they 
could be modeled bioinformatically. Dr. Silvia-Fuertes-Marraco and I are currently 
interpreting the data. 
 
As discussed later (cf 4. Ongoing work and Perspectives), we are planning to analyze 
YF2 blood samples by single-cell RNA Sequencing, which will allow to analyze the 
whole transcriptome. The increased complexity of the resulting data will be analyzed by 
an unsupervised algorithm. 
 
3.2.1.3 Contributions 
 
Dr. Silvia Fuertes-Marraco and I designed the flow cytometry panels. I performed and 
analyzed the flow cytometry data. The viral load was measured by the group of Benton 
Lawson (Emory Center, Atlanta USA). The nAbs titers were quantified by Dr. Rama 
Akondy (Emory Center). Dr. Sina Nassiri performed the FDA and global network 
correlation analysis. I am preparing a manuscript entitled “Restricted adaptive and 
innate immune responses to Yellow Fever virus YF-17D vaccination in individuals with 
pre-existing neutralizing antibodies” with the essential contribution of Dr. Silvia Fuertes 
and Prof. Daniel Speiser. 
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3.2.2 Analysis of A2/LLW-specific effector and long-lasting memory CD8 T cells 
in the early response to YF-17D (aim c) 
3.2.2.1 Background 
 
The most recently and newly described subset of memory T cells is termed stem cell-
like memory T cells (SCM) and has brought major fascination and promise in T cell-
based therapies relying on long-lasting memory cells [52] [97] [173] [174] [251]–[256]. 
Constituting 2-4% of total CD4 and CD8 T cells in the periphery [52], SCM cells 
express CCR7 and CD45RA like Naïve cells (they are sometimes referred to as 
“Naïve-like” since they express most classically naïve markers) but distinctly (in 
contrast to Naïve) also express high levels of CXCR3, CD95, CD58, CD11a, IL-2β and 
LFA-1 [52] [257]. They embrace the capacity of both IL-7- and IL-15-driven homeostatic 
proliferation and highest progeny potential, with the capacity to regenerate (self-
renewal) and generate multiple memory and effector subsets. They are considered as 
the longest lasting memory T cell subset. Amongst others, our group has shown that 
they exhibit a gene expression profile which is between naïve and CM cells [52] [97]. 
TCR rearrangement excision circles analysis indicate that SCM have undergone 
several steps of division [52]. SCM T cells are antigen-experienced and can secrete 
various cytokines (TNFα, IFNγ, IL-2) [52]. Antigen-specific SCM cells have been 
identified for CMV, Flu, HIV, EBV, HCV, YFV and melanoma [52] [97] [251]–[255]. Our 
group identified SCM induced by YF-17D that last for decades [97]. However, this first 
clinical study did not cover the early, acute response, which occurs within the first few 
weeks (peaking at 2 weeks). The YF2 study thus allows us to analyze the distribution 
and dynamics of human CD8 T cell subsets in the early acute response to YF-17D 
vaccination. 
This project was mainly led by my supervisor Dr. Silvia Fuertes and only the data I 
contributed to produce is presented below. The project is detailed in a manuscript in 
preparation in Appendix 3. 
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3.2.2.2 Results 
A2/LLW-specific SCM CD8 T cells appear early after priming with YF-17D 
vaccination 
 
The frequencies of the various A2/LLW-specific subsets were determined by flow 
cytometry following primary YF-17D vaccination (Figure 88A). While the naïve 
compartment remained fairly stable over time, memory cells (CM and SCM) appeared 
and expanded along with effector cells (EM and EMRA) (Figure 88B). After the peak of 
the response, effector cells entered a phase of contraction. To a lesser extent, the 
frequency of memory cells also gradually decreased (Figure 88B). After 6 months, it 
became obvious that EMRA and SCM persist while EM and CM kept contracting 
(Figure 88B). 
 
 
Figure 88 Analysis of A2/LLW-specific CD8 T cells subsets after YF-17D vaccination. A, Representative gating 
strategy to define CD8 T cell subsets: Central memory (CM: CCR+ CD45RA-), Effector memory (EM: CCR7-, 
CD45RA-), Effector memory CD45RA+ (EMRA: CCR7- CD45RA+), CCR7+ CD45RA+ cells are further subdivided 
into Naïve (CD95-) and stem cell-like( (SCM: CD95+). B, Frequency of total or subsets of A2/LLW-specific CD8 T 
cells. The lines represent the average and standard error of the mean (n = 8) per subset as indicated; viral load data 
is complemented (right y-axis). 
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A2/LLW-specific SCM CD8 T cells are activated at the peak of the response 
 
Next, we analyzed the expression of activation markers (CD69, CD38, HLA-DR and 
PD1) among the CD8 differentiation subsets. While CD69 expression was increased 
between day 3 and 7 after vaccination, it was evident that all other activation markers 
were up regulated at the peak of the response in memory subsets (CM and SCM), at 
the same level as the effector subsets (EM and EMRA) (Figure 89). 
 
 
Figure 89 Activation of A2/LLW-specific CD8 T cells subsets at day 14 after YF-17D vaccination. Flow 
cytometry profiles showing each activation marker and subset, as indicated. Total CD8 T cells are shown as a 
reference. Data come from one representative donor. 
 
SCM CD8 T cells retain proximity to the Naïve baseline during YF-17D 
vaccination 
 
In order to visualize globally the dynamics of CD8 T cell differentiation, we applied 
multidimensionality reduction and t-stochastic neighbor embedding (tSNE) to the flow 
cytometry. tSNE analysis comprising 9 differentiation and activation markers was ran 
individually on 7 donors, 2 out which are shown in Figure 90 (cf 6. Material and 
Methods). The differentiation subsets were gated “classically” based on the expression 
of CCR7, CD45RA and CD95 in order to identify them in the tSNE plots. 
We observed that the SCM subset appeared and remained very close to the location of 
baseline Naïve cells. In contrast, effector populations burst out of the baseline Naïve 
location, peaking their distance at day 14, and gradually contracting closer to baseline. 
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Figure 90 individual tSNE plots of two selected donors (LAU5089 and LAU5096).  
 
3.2.2.3 Discussion 
 
Thanks to our study, we substantiate the early appearance of SCM CD8 T cells. YFV-
specific CD8 T memory cells including CM and SCM subsets are activated and expand 
along with the other effector subsets at the peak of the response. Our results preclude 
that memory subsets appear only after the acute peak. It suggests that memory cells 
establish early after priming. Our data indicate that memory arises very early without 
transition through an effector stage. Within a continuum of differentiation phenotypes, 
long-term memory cells persist by preserving highest “naïveness”. 
Our results support models where memory CD8 T cells originate from activated CD8 T 
cells in parallel to the wave of effectors [258] [259]. The ontogeny of memory cells is a 
subject of intense debate, with recent studies supporting contrasting models. This is 
further discussed in Appendix 3.  
 
3.2.2.4 Contributions 
 
Dr. Silvia Fuertes-Marraco and I performed and analyzed the flow cytometry data, 
combining specimens from the YF1 and YF2 cohorts. Dr. Silvia Fuertes  synthesized 
the data for the manuscript in preparation entitled “Human stem cell-like memory CD8 
T cells establish early in the acute response to Yellow Fever virus vaccination” 
(Appendix 3). 
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4. ONGOING WORK AND PERSPECTIVES 
 
In humans, vaccines that are routinely administered provide an ethical way to perturb 
the immune system in a precise and controlled setting. The exact moment of 
immunization is known and it is possible to collect blood samples early and long-term in 
order to study both the innate and adaptive responses. The YF-17D vaccine offers a 
unique opportunity to study the mechanisms of a persistent and powerful immune 
response. Indeed, it has been administered to over 600 million people worldwide with 
rare cases of severe adverse events. Individuals in non-endemic countries have not 
been exposed to Yellow fever, therefore it allows to characterize primary viral 
challenge. This live-attenuated vaccine results in a systemic acute viral infection within 
a few days. A single dose is sufficient to induce nAbs that persist for several decades 
and, remarkably, generates a broad and robust CD8 T cell response. The later is 
particularly of interest as a model to sustain the optimization of cancer 
immunotherapies that rely on the induction of strong cytotoxic responses. 
 
Although the YF-17D vaccine is in use for almost 80 years, the mechanisms leading to 
such a successful immunogenicity remain partially unknown. This thesis provides an 
initial broad insight into the key immune components that are mobilized following 
vaccination against YFV with YF-17D in humans. 
 
In the first part of my thesis, I characterized the genetic and structural basis of the high 
frequency and prevalence of the immunodominant HLA-A*02- restricted YFV-specific 
epitope A2/LLW, in analogy to the immunodominance of the HLA-A*02-restricted 
Melan-A epitope A2/ELA in melanoma. We described the TRAV12-2 bias in A2/LLW-
specific CD8 T cells with functional and structural considerations of the TCR:pMHC 
interaction. The TCR sequences obtained during the first part of my thesis were limited 
to either CD8 T cell clones or T cell lines. However, the data presented in this thesis is 
wired within the scope of a broader characterization of the immune responses following 
YF-17D vaccination. The YF2 study blood specimens used in the second part of my 
thesis will be used further for in depth investigations thanks to recently available 
technologies, outlined below.  
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Single cell genome-wide analysis of A2/LLW-specific clonotypes during YF17D 
vaccination  
 
We aim to analyze directly ex vivo the clonotypes before and during vaccination, 
including several differentiation subsets, at the single cell level. In collaboration with the 
group of Prof. Sarah Teichmann (Cambridge, UK), we are currently analyzing the 
whole transcriptome of A2/LLW-specific CD8 T cells by single-cell RNA sequencing 
(scRNA-seq). This group developed the TraCeR (T cell receptor sequence 
Reconstruction) technology, which enables the reconstruction of full-length αβ paired 
TCR sequences and therefore to track individual clonotypes during the course of 
differentiation [260] [261]. 
In setup experiments, we first made sure that the quality of the data generated from 
frozen material (instead of fresh material) was suitable in order to reconstruct TCR 
sequences by TraCeR. Then, based on the quality of the response, the detectability of 
the CD8 T subsets and the availability of samples within our YF biobank, we selected 
four individuals from the priming group. We chose 5 out of 7 time-points (BL, D14, D28, 
M3, M6), without time-points D3 and D7 because our estimates on sorting yields did 
not calculate that sufficient events would be possibly sorted from D3 and D7. Single 
cells were directly sorted into plates containing lysis buffer. We isolated around 100 
cells per time-point from naïve-like (CCR7+ CD45RA+), effectors (CCR7-), and CM 
(when possible) (CCR7+ CD45RA-). The data passed the quality check and is currently 
analyzed by our collaborator Dr. Santiago Carmona (Dept. of Oncology, CHUV) and 
our teammate Dr. Sina Nassiri (Swiss Institute of Bioinfomatics & Dept. of Oncology, 
CHUV). 
Given that the TCR sequence is a unique identity of each T cell clone, longitudinal 
analyses of TCR sequences may reveal the clonality of the various T cell populations in 
order to delineate the relationships between various differentiation subsets, with 
particular interest in the genealogy of SCM cells. 
 
Some studies on YF-17D vaccination included systems biology approaches such as 
microarrays of PBMCs [112] [113]. However, they were limited in terms of gene 
expression information and protein data. Importantly, these studies were lacking the 
resolution of the different immune cell populations. Nowadays, technologies have 
improved and provide precious information on isolated leukocyte populations and also 
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at the single cell level. Overall, our goal is to obtain a deeper knowledge of the global 
and regulatory landscape of each CD8 T cell subsets. In contrast to flow cytometry, 
where several bias are introduced (as discussed in 3.2.1.3), the scRNASeq technique 
will allow having an unsupervised analysis of a myriad of parameters and potentially 
identifying unexpected phenomena. 
 
Proteomic analyses of adaptive and innate populations by MS-SWATH 
proteomics 
 
We collaborate with the group of Prof. Ruedi Aebersold (Zürich, Switzerland) with the 
aim to characterize by cutting-edge proteomics the global immune components in the 
blood using the technology developed in their lab called Sequential Window Acquisition 
of all Theoretical Mass Spectra (SWATH-MS) [262]. It is a data independent acquisition 
method that combines the advantages of both shotgun and Selected Reaction 
Monitoring methods: i) high throughput data acquisition is easy, ii) the protein and 
peptide detection/multiplexing is broad, iii) the reproducibility of data is high. In addition, 
SWATH-MS allows retrospective targeting. 
We set-up the protocol to FACS-sort and analyze by MS-SWATH the proteome of total 
PBMC and 5 different immune populations: CD4 T cells, CD8 T cells, B cells, NK cells 
and monocytes. We are planning to analyze all individuals from both vaccination 
groups and all time-points. After optimization of the sorting protocol, reference libraries 
for each population have been generated based on 200’000 cells from two donors. In 
addition, we confirmed that 25’000 cells of each population gives enough sensitivity for 
further investigation by SWATH-MS. 
 
Analysis of soluble immunomodulators by multiplex on plasma 
 
While PBMC fractions predominate as the specimens of research in YF-17D 
vaccinology, a few studies also make use of plasma [263] [264]. In order to monitor 
parameters indicative of vaccine efficacy, we quantified neutralizing antibodies and 
viral titers in plasma. Alongside, we will analyze soluble immunomodulators by 
multiplex immunoassays on plasma samples to detect cytokines, chemokines, growth 
factors and soluble receptors. For this analysis, however, we have not yet decided 
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what particular multiplex assay or kit we will use, we hope to find an affordable and 
sensitive assay that includes a maximally broad panel of soluble modulators.  
 
 
Broad correlation analysis across complementary datasets   
 
Subsequently we will merge the data obtained from the aforementioned methods to 
seek the identification of determinants underlying the immune response elicited by YF-
17D vaccination. For quantifying immunogenicity, we will establish scores that include 
immune events such as (i) activation of the innate arm with mechanisms dedicated to 
anti-viral antigen cross-presentation, (ii) titers of nAbs (B cell arm), (iii) development of 
plasmablasts, (iv) frequency and polyfunctionality of YFV-specific T cells, and (v) 
differentiation of T cells and long-lasting stem cell-like memory (SCM) T cells. 
Based on the data gathered by comprehensive methods, immunogenicity scores will 
then be interrogated for correlation to immune determinants. Taken together, we 
expect to obtain high resolution of the immune response to YF-17D and better define 
correlates of optimal immunogenicity, and test whether these may potentially predict 
specific immunogenicity. 
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5. CONCLUDING REMARKS 
 
Globally, my PhD thesis integrates both the analysis of specific immune interactions 
and multiple –omics approaches. Such high-throughput technologies generate 
enormous amount of data. Thus, we are facing the challenge to analyze and interpret 
the data. For instance, the flow cytometry data were analyzed for correlations and 
multiple hits were identified. However, it takes time to make “biological sense” of these 
individual significant correlations. Rather, we should focus on group of parameters and 
molecular signatures that correlate with and predict vaccine efficacy. 
 
In conclusion, studying immune responses to YF-17D vaccination provides important 
insights into the determinants leading to a potent immune response. To our knowledge, 
the YF2 study is the first that compares in detail primary and booster vaccinations side-
by-side, including the global and specific adaptive and innate parameters in parallel to 
nAbs and viral load. With our work, we aim to identify correlates of optimal 
immunogenicity, and test whether these may potentially predict specific 
immunogenicity. This knowledge can be further applied not only to other viral vaccines 
but also to cancer immunotherapies and immune-related diseases. 
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6. MATERIAL AND METHODS 
6.1 Clinical studies: design, population and ethics statement 
 
Peripheral blood mononuclear cells (PBMCs) were obtained in the framework of two 
clinical studies, approved by the Human Research Ethics Committee of the Canton de 
Vaud with healthy volunteers participating under written informed consent. Eligible 
volunteers donated blood according to the standards of the Blood Transfusion Center 
(Service Vaudois de Transfusion Sanguine). 
The first clinical study, “YF1” (protocol 329/12), was cross-sectional and open to 
healthy volunteers aged 18 to 65 years having received the YF-17D vaccine (Stamaril, 
Sanofi Pasteur) with no limit on minimum or maximum vaccination history. The cohort 
consisted of 41 healthy volunteers vaccinated with YF-17D, between 3 months and 35 
years ago, including four individuals having received multiple vaccines. Samples from 
unvaccinated blood donors were also obtained from the Blood Transfusion Center. 
The second clinical study, “YF2” (protocol 324/13), was longitudinal. The study 
population consisted of two groups of healthy volunteers aged 18 to 65 years, who for 
traveling purposes were about to receive the YF-17D vaccine (Stamaril, Sanofi 
Pasteur). One group received the vaccine for the first time (“priming”, n = 10). The 
second group had previously received the YF-17D vaccine < 10 years ago (“boost”, n = 
6). PBMCs, complete blood counts, and sera were obtained before vaccination at 
various time points following vaccination: days 3, 7, 14, 28 ± 2 days, months 3 ± 2 
weeks and 6 ± 2 weeks. 
 
6.2 Biobank: Peripheral blood collection and processing 
 
Peripheral blood samples were collected and immediately processed for 
cryopreservation awaiting experimental use. PBMCs were obtained from anti-
coagulated whole blood diluted 1:1 in phosphate buffered saline (PBS) and overlaid on 
Lymphoprep for density gradient fractionation (30 minutes at 400g without break) and 
were cryopreserved in complete RPMI 1640 supplemented with 40% fetal calf serum 
(FCS) and 10% dimethyl sulfoxide. Plasma samples were obtained from the 
supernatant of EDTA-coated blood tubes after centrifugation at 1’000g for 15 min at RT 
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followed by a second centrifugation at 8’000g for 10 minutes at 4°C, and preserved at -
80oC. 
 
6.3 Viral load quantification 
 
Yellow Fever virus (YFV) load was quantified in plasma from EDTA-anti-coagulated 
blood based on a Taqman Real-time PCR assay to detect YFV genome copies as 
previously described, performed by our collaborator Dr. Benton Lawson in the Center 
For AIDS Research in Emory University (U.S.A.)  [119]. 
 
6.4 Plaque reduction neutralizing test (PRNT) 
 
Plasma samples were analyzed for YFV neutralizing antibodies by a PRNT, performed 
by our collaborator Dr. Rama Akondy in Emory University (U.S.A.). Briefly, plasma was 
heated to 56 °C for 30 minutes to inactivate complement. Various dilutions of the 
plasma were incubated overnight at 4 °C with 200 plaque-forming units of YFV-17D. 
Vero cell monolayers in drained six-well plates were incubated with this virus-plasma 
mixture for 1 hour at 37 °C. The wells were overlaid with a mix of agarose and 2XM199 
medium and plaques counted 3–4 days later using neutral red. 
6.5 Generation and maintenance of T cell clones 
 
All A2/LLW-specific CD8+ T cell clones were generated in the laboratory of Prof. D. 
Speiser by Dr. Silvia Fuertes and Nicole Montandon, from healthy YF-17D (Stamaril, 
Sanofi Pasteur) vaccinees. Purified A2/LLW tetramer-positive populations were 
isolated by FACS as described [97] and cloned by limiting dilution in Terasaki plates, 
cultured in RPMI 1640 medium supplemented with 8% human serum and 150 U/ml 
recombinant human IL-2 (rIL-2). Thereafter, to maintain and expand T cell clones, 
periodic restimulation was done with 1 µg/ml PHA and 106/ml irradiated allogeneic 
PBMC (30 Gy) as feeder cells. The MEL5 clone was generated in the laboratory of A. 
Sewell as previously described [135]. The clones HD421 2/5F and LAU1264 were 
generated in the laboratories of D. Speiser and N. Rufer as previously described [133]. 
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6.6 Generation of T cell lines 
 
To create T cell lines, PBMCs were cultured in priming medium (R10 with 10 mM 
HEPES buffer, 13 MEM nonessential amino acids, 1 mM sodium pyruvate [all from Life 
Technologies], and 20 IU/ml IL-2 (Proleukin; Prometheus, San Diego, CA) with 10-5M 
LLWNGPMAV peptide and anti-human CD28 Ab (10 mg/ml) for 14 days. 
 
6.7 TCR repertoire and clonotype analysis in A2/LLW-specific CD8+ T cell 
clones 
 
Total RNA was isolated using the PicoPure RNA kit per manufacturer’s instructions, 
and cDNA prepared and sequenced as previously described [129]. Briefly, for the Vβ 
repertoire, each cDNA sample was subjected to individual PCRs using a set of 
previously validated forward primers specific for the 22 TRBV subfamilies and one 
reverse primer specific for the corresponding Cβ gene segment. For the Vα repertoire, 
we amplified and sequenced the TRAV12-2 segment using the TRAV12 (forward) and 
TRAC (reverse) primers. PCR amplicons of interest were sequenced from the reverse 
primer by Fasteris S.A. TRAV and TRBV segments were described according to the 
IMGT nomenclature [265]. 
 
6.8 TCR sequencing and analysis of the A2/LLW-specific T cell line 
 
RNAwas extracted using an RNeasy PlusMicro Kit (QIAGEN), following the 
manufacturer’s instructions. The SMARTer RACE kit (Clontech, Paris, France) was 
used to generate full-length cDNA from TCR RNA, also following the manufacturer’s 
instructions. Two sets of primers (external and internal) were designed to perform a 
nested PCR of the CDR3 region of the TCR alpha and beta genes. The PCR products 
were examined by agarose gel electrophoresis and purified by gel extraction before 
sample indexing. All samples were processed further to generate libraries for high-
throughput Illumina sequencing. Libraries were processed with the NEBNext Ultra 
Library preparation kit (New England Biolabs, Cambridge, U.K.) and run on an Illumina 
MiSeq instrument using a MiSeq v2 reagent kit (Illumina, Cambridge, U.K.). TCR gene 
usage was determined using reference sequences from the ImMunoGeneTics 
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database (http://www.imgt.org), and all TCR gene segments were designated 
according to ImMunoGeneTics nomenclature using MiXCR software (v1.8.1). 
 
6.9 51Chromium release assays 
 
The HLA-A*02+ human mutant cell line CEMx721.T2 (American Type Culture 
Collection) was used as target by labeling with 51Cr for 1 hour at 37°C, followed by 
extensive washing. Target cell killing was assessed by chromium release in the 
supernatant upon co-culture with CD8+ T cell clones (effector cells) at the 
Effector:Target ratio of 10:1 for 4 hours at 37°C in V-bottom microwells, in presence of 
serial dilutions of the peptide, measured using a gamma counter and calculated as: % 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 = 100 ×  (𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒)(𝑡𝑜𝑡𝑎𝑙 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒)  
 
6.10 Flow cytometry 	
• For the analysis of antigen-specific populations, CD8+ T cells were first enriched 
from cryopreserved samples using the human CD8+ T cell enrichment kit from 
StemCell Technologies (negative selection, per manufacturer’s instructions). All 
Stainings were performed using phosphate-buffered saline with 5mM EDTA, 0.2% 
bovine serum albumin, and 0.02% sodium azide [fluorescence-activated cell sorting 
(FACS) buffer]. Tetramer stainings were performed for 40 minutes at 4°C. All tetramers 
were purchased from TCmetrix Sàrl. Surface antibody staining was then performed, 
followed by staining with LIVE/DEAD-Fixable-Aqua (Invitrogen), each step at 4°C for 30 
minutes. Cells were fixed overnight in 0.36% formaldehyde (supplemented with 2% 
glucose and 5mM sodium azide). Samples were acquired using either a Gallios flow 
cytometer (Beckman Coulter, three-laser configuration) or LSRII-SORP (Beckton 
Dickinson). The data were processed with FlowJo (Tree Star Inc., v9.5.2). Samples 
with antigen-specific populations below 0.001% tetramer-positive cells in total CD8+ T 
cells were considered negative and populations consisting of less than 20 events were 
not considered eligible for further analysis. 
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• For the YF2 longitudinal study flow cytometry panels, cells were additionally 
fixed overnight in 1X Fix/Perm solution from the Foxp3 staining kit (eBioscience). Cells 
were washed and stained intranuclearly in 1X Perm solution from the Foxp3 staining kit 
(eBioscience). Samples were acquired using an LSRII-SORP flow cytometer (BD 
Bioscience). The data were processed with FlowJo (Tree Star Inc., v9.5.2). For the B 
cell, monocyte, dendritic cell, ILC and NK cell stainigs, cells were pre-incubated with 
FcR blocking reagent (Miltenyi Biotec). 
 
• For the antigen-specific staining protocol performed in Cardiff, Dextramer-PE 
(Immudex, Copenhagen, Denmark) and premium-grade streptavidin-PE (Life 
Technologies) were used with monomeric pMHC. The same batches of streptavidin-PE 
and each individual pMHC were used throughout this study to avoid any possibility of 
batch-to-batch variation. Protease inhibitors (Merck, London, U.K.) and PBS 
(tetramers) or dextramer buffer were added to give a final pMHC multimer 
concentration of 0.1 mg/ml, were stored in the dark at 4°C, and were used within 3 d of 
assembly. Generally, 0.4 mg of tetramer or dextramer was used per stain. Typically, 2–
3 3 106 cells of a T cell line or PBMCs were stained per tube with dextramer or tetramer 
first on ice for 30 min. Cells were washed with PBS and then stained with LIVE/DEAD 
Fixable Violet Dead Cell Stain, ViViD (Life Technologies) for 5 minutes at room 
temperature, and then a mixture of Abs for 20 minutes on ice: anti-CD8–
allophycocyanin (clone BW135/80; Miltenyi Biotec); anti-CD3–PerCP (clone BW264/56; 
Miltenyi Biotec); anti-CD19–Pacific Blue (clone HIB19; BioLegend), and anti-CD14–
Pacific Blue (clone M5E2; BioLegend). FACSAria (Central Biotechnology Service, 
Cardiff University) was used for cell sorting, with desired cells directed into RNA 
extraction buffer (RNeasy Plus Micro Kit; QIAGEN, Heidelberg, Germany). Data were 
analyzed using FlowJo software (Tree Star Inc., v9.5.2). The optimized protocol 
featuring two additional steps: cells were treated with 50 nM dasatinib (PKI) at 37°C for 
30 minutes and were not washed prior to staining with tetramer or dextramer, and 
post– pHLA staining and washing, 0.5 mg (10 mg/ml) of a mouse anti-PE primary 
unconjugated mAb (clone PE001; BioLegend) was used. 
 
• For t-distributed Stochastic Neighbor Embedding (t-SNE) analyses, the tSNE 
plugin in FlowJo 10.4.2 was used. Single live CD8 T cells from each donor were 
downsampled to 5'000 events and the sum of N=13 donors were concatenated into a 
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single file (70'000 events). This file was then gated and color-coded for the 
differentiation subsets. The N=13 concatenate was analysed by tSNE using the plugin 
from FlowJo v10, reducing nine parameters (CCR7, CD45RA, CD95, TCF1, IL7Ra, 
PD1, CD69, HLA-DR, CD38) to two dimensions (tSNE x- and y- axes). For the 
longitudinal tSNE analyses of A2/LLW-specific CD8 T cells, all single live A2/LLW-
specific CD8 T cell events of the longitudinal series were concatenated and thus are 
represented in proportions corresponding to the original numbers of PBMC thawed, 
which are equal across time-points (corresponding to 10e7 PBMC thawed) except for 
the baseline which is 1.5-fold larger (1.5 x 10e7 PBMC thawed). The detection 
threshold for multimer positive populations was 0.01% of total CD8 T cells and at least 
10 events. The positivity threshold for each marker was set according to distinct 
negative and positive populations in bulk CD8 T cells in resting and/or activated 
samples; for the indirect TCF1 staining, the negative signal was further validated with 
secondary antibody-only controls. 
 
6.10.1 Flow cytometry: list of reagents 
Target Fluorochrome Company Clone Cat no 
CD58 FITC BD 1C3 555920 
HLA-DR FITC Biolegend L243 307604 
CD14 FITC BC 
 
B36297 
CD15 FITC BC 
 
B36298 
CD33 FITC Biolegend HIM3-4 303304 
CD34 FITC Biolegend 561 343604 
CD203c FITC Biolegend NP4D6 324614 
CD3 FITC BC 
 
A07746 
CD19 FITC BC 
 
A07768 
CD20 FITC Biolegend 2H7 302304 
FcER1 FITC Biolegend AER-37 334608 
CD138 FITC Biolegend 1D4 344404 
CD56 FITC Biolegend HCD56 318304 
PD1 (CD279) PerCP-eF710 eBioscience eBioJ05 46-2799-42 
CD123 PerCP-Cy5.5 eBioscience 6H6 45-1239-42 
HLA-DR PerCP-Cy5.5 Biolegend 
 
307630 
CD38 PerCP-Cy5.5 Biolegend HIT2 303522 
CD58 PE BD 
 
555921 
IgD PE BD IA6-2 555779 
c-kit(CD117) PE Biolegend 
 
313204 
Ki-67 PE Biolegend Ki67 350504 
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secondary PE eBioscience 
 
12-4739-81 
CD45RA ECD BC 
 
B49193 
HLA-DR ECD BC 
 
IM3636 
CD16 ECD BC 
 
A33098 
CD15S PE-CF594 BD CSLEX1 563527 
CD95 PE-Cy7 Biolegend DX2 305622 
BCMA PE-Cy7 Biolegend 19F2 357508 
HLA-DR PE-Cy7 BD 
 
PN A40579 
CD56 PE-Cy7 Biolegend HCD56 318318 
CCR10 APC Biolegend 
 
341506 
CD83 APC BD 
 
551073 
Nkp44 (CD336) APC Biolegend 
 
325110 
Foxp3 APC eBioscience 236A/E7 17-4777-42 
CD58 APC eBioscience TS2/9 17-0578-42 
Ki-67 A647 Biolegend Ki67 350510 
CD3 A700 Biolegend HIT3a 300324 
CD86 A700 BD 2331 561124 
CD38 A700 eBioscience HIT2 56-0389-42 
CD137 A700 Biolegend 4B4-1 309816 
CD8 APC-AF750 BC B9.11 A94683 
CD40 APC-H7 BD 
 
561211 
CD1c (BDCA-1) APC-Cy7 Biolegend L161 331520 
CCR7 BV421 Biolegend G043H7 353208 
CRTH2 (CD294) BV421 BD BM16 562992 
CD14 Pacific Blue BD M5E2 558121 
CD20 Pacific Blue Biolegend 2H7 302320 
CD141 BV510 BD 1A4 563298 
CD45RA BV510 Biol 
 
304142 
CD3 Krome Orange BC B00068 B00068 
CD16 Krome Orange BC 3G8 P/N B00069 
CXCR5 BV605 Biolegend J252D4 356930 
CD127 BV605 Biolegend 
 
351334 
CD25 BV605 BD 2A3 562660 
CD27 BV605 BD L128 562655 
CD69 BV650 Biolegend FN50 310934 
CD40 BV650 Biolegend 5C3 334338 
CXCR3 BV650 Biolegend G025H7 353730 
CD4 BV785 Biolegend OK-T4 317441 
CD303 (BDCA-2) BV785 Biolegend 201A 354221 
CD138 BV711 Biolegend MI15 356522 
PD1 BV711 Biolegend EH12-2H7 329928 
FVD eF455 eBioscience 
 
65-0868-14 
pElF2S1 - Abcam 
 
ab32157 
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6.10.2 Intracellular cytokine staining assay 
 
A2/LLW-specific CD8+ T cell clones were stimulated with peptide-loaded T2 cells at the 
E:T cell ratio of 1:2 for 4 hours at 37°C in the presence of Brefeldin-A (Sigma-Aldrich) 
and anti-CD107a-FITC antibody (BD Biosciences) or anti-CD107a-PE antibody (BD 
Biosciences). Then, cells were stained with anti–CD8–APC-AF750 antibody (Beckman 
Coulter) at 4°C for 30 minutes. After washing in PBS, cells were incubated with 
LIVE/DEAD-Fixable-Aqua (Invitrogen) at 4°C for 30 minutes, and fixed at 4°C overnight 
(0.36% formaldehyde buffer). Cells were washed and stained intracellularly with anti-
IFNγ-PC7, anti-TNFα-A700 and anti-IL-2-PerPCP-Cy5.5 antibodies (BD Biosciences) 
or anti-IL-2-FITC antibodies (BD Biosciences) in FACS buffer with 0.1% saponin for 
30minutes at 4°C. Samples were acquired and data processed as described above. 
 
6.10.4 Data processing and statistical analysis 
 
Flow cytometry data processed with FlowJo (Tree Star Inc., v9.5.2). Data were plotted 
using the GraphPad Prism software (v.6; GraphPad). Quantifications were made on the 
basis of the FlowJo,Microsoft Excel, GraphPad Prism, and SPICE softwares. Statistical 
values were obtained using the analyses and tests (including normality tests) as 
detailed in the figure legends; where indicated, ns = not significant; *P < 0.05; **P < 
0.01; ***P < 0.001. For statistical comparison of pie charts generated using SPICE, the 
built-in test in SPICE software (v5.3) was used (using 10,000 permutations). 
 
6.10.5 Bioinformatics analysis of broad datasets 
 
In brief, data was first normalized by log- and logit-transformation of raw counts and 
frequency measures, respectively. Having treated measurements prior to vaccination 
as baseline (day 0), we next fit a linear spline model with 4 internal knots located at 
days 3, 7, 14, and 28. Visually, fitting a linear spline with 4 internal knots is equivalent 
to fitting a piecewise linear regression with 4 breakpoints and 5 segments. We chose 
the location of internal knots based on the observation that most features showed 
temporal fluctuations up to 4 weeks post vaccination, and reached a steady state from 
28 days onward. Broadly speaking, the heterogeneity of individual profiles can be 
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explained by either variability at the baseline (random intercepts) or variability in the 
slopes (random slopes). Given our sample size, we could not afford the most flexible 
model (by incorporating both random intercepts and random slopes). Instead, we opted 
for a random intercept model. Intuitively, our random intercept model assumes that 
individual profiles exhibit a consistent temporal dynamic, and that differences among 
individual profiles can be explained by variability at the baseline. Once the model was 
fit and unknown parameters were estimated/predicted for each feature, individual 
profiles were extracted for visualization and downstream analyses. 
 
6.11 NTAmer staining and dissociation kinetic measurements 
 
Dually labeled pMHC multimers built on NTA-Ni2+-His-tag interactions called NTAmers 
(synthetized by TCMetrix Sàrl) were used for dissociation kinetic measurements [197] 
[198]. Stainings with dually PE- and Cy5-labeled A2/LLW-specific NTAmers and data 
analysis were done as previously described [43] [197]. Briefly, staining was measured 
at 4°C using a thermostat device on a SORP-LSR II flow cytometer (BD Biosciences). 
Following 30 seconds of baseline acquisition, imidazole (100mM) was added. PE and 
Cy5 fluorescence were measured during the following 15min. Data were processed 
using the kinetic module of the FlowJo software (v.9.7.6; Tree Star), and corrected 
mean fluorescence intensity values were plotted and analyzed using the GraphPad 
Prism software (v.6; GraphPad). The Cy5 decay values of the NTAmers specific for the 
mutant peptides were normalized to the PE decay value of the WT NTAmer. 
 
6.12 Sizing scan 	
The following mixtures were used to define the MHCI-peptide length preference of 
individual TCRs: X8, X9, X10, X11, X12, and X13 (where X is any of the 19 L-amino acids 
excluding cysteine; Pepscan Presto) [193]. The YF5048 clones was washed and rested 
overnight in R5 medium (RPMI 1640 supplemented with 100 units/ml penicillin, 100 
µg/ml streptomycin, 2mm l-glutamine, and 5% heat-inactivated fetal calf serum (all 
Invitrogen)). In U-bottom 96-well plates, 6 × 104 target cells were incubated with sizing 
scan mixtures at 1mM in duplicate for 2 hours at 37°C. After peptide pulsing, 3 × 
104 YF5048 clone were added and the assay was incubated overnight at 37°C. 
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Subsequently, the supernatant was harvested and assayed for MIP-1β by ELISA 
according to the manufacturer's instructions (R&D Systems). 
 
6.13 Combinatorial peptide library (CPL) scans 
 
The nonamer CPL contains a total of 4.8×1011 ((9+19) ×198) different nonamer 
peptides divided into 180 sub-libraries with each containing 198 different nonamer 
peptides in approximately equimolar concentrations (Pepscan, Lelystad, The 
Netherlands) [190]. Each of the 180 sub-libraries has a fixed amino acid residue but all 
other positions are degenerate. Cysteine was excluded from all degenerate positions to 
avoid oxidation, but was included at the fixed positions. Prior to the assay, CD8+ T cell 
clones were washed and rested overnight in R5 medium (RPMI 1640 supplemented 
with 100 units/ml penicillin, 100 µg/ml streptomycin, 2mm l-glutamine, and 5% heat-
inactivated fetal calf serum (all Invitrogen). For CPL screening, 6 × 104 C1R A2 cells 
[266] were pulsed with each sub-library at 100 µg/ml in duplicate for 2 hours at 37°C. 
After peptide pulsing, 3 × 104 CD8+ T cells were added, and the cultures were 
incubated overnight at 37°C. Subsequently, the supernatant was harvested and 
assayed for MIP-1β by ELISA according to the manufacturer's instructions (R&D 
Systems). 
 
6.14 Protein expression, refolding and purification 
 
HLA A*0201 α-chain and β2m were expressed separately, without post-translational 
modification, as insoluble inclusion bodies (IBs) in competent Rosetta (DE3) 
Escherichia coli cells, using 0.5M IPTG to induce expression as thoroughly described 
recently [160]. Briefly, for a 1L pMHC refold, 30mg HLA-A*0201 α-chain was mixed 
with 30mg β2m and 4mg peptide at 37°C for 15 minutes with 10mM DTT. This mixture 
was then added to cold refold buffer (50mM Tris, pH8, 2mM EDTA, 400mM L-arginine, 
6mM cysteamine hydrochloride, and 4mM cystamine). Refolds were mixed at 4°C for > 
6 h. Dialysis was performed against 10mM TRIS, pH8.1, until the conductivity of the 
refolds was less than two millisiemens per centimeter. The refolds were then filtered 
and purified first by ion exchange using a Poros50HQTM column (GE Healthcare, 
Buckinghamshire, U.K.) and second by gel filtration directly into crystallization buffer 
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(10mM Tris pH8.1 and 10mM NaCl) or PBS buffer (137mM NaCl, 3mM KCl, 8mM 
Na2HPO4, 1mM KH2PO4) using a Superdex200HRTM column (GE Healthcare, 
Buckinghamshire, U.K.). Protein quality was analyzed by Coomassie-stained SDS-
PAGE, either under non-reducing or reducing conditions. 
 
6.15 Crystallization, diffraction data collection, and model refinement 
 
All protein crystals were grown at 18°C by vapor diffusion via the “sitting drop” 
technique. 200nl of each pMHC (20 mg/ml) in crystallization buffer was added to 200nl 
of reservoir solution. A2/LLW-WT crystals were grown in 0.1 M Hepes, pH7, 0.2M 
ammonium sulphate, 20%PEG 4000. 2/LLW-4A crystals were grown in 0.1 M Sodium 
Cacodylate pH 6.0, 0.2 M Ammonium Sulphate, 25% PEG 4000. A2/LLW-7I crystals 
were grown in 0.1 M Mes pH 7.0, 0.2 M Ammonium Sulphate, 25% PEG 8000. 
A2/LLW-8H and A2/LLW-8Q crystals were grown in 0.1 M Sodium Cacodylate pH 6.5, 
0.2 M Amonium Sulphate, 20 % PEG 4000. All crystals were soaked in 30% ethylene 
glycol before cryo-cooling. All crystallization screens and optimization experiments 
were completed using an Art-Robbins Gryphon dispensing robot (Alpha Biotech Ltd., 
UK). Data were collected at 100K at the Diamond Light Source (Oxfordshire, UK) as 
described previously [267]. All data sets were collected at a wavelength of 0.98 Å using 
an ADSC Q315 CCD detector. Reflection intensities were estimated with the XIA2 
package, and the data were scaled, reduced, and analyzed with the SCALA and CCP4 
package. Structures were solved with molecular replacement using PHASER. A 
solution could be obtained with a search model taken from Protein Data Bank entry 
5EU5. Sequences were adjusted with COOT, and the models were refined with 
REFMAC5. Graphical representations were prepared with PyMOL. The reflection data 
and final model coordinates were deposited in the Protein Data Bank. PDB codes are 
the following: 
A2/LLW-WT: 5N6B 
Entries in preparation for: A2/LLW-4A, A2/LLW-7I, A2/LLW-8H, and A2/LLW-8Q. 
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6.16 Measuring the thermal stability of HLA-A*0201–peptide complexes 
 
Thermal stability of A2/peptide complexes was assessed by CD spectroscopy 
monitoring the change of ellipticities Θ at 218nm where the spectra exhibit a minimum. 
Data were collected on an Aviv 215 spectrometer (Aviv Biomedical Inc., Lakewood, NJ) 
equipped with a thermostated cell holder using a 1mm quartz cell. Proteins were 
dissolved in PBS at c = 3.5 µM. Denaturation was monitored from 4°C up to a 
temperature when protein precipitation occurred using a gradient of 0.5°C/min. Melting 
curves were analyzed assuming a two-state native (N) to denatured (D) transition N3 ↔ 
3D with the melting temperature and van't Hoff's enthalpy at the midpoint of the 
transition as fitting parameters [268] [269]. 
 
6.17 In silico TCR:pMHC analyses: Modeling the TCR:pMHC complex and 
Molecular Dynamics (MD) simulations 
 
In silico analyses on TCR:pMHC were performed by our collaborator Prof. Vincent 
Zoete. The 3D structure of the TRAV12-2/TRBV9 TCR in complex with HLA-A2 and the 
LLWNGPMAV peptide was modeled from three experimental structures: 3HG1 [135] 
and 4QOK [270], containing a complex between the TRAV12-2/TRBC1 TCR in 
complex with HLA-A2 and the ELAGIGILTV or EAAGIGILTV peptides, respectively, 
and the experimental structure obtained in this study for the complex between HLA-A2 
and the LLWNGPMAV, LLWNGPIAV, LLWNGPMQV and LLWNGPMAV peptides. The 
sequence alignment between TRBV9 and TRBC1 was performed using the MUSCLE 
program [271]. The sequence identity between TRBV9 and TRBC1 was performed 
using the MUSCLE program. The sequence identity between the variable part of the 
TRBV9 and TRBC1 beta chains is 30%. Based on this sequence alignment, the model 
was obtained using the Modeller program [272] [273]. 1000 models were generated by 
satisfaction of spatial restraints through minimization and simulated annealing, and the 
model with the best Modeller objective function was retained. Molecules were 
visualized and analyzed using UCSF Chimera [274]. 
 
The model of A2/LLW in complex with the MEL5 TCR was obtained with the Modeller 
program, following the method described above to obtain the structural model of 
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A2/LLW with the YF5048 TCR. In this case, however, we used our experimental 
structure of the A2/LLW as a template for the HLA/peptide domain and the 
experimental structure of the complex between A2/ELA and MEL5 (PDB code: 3HG1) 
as a template for the MEL5 TCR. 
 
MD simulations were performed with GROMACS [275] [276] version 2018.3 in periodic 
boundary conditions, using the all-atom CHARMM27 force field [277] and the TIP3P 
water model. The number of Na+ and Cl- ions in solution was adjusted to neutralize the 
system and reach the physiological concentrations of 0.154 M. Before starting the MD 
simulations, missing residues and loops were modelled using the Dunbrack rotamer 
libraries [278] and the Modeller program [279]. Titratable side chains were protonated 
so as to allow hydrogen bonds with neighbouring residues. Electrostatic interactions 
were calculated with the Ewald particle-mesh method [280] with a grid spacing of 1.2 Å. 
A cut-off of 12 Å was applied for the real-space Coulomb and van der Waals 
interactions. Bonds involving hydrogen atoms were constrained using the P-LINCS 
algorithm [281]. The system was coupled to a Parinello-Rahman barostat with a 
relaxation time of 1 ps. The solute and the solvent were separately coupled to two 
nose-hoover thermostats [282], each with a relaxation time of 0.2 ps. A time integration 
step of 2 fs was used, with a temperature of 300 K and a pressure to 1 bar during the 
production trajectory. Initial Cartesian coordinates were taken from the experimental X-
ray structures of pMHC molecules obtained in this study. Peptide mutations, M7I, A8H 
and A8Q were introduced using the swapaa command of UCSF Chimera [274] v 1.12 
and the Dunbrack backbone-dependent rotamer library [278]. Initial structures were 
energy optimized, heated from 0 to 300 K in 0.4 ns, equilibrated for a further 1 ns 
restraining each solute non-hydrogen atom to its original position, and finally 
equilibrated for 2 ns without restraints before data collection. 3 MD simulations were 
carried out for the WT and mutated peptides to assess the reproducibility of the results. 
Each MD simulation had a production time of 140 ns, saving coordinates every 0.05 ns. 
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The repertoire of human αβ T-cell receptors (TCRs) is generated via somatic recombi-
nation of germline gene segments. Despite this enormous variation, certain epitopes
can be immunodominant, associated with high frequencies of antigen-specific T cells
and/or exhibit bias toward a TCR gene segment. Here, we studied the TCR repertoire of
the HLA-A*0201-restricted epitope LLWNGPMAV (hereafter, A2/LLW) from Yellow Fever
virus, which generates an immunodominant CD8+ T cell response to the highly effec-
tive YF-17D vaccine. We discover that these A2/LLW-specific CD8+ T cells are highly
biased for the TCR α chain TRAV12-2. This bias is already present in A2/LLW-specific
naı¨ve T cells before vaccination with YF-17D. Using CD8+ T cell clones, we show that
TRAV12-2 does not confer a functional advantage on a per cell basis. Molecular modeling
indicated that the germline-encoded complementarity determining region (CDR) 1α loop
of TRAV12-2 critically contributes to A2/LLW binding, in contrast to the conventional
dominant dependence on somatically rearranged CDR3 loops. This germline component
of antigen recognition may explain the unusually high precursor frequency, prevalence
and immunodominance of T-cell responses specific for the A2/LLW epitope.
Keywords: Antigen recognition ! Germline ! T cell receptor Alpha Variable (TRAV)-12-2 !
T cell receptor bias ! Yellow Fever virus
! Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Human αβ TCRs are heterodimeric proteins composed of an α- and
β-chain, somatically rearranged during T cell development from
Correspondence: Dr. Silvia A. Fuertes Marraco
e-mail: silvia.fuertesmarraco@unil.ch
a selection of 176 variables (V), diversity (D), joining (J), and
constant (C) genes [1]. The specificity of peptide-MHC (pMHC)
recognition is conferred by the six highly flexible complementarity-
determining region (CDR) loops that make up the antigen-binding
site of the TCR. The CDR1 and CDR2 sequences are entirely
encoded within the Variable genes for each α- and β-chain (T cell
Receptor Alpha Variable, TRAV, and T cell Receptor Beta Variable
genes, TRBV, respectively). CDR1 and CDR2 are therefore entirely
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germline-encoded. In contrast, the CDR3 loops, which generally
make extensive contacts with the antigenic peptide [2, 3], are
encoded by the V(D)J joints and thus hypervariable. The general
consensus is that the somatic hypervariability of the CDR3 loops
contributes most to the broad range of TCR specificities. How-
ever, with more atomic structures of TCR-pMHC complexes, it is
becoming evident that the germline CDR1α loop can sometimes
also contact peptide residues, and in some cases dominate the
contact with the peptide [4–6].
Antigen-specific CD8+ T cells can be biased for certain TRAV
or TRBV segments or feature “public TCRs” shared across the
human population. In addition, TCR bias has been observed in
infection, autoimmunity, and alloreactivity, with many examples
reviewed by Turner et al. [7]. The reasons behind the sharing
of particular TCR segments are not yet fully understood but may
have critical implications for the understanding and induction of
optimal, protective antigen-specific T cell responses.
Recently, we described the remarkable decade-long persis-
tence of human stem cell-like memory (SCM) CD8+ T cells
specific for the HLA-A*0201-restricted Yellow Fever virus (YFV)
Non-Structural protein 4b214-222 epitope (sequence LLWNGPMAV;
hereafter, A2/LLW) in the context of YF-17D vaccination [8]. Sev-
eral studies have shown that this A2/LLW epitope is highly dom-
inant and prevalent amongst YF-17D vaccinees [9–11]. At the
peak of the T cell response, up to 25% of the peripheral CD8+
T cells can be specific for A2/LLW [9]. In our hands, A2/LLW-
specific CD8+ T cells could be detected in 38/41 HLA-A*0201
positive individuals after vaccination with YF-17D (>90% preva-
lence) [8]. Interestingly, we also revealed that na¨ıve A2/LLW-
specific CD8+ T cells were readily detectable in 3 out of 10 unvacci-
nated donors [8]. The reasons behind this unusual high frequency
and prevalence of A2/LLW-specific CD8+ T cells warranted further
investigation. Here, we show that A2/LLW-specific TCRs are highly
biased for the TCRα chain germline segment TRAV12-2. This find-
ing is in common with another human specificity for which there
is an extraordinarily high frequency of na¨ıve T cells: the HLA-
A*0201-restricted epitope ELAGIGILTV (heteroclitic analog to
EAAGIGILTV from Melan-A, and hereafter, A2/ELA) [12, 13].
Pertinently, A2/ELA-specific CD8+ T cells are also known to be
biased for TRAV12-2 and the germline-encoded CDR1α loop in
an A2/ELA-specific TCR featuring TRAV12-2 (MEL5 TCR) makes
major contributions to antigen recognition, thereby providing a
so called “innate-like” binding of the peptide [13–18]. We per-
formed functional and structural studies to further investigate the
TRAV12-2 bias in A2/LLW-specific CD8+ T cells.
Results
A2/LLW-specific CD8+ T cells are biased for the
segment TRAV12-2, before and after vaccination
Initially, genome-wide analysis of A2/LLW-specific CD8+ SCM
and various differentiation subsets in total CD8+ T cells [8, 19]
revealed that the most prominent feature was the highly signifi-
cant enrichment of the TRAV12-2 in A2/LLW-specific CD8+ T cells
(Fig. 1A). We next investigated this TRAV12-2 enrichment in
A2/LLW-specific CD8+ T cells from eight YF-17D vaccinees at the
protein level (Figs. 1B and E). We also compared A2/LLW-specific
CD8+ T cells in these vaccinees to those in unvaccinated donors
in order to address whether vaccination induced the observed
TRAV12-2 bias (Fig. 1E). In addition, we analyzed healthy donors
for other antigen specificities such as A2/ELA, which is known to
be biased for TRAV12-2 [13], and other viral antigen specifici-
ties that are not known to exhibit such bias: the HLA-A*0201-
restricted epitopes BMFL1 from Epstein Barr Virus (EBV) and
pp65 from cytomegalovirus (CMV) as well as two other YF epi-
topes that were detectable in two YF-17D vaccinees (the HLA-
A*0201-restricted VMLFILAGL from NS4a protein, A2/VML, and
HLA-B*07-restricted RPIDDRFGL from NS5 protein, B7/RPI). In
accordance with our previous study [8], we found that vaccinees
had easily detectable and largely differentiated A2/LLW-specific
CD8+ T cells (Figs. 1B to D), while unvaccinated donors showed
lower but detectable frequencies of na¨ıve A2/LLW-specific CD8+
T cells (i.e. above 0.001%) (Figs. 1C and D). As expected, na¨ıve
A2/ELA-specific CD8+ T cells were also detectable in healthy
donors, while the other viral antigen specificities were variably
detected amongst donors and displayed differentiated phenotypes
(Figs. 1C and D). The TRAV12-2 segment was used by the major-
ity (median 55.5%) of A2/LLW-specific CD8+ T cells (Fig. 1E), in
contrast to total CD8+ T cells (median 12.5%). The TRAV12-2 bias
reached a similar extent as in Melan-A-specific CD8+ T cells from
healthy donors (median 57.7%), in contrast to the absence of bias
in the other specificities (other two YF-17D epitopes and CMV-
and EBV-specific epitopes) (Fig. 1E). Interestingly, we found that
the TRAV12-2 bias was already evident in na¨ıve A2/LLW-specific
CD8+ T cells, prior to vaccination (median 69.2%).
Despite the TRAV12-2 bias, A2/LLW-specific TCRs are
mostly unique and public sequences infrequent
We generated and analyzed 57 A2/LLW-specific CD8+ T cell
clones derived from four different YF-17D vaccinees. As shown in
Fig. 2A, the Vα gene segments were predominated by TRAV12-2,
with 45 of 57 clones positive for TRAV12-2 (78.9%). The TRAJs
were relatively more diverse, using 15 of the 61 TRAJ human
genes, yet consisting predominantly of the TRAJ30 (45.1%) (Fig.
2B). In contrast, the Vβ repertoire was highly heterogeneous,
with 10 different Vβ segments used, although a moderate bias for
some TRBV genes was noted: TRBV9 was used by 16 clones and
TRBV2 used by 10 clones (Fig. 2C). There was no evident TRBJ
bias (Fig. 2D). In addition, TRAV12-2 CDR3 length consisted pre-
dominantly of 8 amino acids whereas CDR3β sequences showed a
broader distribution (Fig. 2E). Most TCRs were unique clonotypes
(Supporting Information Table 1), with no conserved motif in the
CDR3 loop observed. We identified two public TRAV sequences:
“CAVTDDKIIFG” was shared by all four donors and
“CAVGDDKIIFG” by three out of four donors.
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Figure 1. A2/LLW-specific CD8+ T cells are strongly biased for TRAV12-2 similarly to A2/ELA-specific CD8+ T cells. (A) TRAV12-2 mRNA
expression in A2/LLW-specific stem cell-like (SCM) CD8+ T cells compared to reference differentiation subsets in total CD8+ T cells (N
= 8 YF-17D vaccinees), including: Naı¨ve, SCM, central memory (CM) and effectors (E). Samples were isolated from PBMCs by FACS and
total RNA analyzed by microarray. (B) Representative gating strategy for the flow cytometry analysis of CD8+ T cell subsets in total
or tetramer positive populations and TRAV12-2 expression therein. EM: effector memory; EMRA: effector memory CD45RA+. (C) Fre-
quencies (%) of various antigen specificities amongst circulating CD8+ T cells (mean and SEM), including A2/LLW in YF-17D vaccinees
(N = 8) and unvaccinated individuals (N = 5), A2/VML (N = 2) and B7/RPI (N = 2) in YF-17D vaccinees, as well as A2/CMV (N = 8; stars repre-
sent CMV-seronegative donors = 5/8), A2/EBV (N = 8) and A2/ELA (N = 8). Data are representative of two independent experiments. (D) Subset
distribution of antigen-specific CD8+ T cell populations (mean and SEM). (E) Subject-paired comparison of TRAV12-2 expression between antigen-
specific and total CD8+ T cells (“vac.” = YF-17D vaccinee; “unv.” = unvaccinated with YF-17D).
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Figure 2. TCR repertoire analysis of A2/LLW-specific CD8+ T cell clones generated from four vaccinated donors. Total RNA was isolated from 57
A2/LLW-specific CD8+ T cell clones, cDNA prepared, analyzed by PCRwith primers specific for each TRAV and TRBV gene segment, and sequenced.
(A) TRAV gene usage. (B) TRAJ gene usage. (C) TRBV gene usage. (D) TRBJ gene usage. (E) CDR3 length distribution according to IMGT definition.
On a per cell basis, TRAV12-2 does not confer
functional advantages to A2/LLW-specific CD8+ T cells
One hypothesis could be that TCRs with TRAV12-2 mediate
increased T cell function. Analysis of various functional proper-
ties in A2/LLW-specific CD8+ T cell clones showed that TRAV12-
2-positive clones did not differ from TRAV12-2-negative clones,
whether in killing capacity (EC50 in Fig. 3A), TCR avidity (Koff
in Fig. 3B) or degranulation and secretion of IFN-γ, TNF-α, and
IL-2 after 4-hours peptide stimulation (Fig. 3C and D). Altogether,
expression of TRAV12-2 did not confer a particular functional
advantage in A2/LLW-specific CD8+ T cell clones.
The LLW peptide binds with high stability
to HLA-A*0201
The TRAV12-2 bias in A2/LLW-specific TCRs is reminiscent of
the TRAV12-2 bias observed in A2/ELA-specific CD8+ T cells. In
the A2/ELA-specific MEL5 TCR structure, the germline-encoded
CDR1α loop makes important interactions with the ELA peptide
in complex with HLA-A*0201 providing an explanation for the
preferential TRAV12-2 usage and high frequency of this speci-
ficity [5, 14–16, 20–22]. In order to determine the structural char-
acteristics that govern the TCR recognition of the LLW peptide,
we intended to solve the crystal structure of a TRAV12-2 posi-
tive TCR specific for A2/LLW in complex with its cognate pMHC
(A2/LLW). Unfortunately, despite several attempts with differ-
ent TCRs, we were unable to refold a functional A2/LLW-specific
TRAV12-2 positive TCR. We were able to solve the atomic struc-
ture of the A2/LLW pMHC complex at 1.59A˚ resolution. Electron
density around the peptide was unambiguous (Fig. 4A). The gen-
eral features of the binding are similar to those observed in other
peptide-HLA-A*0201 complexes: the nonamer adopts a confor-
mation with central bulge between residues at position 4 and 6
where the side chains are protruding toward the TCR (Fig. 4B),
while the peptide termini provide binding into the HLA binding
pockets with many specific interactions (Figs. 4A and C).
To assay more directly the peptide binding affinity, we per-
formed circular dichroism (CD) temperature melting experiments.
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Figure 3. TRAV12-2 expression does not confer a functional advantage. Functional properties of A2/LLW-specific CD8+ T cell clones were assessed
by various methods. (A) Killing capacity (51-chromium release assay) with LLW peptide titration in A2/LLW-specific CD8+ T cell clones (TRAV12-2
positive N= 37, TRAV12-2 negativeN= 10). Data are representative of two independent experiments (mean and SEM; t-test p value). (B) Monomeric
dissociation constant (Koff) rates measured in CD8+ T cell clones (TRAV12-2 positive N = 25, TRAV12 negative = 8) using NTAmers (mean and SD;
t-test P value). (C and D) Intracellular cytokine staining of CD8+ T cell clones (TRAV12-2 positive N = 11, TRAV12-2 negative N = 6) following LLW
peptide stimulation for 4 h, showing representative flow cytometry gating strategy in C. Data are representative of two independent experiments.
The A2/LLW complex showed a melting temperature Tm of 66.5°C
and transition enthalpies !HvH of ca. −500 kJ/mol (Fig. 5). Thus,
the A2/LLW complex is very stable when compared to other pMHC
complexes that are also recognized by TRAV12-2 positive TCRs
(Tm / !HvH 66.0°C/-610 kJ/mol and 63.0°C/-380 kJ/mol for
A2/Tax from the human T-lymphotropic virus type 1 (HTLV-1)
and A2/ELA, respectively).
The germline-encoded CDR1α loop of TRAV12-2
contributes to pMHC binding
To investigate the structural determinants of a TRAV12-2 positive
TCR interacting with A2/LLW, we supported our experimental
A2/LLW crystal data with two complementary strategies. First,
we combined our structure of the A2/LLW and the previously
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Figure 4. LLW peptide binds stably to HLA-A*0201. (A) Electron density at 1σ contour level around the peptide of the A2/LLW complex showing
the overall conformation of the peptide. Blue arrows (TCR-exposed) and orange arrows (MHC-buried) indicate direction of amino acid side chains.
(B) Surface and stick representation of HLA-A*0201 and peptide residues, respectively. (C) LIGPLOT schematic diagram showing the various
interactions of the LLW peptide with HLA-A*0201. Purple lines are peptide covalent bonds, orange lines are HLA-A2 covalent bonds, dotted green
lines are polar/H-bond contacts, and open red arcs indicate a protein atom in a non-polar contact.
Figure 5. Thermal stability of pMHCs. (A) Temperature stability of
the HLA-A2*0201 molecules with the ELA (ELAGIGILTV, square/straight
line), Tax (LLFGYPVYV, triangles/dashed line), LLW (LLWNGPMAV,
close circles/dash-dotted line), and LLW-4A (LLWAGPMAV, open cir-
cles/dashed line) peptides assayed by circular dichroism spectroscopy.
Lines represent data fits as described in Methods. (B) Apparent melting
temperature Tm and van’t Hoff’s enthalpy of unfolding!HvH (mean and
SD). Errors bars represent S.D. resulting from the multivariable curve
fitting.
solved structures of the MEL5 TCR to perform in silico mod-
eling of the A2/LLW-specific YF5048 TCR (TRAV12-2/TRBV9;
Fig. 6A and Supporting Information Table 2). This A2/LLW-
specific TCR from clone 5048 NN4 (hereafter YF5048) was chosen
out of our A2/LLW-specific clone database due to its closest sim-
ilarity to the MEL5 TCR sequence for the α chain (just 3 amino
acids different; Supporting Information Fig. 1A). The overall con-
formation of the LLW peptide binding to the MHC molecule is
similar to the ELA peptide thus facilitating the modeling (Support-
ing Information Fig. 1B). Figure 6A and Supporting Information
Table 2 show the molecular interactions taking place between the
TRAV12-2 TCR and the A2/LLW complex. In this model, most
of the interactions between the TCR and the peptide originate
from the α chain encoded by TRAV12-2. Five peptide residues
are pointing toward the TCR: Leu1, Asn4, Gly5, Met7 and Ala8;
and these predominantly contact the CDR1α loop. In particular,
Asn4 extends into a polar pocket of TRAV12, where its side chain
is making a network of hydrogen bonds with the side chains of
CDR1α Ser32 and CDR3α Asp92, as well as non-polar interactions
with CDR1α Gln31. In turn, the CDR3β loop of YF5048 expands
between the Asn4 and Met7 peptide residues, and exchanges
two hydrogen bonds between the backbone of Ser98 and the
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Figure 6. Molecularmodeling indicates that germline-encodedCDR1 in
TRAV12-2 makes major contributions to the binding with the A2/LLW
complex. Calculated 3D structure of the YF5048 TRAV12/TRBV9 TCR
bound to the HLA-A2/LLWpeptide complex (A) and experimental struc-
tures of the MEL5 TRAV12/TRBV30 TCR bound to HLA-A2/ELA peptide
complex, PDB ID 3G1 (B) or the HLA-A2/Tax peptide complex, PDB ID
4FTV (C), with ribbons representing α- and - β chains in dark and light
orange, respectively; the MHC molecule in tan ribbon, and peptides in
ball and stick representation. TCR and MHC side chains are shown in
thick lines, with carbon atoms colored in orange and tan, respectively.
Hydrogen bonds are displayed as magenta thin lines.
backbones of peptide residues Gly5 and Pro6 (Fig. 6A). This 3D
model of A2/LLW/YF5048 presents important structural similari-
ties with the experimental structures of the ELA and Tax peptides
(Fig. 6). The backbone of the 3 first and last residues are nearly
superimposed, and the corresponding side chains occupy the same
MHC pockets: Leu2 of LLW, ELA and Tax in P2; Ala8 of LLW, Thr9
of ELA and Tyr8 of Tax in P8; Val9 of LLW and Tax, and Val10 of
ELA in P9. In line with this, residues Leu1 of LLW, and Glu1 of ELA
are facing the TCRα, while Met7 of LLW, Leu8 of ELA and Val7
of Tax are pointing toward the TCRβ. Important structural differ-
ences arise for the central residues of the peptides. While pocket
P3 of MHC is occupied by Trp3 of LLW and Phe3 of Tax, it is occu-
pied by Gly6 and part of the Ile5 backbone of the ELA peptide,
due to a large backbone rearrangement. In addition, the peptide
residue pointing toward TCRα and possibly making interactions is
Asn4 for LLW, Ile5 for ELA and Tyr5 for Tax.
The second strategy to investigate the structural determinants
of the A2/LLW-specific TRAV12-2 was to functionally interrogate
the A2/LLW-specific CD8+ T cell clone YF5048 using amino acid
substitutions of the LLW index peptide and combinatorial peptide
library (CPL) screening. Alanine substitutions at each position of
the LLW peptide revealed that the central region of the peptide
(positions 3–5) was key for TCR recognition as these substitu-
tions were deleterious to recognition; in particular the Asn4→Ala4
(LLW-4A) was very informative as it completely abrogated the
response of the YF5048 clone (Fig. 7A). This suggested that the
TCRmakes the majority of its critical contacts in the central region
of the peptide, which is consistent with the conformation of the
peptide accommodating into a central bulge (Figs. 4A and B). The
dramatic effect of the Asn4→Ala4 mutation is in line with the crit-
ical interactions made by the TRAV12-2 CDR1α loop of the TCR
with the Asn (Fig. 6A and Supporting Information Table 2). Inter-
estingly, both A2/LLW and the mutated A2/LLW-4A complexes
were found to have the same Tm of 66.5°C, ruling out the possi-
bility that the absence of response to the mutated peptide LLW-4A
is a consequence of the instability of its complex with HLA-A*02
(Fig. 5).
To further explore the observations of the alanine scan we per-
formed a nonamer CPL screen of the YF5048 clone, which revealed
positions of the peptide where index residues gave similar (posi-
tions 1, 4 and 6) or superior (positions 2, 3, 5 and 9) activation
compared to non-index amino acids (Fig. 7B). In contrast, index
residues were seen minimally at positions 7 and 8, with relatively
high responses seen in both cases for non-index amino acids (Fig.
7B). In concordancewith the alanine scan in the LLWpeptide back-
bone, activation toward the index residues at positions 3 (Trp) and
5 (Gly) were dominant over the other amino acid residues. Despite
the dramatic loss of YF5048 activation toward the Asn4→Ala4 in
the index peptide, non-index residues (namely Arg, Thr and Trp)
also gave activation that was comparable or superior (Arg) to the
Asn at position 4 (Fig. 7B). In light of this result, we performed
an Asn4→Arg4 substitution of the index peptide, which ablated
recognition of the peptide by YF5048 (Supporting Information
Fig. 3A and 3B) and therefore supported the previous data that
showed the importance of the Asn4 for TCR recognition. The loss
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Figure 7. Peptide recognition signature of an individual TCR derived from clone YF5048. The A2/LLW-specific CD8+ T cell clone YF5048 was
functionally interrogated using amino acid substitutions of the LLW index peptide and CPL screening (A) Alanine-scan of the LLW peptide
assessed by MIP-1β activation with graded concentrations of the peptides (mean and SEM). Data are representative of 2 independent experiments.
(B) Nonamer CPL scan for clone YF5048 assayed by MIP-1β activation (mean and SD). Index peptide residues are represented as dashed-pattern
bars. Upwards arrows (TCR-exposed) and downwards arrows (MHC-buried) indicate direction of amino acid side chains. Data are representative
of 3 independent experiments.
of reactivity toward the peptide LLWRGPMAV suggested that the
Asn4→Arg4 substitution alone was not sufficient to be seen by the
TCR and required further amino acid changes at other positions
of the index peptide to achieve activation. The ability of a CPL to
identify amino acids that can be substituted and recognized by a
clonewas demonstrated using second TRAV12-2 positive A2/LLW-
specific clone, YF5031. CPL data for YF0531 showed that this clone
preferred the index residue sub-libraries at the central positions
of the peptide (Supporting Information Fig. 2A), akin to YF0548
(Fig. 7B). Maintaining this central region with substitutions at
5 other positions (KQWNGFIPV) substitutions in bold and under-
lined) gave a peptide sequence that activated YF0531 (Supporting
Information Fig. 3C), thereby further highlighting the importance
of the central residues for TRAV12-2 TCR recognition of the YF
peptide. We also performed CPL screening of TRAV12-2 negative
clones to explore their reactivity toward the central region of the
peptide. Whereas the TRAV12-2 positive clones YF5048 (Fig. 7B)
and YF5031 (Supporting Information Fig. 2A) were focused on
index residues Trp3 and Gly5, TRAV12-2 negative clone YF5001
recognized index and multiple non-index amino acid residues at
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Figure 8. Absence of cross-reactivity between A2/LLW and A2/ELA epitopes. Recognition of the LLW and ELA peptides by A2/LLW-specific and
A2/ELA-specific CD8+ T cell clones was assessed by chromium release assay. (A) Cross-reactivity analysis of TRAV12-2 positive A2/LLW-specific
CD8+ T cell clones toward the LLWNGPMAV (LLW, solid line) and ELAGIGLTV (ELA, dashed line) (mean and SD). (B) Cross-reactivity analysis
of TRAV12-2 positive A2/ELA-specific CD8+ T cell clones toward the LLWNGPMAV (LLW, solid line) and ELAGIGLTV (ELA, dashed line) (mean
and SD).
these positions. Although YF5001 recognized the Asn4 sub-library,
other amino acid sub-libraries (Ile, Arg and Try) were of compa-
rable or greater potency (Supporting Information Fig. 2B). The
second TRAV12-2 negative clone YF5048NN1, however, exhib-
ited a focused recognition across the central region of the peptide;
preferring only Trp (index) at position 3, and Gly (index) or Thr
(non-index) at position 5 (Supporting Information Fig. 2C). Inter-
estingly, any response by YF5048NN1 toward the TRAV12-2 TCR
critical Asn at position 4 was unconvincing and instead domi-
nated by activation toward the Ser-fixed sub-library (Supporting
Information Fig. 2C). Taken together these data further support
the importance of the central amino acid residues, especially the
Asn4, of the LLW peptide in the binding of TRAV12-2 positive
TCRs.
In conclusion, the complementary approaches of modeling
and cell functional assays demonstrated the key elements that
mediate the TRAV12-2 positive YF5048 TCR interaction with the
A2/LLW complex and support that the germline-encoded CDR1α
loop of TRAV12-2 makes critical contributions to cognate peptide
recognition.
A2/LLW and A2/ELA TRAV12-2 positive TCRs
preserve their respective specificity
Given the germline nature of the CDR1α loop of TRAV12-2 that
is critical to peptide recognition of both A2/LLW and A2/ELA
specificities, we addressed whether there was any cross-reactivity
between T-cells with these TRAV12-2-dominated specificities. The
TRAV12-2 positive A2/LLW-specific clones did not respond to
the ELA peptide (Fig. 8A) and the TRAV12-2 positive A2/ELA-
specific clones did not respond to the LLW peptide (Fig. 8B) indi-
cating there was no common, shared TRAV12-2-mediated mode
of antigen recognition. These functional data were supported by
in silico modeling of the MEL5 TCR together with the A2/LLW
complex showing unfavorable interactions (Fig. 9A). In fact, the
most important difference in the interaction scheme of A2/LLW
with the A2/LLW-specific YF5048 TCR versus with the A2/ELA-
specific MEL5 TCR involves the CDR3β loop. In the A2/LLW/MEL5
structural model, the Asn4 residue of the LLW peptide is situated
close to the Leu98 residue of the CDR3β loop. The contact between
the backbone carbonyl of Asn4 and the side chain of Leu98 prevent
the former from making any hydrogen bond with its surrounding,
and is unfavorable to the binding between A2/LLW and MEL5
(Fig. 9A). In contrast, in the A2/LLW/YF5048 structural model,
the key residue in CDR3β loop is Gly97, which does not sterically
hinder the backbone carbonyl of the peptide Asn4 residue (Fig.
9B). In the A2/ELA/MEL5 structure, due to a different position
of the peptide backbone, the Gly4 residue of ELA (corresponding
to Asn4 in LLW) is situated far from Leu98 in the CDR3β loop,
and its backbone carbonyl is unhindered by this non-polar side
chain (Fig. 9C). This key difference in the CDR3β loops explains
the unfavorable interaction between MEL5 and A2/LLW, compat-
ible with the lack of cross-reactivity observed between TRAV12-
2 positive TCRs toward LLW or ELA. These data highlight the
importance that the CDR3β loop plays in TCR specificity as
although this loop plays a minimal role in pMHC contact it can act
to interfere with engagement.
Discussion
In this study, we analyzed the TCR repertoire of CD8+ T cells
specific for the immunodominant A2/LLW epitope in YF-17D vac-
cinees and controls. We revealed and quantified the TRAV12-2
bias in A2/LLW-specific CD8+ T cells. Various functional assays
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Figure 9. Calculated structures of theMEL5 andYF50408 TCRs bound to
the HLA-A2/LLWpeptide complex and the experimental 3D structure of
the MEL5 TCR bound to the HLA-A2/ELA peptide complex. Calculated
structures of the MEL5 and YF50408 TCRs bound to the HLA-A2/LLW
peptide complex, (A) and (B), respectively. Experimental 3D structure
of the MEL5 TCR bound to the HLA-A2/ELA peptide complex (C). Repre-
sentation: α and β chains are in dark and light orange ribbons, respec-
tively; the MHC molecule in tan ribbon; peptides in ball and stick; TCR
side chains in thick lines representation, with carbon atoms colored
in orange; the transparent surfaces of Asn4 (of LLW) or Gly4 (of ELA),
in contact with CDR3 Leu98 (MEL5) or Gly97 (YF5048), are colored in
magenta.
using T-cell clones demonstrated that TRAV12-2 does not pro-
vide a functional advantage on a per cell basis. Together with
the fact that this strong TRAV12-2 bias was already present in
na¨ıve A2/LLW-specific CD8+ T cells before YF-17D vaccination, it
rather suggests that TRAV12-2 might confer a selective advantage
for high frequency and prevalence by favoring thymic output of
na¨ıve cells. We thus sought to investigate how TRAV12-2 may pro-
vide such advantage by investigating the mode of antigen binding
and structural considerations of the TCR-peptide-MHC complex.
The A2/ELA epitope represents a well-known model anti-
gen for which T cells are biased for TRAV12-2 usage [13–17].
A2/ELA-specific CD8+ T cells exhibit high frequency and preva-
lence in HLA-A*0201 healthy individuals as well as melanoma
patients, showing na¨ıve and differentiated phenotypes, respec-
tively. Intriguingly, the binding between the MEL5 TCR express-
ing TRAV12-2 and the ELA peptide in complex with HLA-A*0201
occurs via dominant contacts with the CDR1 loop of TRAV12-
2 [13, 18, 21, 22]. The TRAV12-2 gene is also expressed by the A6
TCR, which is specific for the A2/Tax epitope of the HTLV-1 [4].
The CDR1α and CDR2α loops of the A6 TCR utilize an antigen-
binding mode virtually identical to that seen in the MEL5-A2/ELA
complex, making contacts between the CDR1α loop and the Tax
peptide. A study in HTLV-I-Associated Myelopathy/Tropical Spas-
tic Paraparesis (HAM/TSP) patients revealed that TRAV12-2 tran-
scripts are predominant [23] and the frequency of na¨ıve cells with
this specificity is very high [24]. Therefore, A2/Tax-specific CD8+
T cells constitute another documented example of high na¨ıve fre-
quency associated with TRAV12-2 bias.
Unfortunately, our extensive attempts to generate a TRAV12-2
TCR A2/LLW co-crystal structure failed so we resorted to molec-
ular modeling of this interaction taking advantage of the high
sequence similarity between the A2/LLW-specific TCR YF5048 and
the A2/ELA-specific TCR MEL5. Conveniently, the LLW peptide in
the free A2/LLW structure we solved adopts a similar conforma-
tion to the ELA peptide in the A2/ELA/MEL5 TCR complex. Mod-
eling showed that the YF5048 TCR α-chain positioned above the
N-terminus of the peptide, making contacts predominantly with
Asn4 in the middle of the peptide via the CDR1α loop of TRAV12-
2. The importance of this interaction is further supported by our
results from the mutagenesis scan across the LLW peptide and
CPL screen, highlighting Asn4 as a critical residue for TCR recog-
nition by TRAV12-2 positive TCRs. Our modeling data suggests
that the germline-encoded TRAV12-2 CDR1α loop of A2/LLW-
specific CD8+ T cells makes critical contacts with both MHC and
peptide in a comparable manner to the CDR1α loops in the MEL5
and A6 TRAV12-2 positive TCRs; the MEL5 and A6 [4, 18]. These
three paralleled examples of TRAV12-2 biased responses endorse
the concept that the interactions between the TCR and the antigen
can rely substantially on TCR segments that already pre-exist in
the germline rather than on somatic CDR3 rearrangement. How-
ever, it is important to note that this observation does not apply
to all immunodominant T cell responses, as many public TCRs or
immunodominant epitope-specific TCRs bind their cognate pep-
tide predominantly via residues encoded in the CDR3 rearranged
loops [6, 25].
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Importantly, we showed that TCRs sharing this heritable
TRAV12-2 CDR1α component of antigen binding still preserve
their respective antigen specificity. Indeed, we demonstrated that
there is no cross-reactivity between the LLW and ELA specificities.
Based on in silico modeling, the CDR3β loop sterically hindered
engagement of the non-cognate peptide. Thus, even these exam-
ples of a TRAV germline-encoded antigen binding mode are still
heavily reliant on permissive sequences within the TRBV non-
germline CDR3 loop.
It is intriguing that these three examples of TCRs binding their
epitope with a germline component all involve the CDR1α loop
of TRAV12-2 and HLA*0201. It is conceivable that TCRs express-
ing the TRAV12-2 could have a selective advantage for binding
to cognate antigen restricted by HLA-A*0201 or that other anti-
gen specificities (not only restricted by HLA-A*0201) also har-
bor biases for certain germline-encoded TCR segments but that
these have not yet been identified. The HLA-A*0201 allele and
its associated antigen specificities are the most studied because
HLA-A*0201 is prevalent at 30–50% in Caucasian populations
and is the most prevalent HLA subtype amongst the global human
population, potentially inducing a research bias [26]. Indeed, the
TCR/pMHC structural database is dominated by interactions with
HLA A2. More studies need to be conducted to appreciate the
extent to which this phenomenon of germline-encoded TCR recog-
nition applies to other specificities and TRAV/TRBV families.
Despite the tremendous theoretical genetic diversity of the TCR
repertoire, most studies showed that the adult TCR repertoire is
a consequence of a process that is far from random and TCR
bias is commonly found in immune responses [27]. A specificity
and/or TCR bias could reflect an evolutionary advantage during
infection and other diseases. Several lines of evidence indicate
that the germline-encoded TCR segments have features that pro-
mote binding to MHCmolecules, suggesting co-evolution between
TCR and MHC molecules [28–30]. Our data suggests that there
is also co-evolution between the TCR and the cognate peptide.
Indeed, we observed that TRAV12-2 TCR bias is present before
YF-17D vaccination. In agreement with our functional studies on
A2/LLW-specific clones, it was reported that TRAV12-2 usage in
A2/ELA-specific CD8+ T cells was independent from functional
avidity [15]. In fact, the origin of the large na¨ıve A2/ELA-specific
CD8+ T cell population was attributed to preferential thymic selec-
tion [31, 32]. Given that antigen recognition features a germline-
encoded component, there is presumably a genetic advantage that
confers higher chances for thymic output of TCR constructions
involving the CDR1α of TRAV12-2. Thus, although TRAV12-2 does
not confer a functional advantage on a per cell basis, it may provide
an advantage at the level of the organism by skewing the na¨ıve
CD8+ T cell compartment toward these specificities recognized by
TRAV12-2 CDR1α. This possibly explains the high frequency and
prevalence of specificities such as A2/LLW and A2/ELA.
In summary, we discovered the TCR bias for TRAV12-2 in
A2/LLW-specific CD8+ T cells and demonstrated that there is
no functional advantage in featuring TRAV12-2 on a per cell
basis. Rather, our structural modeling suggests that the germline-
encoded CDR1α loop centrally contributes to peptide binding
similar to two other TRAV12-2 positive TCR specificities. We
also demonstrated that TCRs sharing this TRAV12-2 CDR1α –
mediated mode of antigen binding still preserve their own antigen
specificity.
Materials and methods
Peripheral blood samples
All PBMC samples were obtained in the framework of our previ-
ously published clinical study, approved by the Human Research
Ethics Committee of the Canton de Vaud (protocol 329/12) with
healthy volunteers participating under written informed consent
[8].
Generation of T cell clones
All A2/LLW-specific CD8+ T cell clones used in this study were
generated in the laboratory of D. Speiser, derived from 4 healthy
YF-17D (Stamaril, Sanofi Pasteur) vaccinees. Purified A2/LLW
tetramer-positive populations were isolated by FACS as described
[8] and cloned by limiting dilution in Terasaki plates, cultured in
RPMI 1640 medium supplemented with 8% human serum and
150 U/mL recombinant human IL-2 (rIL-2). Thereafter, T cell
clones were expanded by periodic restimulation with 1 µg/mL
PHA and 106/mL irradiated allogeneic PBMC (30 Gy) as feeder
cells. The MEL5 clone was generated in the laboratory of A.
Sewell as previously described [18]. The clones HD421 2/5F and
LAU1264 were generated in the laboratories of D. Speiser and N.
Rufer as previously described [15].
TCR repertoire and clonotype analysis
in A2/LLW-specific CD8+ T cell clones
Total RNA was isolated using the PicoPure RNA kit per manu-
facturer’s instructions, and cDNA prepared and sequenced as pre-
viously described [21]. Briefly, for the Vβ repertoire, each cDNA
sample was subjected to individual PCRs using a set of previously
validated forward primers specific for the 22 TRBV subfamilies and
one reverse primer specific for the corresponding Cβ gene segment.
For the Vα repertoire, we amplified and sequenced the TRAV12-2
segment using the TRAV12 (forward) and TRAC (reverse) primers.
PCR amplicons of interest were sequenced from the reverse primer
by Fasteris S.A. TRAV and TRBV segments were described accord-
ing to the IMGT nomenclature [33].
51Chromium release assays
The HLA-A*02+ human mutant cell line CEMx721.T2 (Ameri-
can Type Culture Collection) was used as target by labeling with
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51Cr for 1 h at 37°C, followed by extensive washing. Target cell
killing was assessed by chromium release in the supernatant upon
co-culture with CD8+ T cell clones (effector cells) at the Effec-
tor:Target ratio of 10:1 for 4 h at 37°C in V-bottom microwells,
in presence of serial dilutions of the peptide (LLWNGPMAV or
ELAGIGILTV), measured using a gamma counter and calculated
as:
% specific lysis = 100× (experimental − spontaneous release)
(total − spontaneous release)
Flow cytometry
CD8+ T cells were first enriched from cryopreserved sam-
ples using the human CD8+ T cell enrichment kit from
StemCell Technologies (negative selection, per manufacturer’s
instructions). Stainings were performed using phosphate-buffered
saline with 5 mM EDTA, 0.2% bovine serum albumin,
and 20 mM sodium azide [fluorescence-activated cell sort-
ing (FACS) buffer]. Tetramer stainings were performed for
40 min at 4°C. All tetramers were purchased from TCmetrix
Sa`rl : HLA-A*0201/LLWNGPMAV (NS4b214-222, Yellow Fever
Virus), HLA-A*0201/VMLFILAGL (NS4a54-62, Yellow Fever Virus),
HLA-B*0701/RPIDDRFGL (NS5211-219, Yellow Fever Virus),
HLA-A*0201/GLCTLVAML (BMFL1280-288, Epstein Barr Virus),
HLA-A*0201/NLVPMVATV (pp65495-503, Cytomegalovirus), HLA-
A*0201/ELAGIGILTV (Melan-A26-35 (A27L), Melanoma). Surface
antibody staining was then performed, followed by staining
with LIVE/DEAD-Fixable-Aqua (Invitrogen), each step at 4°C for
30 min. Cells were fixed overnight in 0.36% formaldehyde (sup-
plemented with 2% glucose and 5 mM sodium azide). Samples
were acquired using a Gallios flow cytometer (Beckman Coulter,
three-laser configuration). The data were processed with FlowJo
(Tree Star Inc., v9.5.2). Samples with antigen-specific populations
below 0.001% tetramer-positive cells in total CD8+ T cells were
considered negative and populations consisting of less than 20
events were not considered eligible for further analysis.
Intracellular cytokine staining assay
A2/LLW-specific CD8+ T cell clones were stimulated with LLW
peptide-loaded T2 cells at the E:T cell ratio of 1:2 for 4 h at
37°C in the presence of Brefeldin-A (Sigma-Aldrich) and anti-
CD107a-FITC antibody (BD Biosciences). Then, cells were stained
with anti–CD8–APC-AF750 antibody (Beckman Coulter) at 4°C
for 30 min. After washing in PBS, cells were incubated with
LIVE/DEAD-Fixable-Aqua (Invitrogen) at 4°C for 30 min, and
fixed at 4°C overnight (0.36% formaldehyde buffer). Cells were
washed and stained intracellularly with anti-IFNγ-PC7, anti-TNFα-
A700 and anti-IL-2-PerPCP-Cy5.5 antibodies (BD Biosciences) in
FACS buffer with 0.1% saponin for 30 min at 4°C. Samples were
acquired and data processed as described above.
NTAmer staining and dissociation kinetic
measurements
Dually labeled pMHC multimers built on NTA-Ni2+-His-tag inter-
actions called NTAmers (synthetized by TCMetrix Sa`rl) were used
for dissociation kinetic measurements [34, 35]. Stainings with
dually PE- and Cy5-labeled A2/LLW-specific NTAmers and data
analysis were done as previously described [34, 36]. Briefly, stain-
ing was measured at 4°C using a thermostat device on a SORP-
LSR II flow cytometer (BD Biosciences). Following 30 s of baseline
acquisition, imidazole (100 mM) was added. PE and Cy5 fluores-
cence were measured during the following 5 min. Data were pro-
cessed using the kinetic module of the FlowJo software (v.9.7.6;
Tree Star), and corrected mean fluorescence intensity values were
plotted and analyzed using the GraphPad Prism software (v.6;
GraphPad).
Combinatorial peptide library (CPL) scans
The nonamer CPL contains a total of 4.8 × 1011 ((9+19) × 198)
different nonamer peptides divided into 180 sub-libraries with
each containing 198 different nonamer peptides in approximately
equimolar concentrations (Pepscan, Lelystad, The Netherlands)
[37]. Each of the 180 sub-libraries has a fixed amino acid residue
but all other positions are degenerate. Cysteine was excluded from
all degenerate positions to avoid oxidation, but was included at
the fixed positions. Prior to the assay, CD8+ T cell clones were
washed and rested overnight in R5 medium (RPMI 1640 supple-
mented with 100 units/mL penicillin, 100 µg/mL streptomycin,
2 mm l-glutamine, and 5% heat-inactivated fetal calf serum (all
Invitrogen). For CPL screening, 6 × 104 C1R A2 cells [38] were
pulsed with each sub-library at 100 µg/mL in duplicate for 2 h
at 37°C. After peptide pulsing, 3 × 104 CD8+ T cells were added,
and the cultures were incubated overnight at 37°C. Subsequently,
the supernatant was harvested and assayed for MIP-1β by ELISA
according to the manufacturer’s instructions (R&D Systems).
Protein expression, refolding, and purification
HLA A*0201 α-chain and β2m were expressed separately, with-
out post-translational modification, as insoluble inclusion bodies
(IBs) in competent Rosetta (DE3) Escherichia coli cells, using 0.5M
IPTG to induce expression as thoroughly described recently [39].
Briefly, for a 1L pMHC refold, 30 mg HLA-A*0201 α-chain was
mixed with 30 mg β2 m and 4 mg peptide at 37°C for 15 min
with 10 mM DTT. This mixture was then added to cold refold
buffer (50 mM Tris, pH8, 2 mM EDTA, 400 mM L-arginine, 6 mM
cysteamine hydrochloride, and 4 mM cystamine). Refolds were
mixed at 4°C for > 6 h. Dialysis was performed against 10 mM
TRIS, pH8.1, until the conductivity of the refolds was less than
two millisiemens per centimeter. The refolds were then filtered
and purified first by ion exchange using a Poros50HQTM col-
umn (GE Healthcare, Buckinghamshire, U.K.) and second by gel
filtration directly into crystallization buffer (10 mM Tris pH8.1
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and 10 mM NaCl) or PBS buffer (137 mM NaCl, 3 mM KCl, 8 mM
Na2HPO4, 1mMKH2PO4) using a Superdex200HRTM column (GE
Healthcare, Buckinghamshire, U.K.). Protein quality was analyzed
by Coomassie-stained SDS-PAGE, either under non-reducing or
reducing conditions. HLA-A*0201 was refolded with the peptides
LLWNGPMAV (A2/LLW) or LLWAGPMAV (A2/LLW-4A).
Crystallization, diffraction data collection, and model
refinement
All protein crystals were grown at 18°C by vapor diffusion via the
“sitting drop” technique. 200 nL of each pMHC (20 mg/mL) in
crystallization buffer was added to 200 nL of reservoir solution.
A2/LLW crystals were grown in 0.1 M Hepes, pH7, 0.2 M ammo-
nium sulphate, 20%PEG 4000. All crystals were soaked in 30%
ethylene glycol before cryo-cooling. All crystallization screens and
optimization experiments were completed using an Art-Robbins
Gryphon dispensing robot (Alpha Biotech Ltd., UK). Data were
collected at 100 K at the Diamond Light Source (Oxfordshire, UK)
as described previously [40]. All data sets were collected at awave-
length of 0.98 A˚ using an ADSC Q315 CCD detector. Reflection
intensities were estimated with the XIA2 package, and the data
were scaled, reduced, and analyzed with the SCALA and CCP4
package. Structures were solvedwithmolecular replacement using
PHASER. A solution could be obtained with a search model taken
from Protein Data Bank entry 5EU5. Sequences were adjusted
with COOT, and the models were refined with REFMAC5. Graph-
ical representations were prepared with PyMOL. The reflection
data and final model coordinates were deposited in the Protein
Data Bank (PDB code: 5N6B).
Measuring the thermal stability of
HLA-A*0201–peptide complexes
Thermal stability of A2/peptide complexes was assessed by CD
spectroscopy monitoring the change of ellipticities ! at 218nm
where the spectra exhibit a minimum. Data were collected on
an Aviv 215 spectrometer (Aviv Biomedical Inc., Lakewood, NJ)
equipped with a thermostated cell holder using a 1 mm quartz
cell. Proteins were dissolved in PBS at c = 3.5 µM. Denatura-
tion was monitored from 4°C up to a temperature when protein
precipitation occurred using a gradient of 0.5°C/min. Melting
curves were analyzed assuming a two-state native (N) to dena-
tured (D) transition N3 ↔ 3D with the melting temperature and
van’t Hoff’s enthalpy at the midpoint of the transition as fitting
parameters [41, 42].
Modeling the TCR-p-MHC complex
The 3D structure of the TRAV12-2/TRBV9 TCR in complex with
HLA-A2 and the LLWNGPMAV peptide was modeled from three
experimental structures: 3HG1 [18] and 4QOK [43], containing
a complex between the TRAV12-2/TRBC1 TCR in complex with
HLA-A2 and the ELAGIGILTV or EAAGIGILTV peptides, respec-
tively, and the experimental structure obtained in this study for
the complex between HLA-A2 and the LLWNGPMAV peptide. The
sequence alignment between TRBV9 and TRBC1 was performed
using the MUSCLE program [44]. The sequence identity between
the variable part of the TRBV9 and TRBC1 TCR beta chains is 30%.
Based on this sequence alignment, the model was obtained using
the Modeller program [45, 46]. 1000 models were generated by
satisfaction of spatial restraints through minimization and simu-
lated annealing, and the model with the best Modeller objective
function was retained. Molecules were visualized and analyzed
using UCSF Chimera [47].
The model of A2/LLW in complex with the MEL5 TCR was
obtained with the Modeller program, following the method
described above to obtain the structural model of A2/LLW with
the YF5048 TCR. In this case, however, we used our experimen-
tal structure of the A2/LLW as a template for the HLA/peptide
domain and the experimental structure of the complex between
A2/ELA and MEL5 (PDB code: 3HG1) as a template for the MEL5
TCR.
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Abstract 
 
The establishment of long-term memory is a fundamental feature of the cytotoxic 
CD8 T cell response. Yet when do memory cells arise, especially in humans, is poorly 
documented, the pathways of effector / memory cell differentiation being largely 
debated. Based on a cross-sectional study, we previously reported that the live-
attenuated Yellow Fever virus vaccine YF-17D induces a stem cell-like memory 
(SCM) CD8 T cell population persisting for at least 25 years. Here we present 
longitudinal data revealing that CD8 T cells with an activated (I would remove 
“activated”) SCM T cell phenotype are distinctly detectable within two weeks 
following YF-17D vaccination (in the acute phase). These cells, which express the 
central memory transcription factor T cell factor-1 (TCF1), preferentially persist, 
consistent with the role of TCF1 in memory establishment. By performing t-
distributed Stochastic Neighbour Embedding of flow cytometry data, we obtained a 
rich time-lapse representation of the dynamics of the CD8 T cell response: SCM cells 
appear early (2 weeks?) and remain closely related to the baseline Naïve cells (not 
clear what you mean, their abundance?), while effector cells burst out of baseline and 
gradually contract after the peak of the response. Thus we observe cells with memory 
phenotypes very early in the response. As opposed to models where memory cells 
develop from effector cells, our data support differentiation models where long-term 
memory cells are established by the early decision to retain proximity to the Naïve 
state in a memory-dedicated pool of cells. 
 
 
 
Keywords: Stem cell-like memory, CD8 T cell, Yellow Fever virus, YF-17D 
vaccination, acute phase, T cell factor 1,   
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Introduction 
 
The capacity to remember a pathogen and effectively protect the organism against it 
long-term is a fundamental property of the adaptive immune response. This is also 
relevant for tumour immunology since it is now well established that strong and long-
lasting cytotoxic CD8 T cell responses correlate with better prognosis for cancer 
patients (1), and that innovative immunotherapies can defeat various types of 
metastatic cancers with unprecedented long-term success (2). 
 
Once naïve T cells are primed upon antigenic encounter, the various functionalities of 
CD8 T cells are ensured by a heterogeneity of cells, with varying degrees of memory 
and effector functions. Initially classified into only two functional types (effector or 
memory), the heterogeneity of CD8 T cells has been more comprehensively defined 
over the last decade. The venue of transcriptomic and epigenetic profiling 
complementing functional assays has revealed a continuum of phenotypes with 
varying longevity, self-renewal, proliferative potential, expression of homing, 
costimulatory and transcription factors, and functions including cytokine secretion 
and cytotoxicity (3-7). Globally, effector cells display cytotoxicity and readily 
produce cytokines, while memory cells resemble more the naïve cells based on their 
high proliferative capacity and potential to generate effector progeny, together with 
long-term persistence and self-renewal (so called stemness) (although the latter are 
not features of naive cells...). Traditionally, surface markers (including distinct 
homing molecules) and transcription factors have been used to define the various 
CD8 T cell subsets. In humans, classic subsets are primarily identified on the basis of 
surface C-C motif chemokine receptor 7 (CCR7) and CD45RA expression, with naïve 
cells being CCR7+ CD45RA+, the central memory (CM) being CCR7+ CD45RA-, 
and the CCR7- effector memory subsets split into CD45RA- effector memory (EM) 
and effector memory CD45RA+ (EMRA) cells (8). More recently, the stem cell-like 
memory (SCM) subset was revealed among CCR7+ CD45RA+ cells (within the 
classic Naïve gate) on the basis of positive expression of markers such as CD58, 
CXCR3, IL2Rb and the more prominently used CD95 marker (9,10). 
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Along with the increasingly comprehensive characterization of the heterogeneity of 
CD8 T cell phenotypes and functions, several models have emerged to describe the 
differentiation pathways of antigen-experienced CD8 T cells, starting when Naïve 
cells are primed, to explain the genealogy of memory and effector cells. The initially 
proposed model of CD8 T cell differentiation is linear: it suggests a sequential 
differentiation of naïve cells, first into effectors that predominate in the acute phase, 
followed by differentiation of a fraction of effector cells into memory cells, as the 
response contracts and most effector cells die out or become terminally senescent. In 
the mouse system, the linear model evolved to describe early effector cells (EEC) that 
give rise to two types of effector cells: one short-lived effector cells (SLEC) and 
another memory precursor effector cells (MPEC) – long-term memory predominantly 
originates from MPECs (11-13). Alternative models have proposed that memory cells 
differentiate without an obligatory acute effector stage (it is contradictory if you use 
effector twice). For instance, the so-called bifurcative model proposes an immediate 
divergence from the naïve cell: in a first asymmetric cell division, the antigen-primed 
naïve cell splits into distinct daughter cells, each with a distinct memory or effector 
fate (14,15). More recently, the proposed models integrate the large and gradual 
heterogeneity of memory and effector cells, based on the observed continuum of 
whole transcriptome and epigenetic profiles (3,16,17). These suggest that CD8 T cells 
may undergo progressive differentiation, from the naïve, to the SCM, CM, EM and 
EMRA cell stages, and all the various subsets may give rise to effector progeny or 
show effector function in their activated state (7,18).  
 
      To date, it is still controversial whether memory results from an early decision to 
diverge from effector fate or whether a fraction of effectors gives rise to memory 
cells. Studies in the last year continued debating whether long-lived memory cells 
display an epigenetic imprint that would correspond to an effector phenotype past 
(19,20) or whether stemness (highest memory potential) is preserved epigenetically in 
antigen-primed naïve cells that become memory cells and it is the silencing of 
memory / stemness genes that drives effector differentiation (21). One limitation is 
that nascent memory cells are not easily detectable or may not be distinguished from 
effector cells in the activated, acute phase (22). Markers such as IL7Ra have been 
highlighted to identify the precursors of long-lived memory cells (the MPECs in 
mice), distinct from the majority of activated cells that die after the acute phase (23). 
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One major factor that is essential to sustain central memory formation is the 
transcription factor T cell factor 1 (TCF1, encoded by the TCF7 gene) (24-27). TCF1 
is expressed at high levels in Naïve and memory but not in effector cells (4,28,29), 
and is epigenetically regulated during CD8 T cell differentiation (3,30) as one major 
gene involved in effector differentiation arrest and maintenance of stemness 
(21,31,32). Recently, we showed that inflammatory cytokines supress TCF1 and 
facilitate effector differentiation (33).  
•  
Overall, studies on the identification of precursors and discernment of early fate 
decisions rely on genetic manipulation and the adoptive transfer or deletion of cells to 
test their progeny potential, which is limited to mouse models. Yet a major level of 
complexity in the study of CD8 T cell differentiation is the idiosyncrasies in mouse 
versus human systems. While fundamental phenomena may be shared, in practice, 
there is a basic difference in the markers used to classify CD8 T cell subsets. 
Therefore, and in complement to the ontological questions that can readily be 
addressed in the mouse experimental system, the evidence that originates from the 
study of human CD8 T cells is uniquely valuable. One human model that has been 
particularly informative to fully apprehend optimal immunogenicity in humans, 
including the study of CD8 T cell differentiation, is the acute response to the live-
attenuated Yellow Fever virus vaccine YF-17D (34,35). We previously found that 
YF-17D vaccination induces a population of stem cell-like memory cells and showed 
that these memory cells last for decades (36,37). However, the earliest time-point 
after vaccination that we studied was 3.6 months, well after the acute phase that is the 
first 2 weeks of the response. There is currently no information on when SCM cells 
can be detected during an immune response in humans. Here, we aimed to study the 
distribution and dynamics of human CD8 T cell subsets during the first few days to 
months after YF-17D vaccination based on a longitudinal clinical study protocol (i.e. 
including the acute phase of the response), combined with analysis in the decade-
long-term based on our previous cross-sectional study cohort.  
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Materials and Methods 
 
Study design, population and ethics statement 
Samples used in this study originated from peripheral blood of healthy volunteers 
aged 18 to 65 years that participated in one of two study protocols on YF-17D 
vaccination (Stamaril, Sanofi Pasteur). Donors from the first cohort “YF1” (study 
protocol 329/12) had a history of YF-17D vaccination ranging from 3.6 months to 
23.74 years (cross-sectional) and donated blood in the local Blood Transfusion Center 
(Service régional vaudois de transfusion sanguine, 1066 Epalinges), as we described 
previously ((36). Donors from the second cohort “YF2” (study protocol 324/13) were 
in the prospect of receiving the YF-17D vaccine in view of travelling to endemic 
areas and participated to longitudinal sampling before and several time-points after 
YF-17D vaccination, in collaboration with the local vaccine center Centre de 
vaccination et de médecine des voyages (Policlinique Médicale Universitaire (PMU), 
Lausanne). The full metadata details of the two cohorts are listed in Table S1. The 
study protocols were approved by the Swiss Ethics Committee on research involving 
humans of the Canton of Vaud (CH). All participants provided written informed 
consent. 
 
Peripheral blood collection and processing 
Peripheral blood samples were collected and immediately processed for 
cryopreservation awaiting experimental use. Peripheral blood mononuclear cells 
(PBMC) were obtained from anti-coagulated whole blood diluted 1:1 in phosphate 
buffered saline (PBS) and overlaid on Lymphoprep for density gradient fractionation 
(30 min at 400g without break) and were cryopreserved in complete RPMI 1640 
supplemented with 40% fetal calf serum (FCS) and 10% dimethyl sulfoxide. Plasma 
samples were obtained from the supernatant of EDTA-coated blood tubes after 
centrifugation at 1’000g for 15 min at RT followed by a second centrifugation at 
8’000g for 10 min at 4oC. 
 
Assay to determine copy numbers of the Yellow Fever virus YF-17D 
	 246	
Yellow Fever virus (YFV) load was quantified using 1ml of plasma from EDTA-
anticoagulated blood based on a Taqman Real-time PCR assay to detect YFV genome 
copies as previously described (38). 
 
Flow cytometry staining, acquisition and analysis 
On the day of the experiment, frozen vials of PBMC were thawed in RMPI containing 
10 ug / ml of DNAse I (Sigma) and resuspended in fluorescence-activated cell sorting 
buffer (FACS buffer: PBS with 5mM EDTA, 0.2% Bovine Serum Albumin and 0.2% 
sodium azide). Thawed PBMC were subjected to CD8+ T cell selection using the 
negative enrichment kit from Stem Cell. CD8 T cell-enriched samples were then 
stained for flow cytometry according to target panels and cytometers as summarized 
in Table S2 and with reagents as listed in Table S3. Stainings were made in sequence 
depending on the target, as follows: 1) first, cells were stained with multimers for 30 
min at 4°C in FACS buffer and washed in FACS buffer, 2) surface antibodies were 
added in FACS buffer and washed with PBS prior to 3) staining with fixable viability 
dye in PBS and washed with PBS, 4) cells were then fixed overnight at 4°C and 
washed in permeabilisation buffer before 5) intracellular staining in permeabilisation 
buffer at 4°C (the primary rabbit anti-TCF1 and the secondary fluorochrome-
conjugated anti-rabbit IgG were stained in two subsequent steps). The fixation and 
permabilisation buffers were from the Foxp3 staining kit from eBioscience. Washes 
were made by centrifugation at 450g for 7 min. Samples were resuspended in FACS 
buffer for acquisition. For samples in the YF2 study, the baseline sample vial 
originally contained 1.5 x 10e7 frozen PBMC and the remainder of time-points’ vials 
contained 10e7 frozen PBMC – the complete volume of stained samples was finally 
acquired. Cytometers were the Gallios (Beckman Coulter, 3 laser, 10-color) and the 
LSR II Special Order Research Product (Beckton Dickinson, 5 laser including UV, 
13- or 14-color). Before each acquisition, the cytometer setup and tracking (CST) was 
ran in order to normalize channel voltages across experiments using the same 
instrument configuration and experimental layout. Flow cytometry FCS data files 
were analyzed in FlowJo 9.7.7, except for the analyses using t-distributed Stochastic 
Neighbor Embedding for which the corresponding plugin in FlowJo 10.4.2 was used. 
Downsampling, concatenation or exports of specific populations and samples were 
performed as indicated in the figure legends also in FlowJo 10.4.2. For the 
longitudinal tSNE analyses of A2/LLW-specific CD8 T cells, all single live A2/LLW-
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specific CD8 T cell events of the longitudinal series were concatenated and thus are 
represented in proportions corresponding to the original numbers of PBMC thawed, 
which are equal across time-points (corresponding to 10e7 PBMC thawed) except for 
the baseline which is 1.5-fold larger (1.5 x 10e7 PBMC thawed). The detection 
threshold for multimer positive populations was 0.01% of total CD8 T cells and at 
least 10 events (horizontal dotted line in Figure 1 C and D). The positivity threshold 
for each marker was set according to distinct negative and positive populations in 
bulk CD8 T in resting and/or activated samples; for the indirect TCF1 staining, the 
negative signal was further validated with secondary antibody-only controls.   
 
Quantifications and statistical analyses 
Flow cytometry data analyzed with FlowJo was quantified based on tabulated exports 
of the frequencies and events in the gates of interest. Calculations and data display 
thereafter was performed using the softwares Microsoft Excel 15.21.1, GraphPad 
prism 7.0c and SPICE v5.35 (for co-expression analyses). Statistical values were 
obtained as detailed in each figure legend (on the basis of normality tests), where 
trend = p>0.05 and <0.10, * = p<0.05, ** = p<0.01, *** = p<0.001 and ns = not 
significant. For the SPICE analyses, p-values originate from the built-in t-test in 
SPICE using 10'000 permutations. Longitudinal modeling of the flow cytometry data 
was achieved using linear mixed effects splines. In brief, linear splines with 3 internal 
knots and a random intercept was fit using the lme4 package in R (39). Pairwise 
comparison of fits to individual subsets was performed by fitting a null model to 
pooled data from the two subsets, a full model with distinct fits capturing the trends in 
each subset, and using the likelihood ratio test to assess the difference between these 
two nested models using the Chi square distribution. Resulting p-values were further 
adjusted for multiple comparisons using the Bonferroni method.   
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Results 
 
CD8 T cells with a CCR7+ memory phenotype expand in the acute phase of YF-
17D vaccination 
 
In order to study the early dynamics of CD8 T cell differentiation, we recruited 
healthy volunteers that were going to receive the YF-17D vaccine in order to obtain 
peripheral blood samples before and at several time-points after vaccination 
(including early days and up to 6 months after vaccination). The study schedule and 
cohort are detailed in Table S1 A: “YF2 cohort”. Using peptide-MHC multimers, we 
detected CD8 T cells specific for the immunodominant HLA-A*02-restricted epitope 
of the Non-Structural 4b protein of Yellow Fever virus (the LLWNGPMAV epitope 
(40-42)), hereafter referred to as “A2/LLW”) in eight HLA-A*02+ vaccinees. The 
phenotypes of CD8 T cell differentiation were determined based on the classic 
markers CCR7 and CD45RA (8) as shown in Figure 1A to detect Central Memory 
(CM: CCR7+ CD45RA-), Effector Memory (EM: CCR7- CD45RA-) and Effector 
memory CD45RA+ (EMRA: CCR7- CD45RA+); within the CCR7 CD45RA double-
positive gate, Naïve and stem cell-like memory (SCM) subsets were discriminated 
based on CD95 expression (9,10,18). Of note, the aforementioned subset 
nomenclature describes resting human CD8 T cells; for the purpose of longitudinal 
consistency we maintain this nomenclature yet highlight that acutely activated human 
effector cells downregulate CCR7 and phenotypically coincide with EM and EMRA 
(18). 
 
We observed a massive expansion of A2/LLW-specific CD8 T cells with a peak 
around day 14 post-vaccination, with largely predominant CCR7- phenotypes (Figure 
1B and C: “Total A2/LLW+”, “EM” and “EMRA” plots), in agreement with our prior 
analyses (40) (I thought this early time point has not been analyzed before?). 
Remarkably, detailed longitudinal quantification also showed expansion of CCR7+ 
memory phenotype cells: both CM and SCM cells were clearly detected and 
expanded by day 14 (Figure 1 C and D). After the peak at day 14, EM cells 
contracted, while EMRA cells continued to increase slightly until day 28. At the later 
time-points, especially by 6 months, it was evident that EMRA and SCM subsets 
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persisted, while EM and CM subsets continued to fade away. This later observation 
was in line with our previous report where the EMRA and SCM subsets were the two 
subsets predominantly detected in the long-term (range of years to decades), the SCM 
cells being the most stable memory cell subset described so far (36).  
 
In addition, we determined whether CCR7+ memory phenotype cells detected during 
the early phase post-vaccination co-existed with antigen, i.e. before viral clearance. 
Live-attenuated vaccine virus YF-17D was detectable at days 3 and/or 7 in the plasma 
of five out of the eight vaccinees (Figure 1D and Figure S1). When considering 
samples that showed >0.01% A2/LLW+ CD8 T cells two donors had significant CM 
(in donor LAU 5088) or both CM and SCM populations (in donor LAU 5080) among 
A2/LLW+ cells at the same time-point when virus was detectable (Figure S1). These 
data show that cells with a memory phenotype can arise before antigen is cleared, 
well ahead of the contraction phase of the response. 
 
 
SCM and CM phenotype cells are activated at the peak of the response 
 
In parallel to the rise in frequencies, the acute phase of the T cell response is 
characterized by the expression of activation markers as previously described in total 
A2/LLW+ CD8 T cells (40,42,43). In order to address how activation compared 
across CD8 T cell subsets, we measured the longitudinal expression of activation 
markers: CD69, CD38, HLA-DR and PD1, within each subset. At the peak of the 
response (day 14), the analyses clearly showed that the SCM and CM subsets were 
extensively activated, in fact as much as the CCR7- EM and EMRA subsets (Figure 
2). The early activation marker CD69 was most highly expressed at days 3 and 7, 
while HLA-DR, CD38 and PD1 peaked at day 14 (Figure S2). Beyond day 14, CD38 
clearly diminished while HLA-DR and PD1 partially persisted (Figure S2).  
 
Of note, in the aforementioned longitudinal analyses, we observed that A2/LLW+ 
CD8 T cells were still present in the Naïve gate (as defined by CCR7+ CD45RA+ 
CD95-) after vaccination and that they remained relatively stable over time (Figure 1). 
Interestingly, these post-vaccination Naïve cells did show substantial activation at the 
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peak of the response (Figure 2 and S2). The nature of these Naïve-gated cells will be 
discussed.  (in my mind this paragraph is a problem) 
 
 
TCF1+ CD8 T cells preferentially persist for decades 
 
Given the central function of T cell factor 1 in memory establishment (24-26,31,32), 
we next monitored the expression of TCF1 in the various CD8 T cell subsets 
following YF-17D vaccination. First, by analyzing resting total CD8 T cells in a large 
number of donors (N=33), we observed a wide heterogeneity in TCF1 levels in 
human CCR7- CD8 T cell subsets (EM and EMRA). In line with mouse and human 
gene expression data (3,4,28,29), we observed the hierarchical expression of TCF1: 
Naïve and memory subsets (including CM and SCM) expressed high levels of TCF1, 
while effector subsets (EM and EMRA) had low-to-negative levels of TCF1 (Figure 
3). Similar to the inter-donor variability in subset distribution (Figure 3A and C), this 
single cell protein data in N=33 donors revealed that the fraction of TCF1+ cells was 
widely variable within CCR7- subsets across donors (EM and EMRA, Figure 3B and 
D). 
 
We then analyzed the profiles of TCF1 in A2/LLW-specific CD8 T cells at various 
time-points following vaccination with YF-17D. (At 2? weeks post vaccination (? 
corrcct),  
- should you not rather concentrate on Tcf1 expression by SCM and CM at the 
early timepoints and then describe the downregulation in effector cells 
- are the late time points really of interest oin this context 
 
the frequency of TCF1 positive cells was low among antigen-sepecific  CCR7 
negative subsets (EM and EMRA, Figure 4 A and B), providing evidence of TCF1 
downregulation during the acute response in humans in vivo. The maximum drop in 
TCF1 occurred at day 28 (Figure 4 A and B), and appeared thus delayed relative to 
the activation peak at day 14 (Figure S2) (what do you make of this?). After day 28, 
the CCR7- populations (EM or EMRA) showed a gradual increase in the percentages 
of TCF1+ cells, particularly visible in the decade-persisting EM and EMRA cells 
(Figure 4B). Based on longitudinal modeling of the percentage of TCF1+ cells per 
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subset and the comparison of the trends across subsets, the CCR7- subsets (EM and 
EMRA) were found to exhibit a distinct profile compared to CCR7+ subsets (Naïve, 
SCM, and CM) (Figure 4C). While CM cells showed a trend closer to the trends in 
Naïve and SCM, they were statistically distinct to all subsets; the trends of Naïve and 
SCM were not distinguishable (Figure 4C).  
 
Within the CCR7- subsets, we addressed whether the increase in the percentage of 
TCF1+ cells in the longer-term was linked to an overall or a relative increase in 
TCF1+ cells. We considered the frequencies of TCF1 positive or negative cells in 
each CCR7- subset in relation to the total CD8 T cells and from the peak of the 
response (day 14), and observed that : 1) both TCF1 positive and TCF1 negative 
populations declined with time (Figure 4D), and 2) TCF1 positive populations 
declined less than TCF1 negative populations (Figure 4 D and E), in both EM and 
EMRA subsets. Rather than re-expression of TCF1 in CCR7- cells, these relative 
frequencies suggest that TCF1 positive cells persist better than TCF1 negative cells in 
the long-term. 
 
We further studied the expression of the Interleukin 7 Receptor alpha chain (IL7Ra) 
in the EMRA subset and found a pattern of IL7Ra expression globally correlating 
with that of TCF1 expression (Figure 5 and S5). In particular, both TCF1 and IL7Ra 
were enriched in EMRA cells persisting beyond six months and further co-enriched 
when persisting over three years. Similar trends were observed for the EM 
populations; however, because the EM subset in total CD8 T cells inherently features 
a substantial fraction of IL7Ra+ cells (as opposed to the scarcer fraction of IL7Ra+ in 
total EMRA), the TCF1 and IL7Ra co-enrichment was not significant; CCR7+ 
subsets express high levels of IL7Ra similar to high levels of TCF1+ (data not 
shown). This is in line with our previous analysis where A2/LLW-specific EMRA but 
not A2/LLW-specific EM showed significant enrichment of the IL7Ra as compared to 
their counterparts in total CD8 T cells (36).  
 
 
SCM CD8 T cells retain proximity to the Naïve baseline (clarfy whether you 
mean abunadance or phenotype of both), while effectors burst out of baseline 
and gradually contract 
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In order to detail the dynamics of the CD8 T cell response including multiple 
differentiation and activation markers, we applied multi-dimensionality reduction and 
unsupervised clustering to flow cytometry data using t-distributed Stochastic 
Neighbor Embedding (tSNE), and then further generated time-lapse representations. 
We applied this analysis strategy to samples from our longitudinal YF2 cohort, alone 
and in combination with long-term samples from the cross-sectional YF1 cohort. As 
detailed in the methods section, concatenated tSNE was possible for samples acquired 
with the same antibody panel and acquired under the same instrument configuration 
and normalized settings (Table S2). 
 
First, tSNE was ran on single live total CD8 T cells from a pool of n=13 donors, 
analyzing nine differentiation and activation markers: CCR7, CD45RA, CD95, TCF1, 
IL7Ra, PD1, CD69, CD38 and HLA-DR. The differentiation subsets were then gated 
using the standard strategy (Figure 6A, similar to Figure 1A) in order to be located 
within the tSNE plots. The tSNE analysis of this n=13 donor pool of total CD8 T cells 
showed a distinct Naïve lobe, with SCM cells bridging this Naïve lobe into the 
remaining differentiation subsets which were arranged in a gradient and formed a 
second lobe (Figure 6 B: subset overlay, and C: individual subset populations). The 
localization of the subsets gated based on CCR7, CD45RA and CD95 (Figure 6 A) 
corresponded well with the tSNE clustering, including the expression patterns 
expected for the other six markers (Figure 6D) : for instance, IL7Ra and TCF1 were 
low while PD1 was high only in the CCR7- populations. In independent analyses, we 
analyzed N=16 donors, applying the 9-marker tSNE to each donor individually 
(Figure S6). We found that the pattern described above is reproducible across donors 
and tSNE runs, with donors showing variable sizes of the Naïve and differentiated 
lobes as expected based on the natural variability of the frequencies of CD8 T cell 
subsets (Figure 3). Of note, SCM where found in the bridge between lobes and also 
interspersed within the Naïve lobes. 
 
We next applied this 9-marker tSNE analysis to longitudinal series of YF-17D 
vaccination samples, running tSNE individually on each series of 7 donors. The 
subset overlay tSNE plots were generated as in Figure 6, by gating subsets in each 
time-point of the longitudinal concatenated file (Figure S7). We then represented each 
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time-point and generated time-lapse animations of the data. We found a remarkable 
pattern of the dynamics of CD8 T cell differentiation during YF-17D vaccination 
across donors: SCM cells appear and remain very close to the location of baseline 
Naïve cells (Figure 7A; Video 1 showing N=7 subset overlays, and Video 2 showing 
each marker for donor LAU 5089 à video links inserted here). In contrast, effector 
CCR7- populations burst out of the baseline Naïve location, peaking their distance at 
days 14-28, and gradually contracting. Intriguingly, we observed a population of cells 
that permanently allocated to the region of the baseline cells (with a Naïve and SCM 
phenotype), throughout the response. 
 
To address how do decade-persisting CD8 T cells compare to the early dynamics, in 
further analyses, we concatenated N=6 longitudinal series of early vaccination 
samples (longitudinal cohort, up to 6 months; 7 time-points per series) with N=13 
samples from the long-term, cross-sectional study. We found that in both tSNE 
dimensions (x and y), the long-term samples also featured a population that clustered 
in the baseline location, in a prolongation of the cells that stay permanent in the 
region that Naïve cells occupy at baseline and throughout vaccination (Figure 7B). 
Conclude..... 
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Discussion 
 
To date, the differentiation pathways and fates of antigen-primed CD8 T cells are 
largely debated, a major question being whether memory cells establish from a 
fraction of acute effectors or from precursors that diverge from the effector fate. With 
respect to the existing experimental evidence, one basic question still is : how early do 
memory subsets appear? Specifically concerning the more recently coined SCM 
subset, the existing evidence is limited to one study using the macaque model of 
Simian Immunodeficiency Virus infection, where antigen-specific CD8 SCM cells are 
observed as early as day 7 of infection (supplementary data showing CM9/TL8-
specific CD8 T cells in (44)). Based on our clinical studies in YF-17D vaccinees, we 
show first evidence in humans, in vivo, that antigen-specific CD8 T memory cells 
including CM and SCM subsets are activated and expand during the acute phase of 
the response. The analysis of samples before day 14 was challenging due to the low 
frequencies of antigen-specific cells and due to the medical restrictions for blood 
withdrawals that precluded closer intervals in our study. Nevertheless, two donors 
showed rising memory cells as early as day 3 and 7, while virus was still detectable 
(day 3). Our data clearly exclude that memory subsets appear only once the antigen is 
cleared or after the acute peak, and provide evidence that cells with a memory 
phenotype establish early after priming, within the acute phase.  
 
The particular value of this human experimental evidence is highlighted by the 
challenge in studying memory development based on phenotypic markers, and the 
fact that these markers globally vary between mouse and human systems. In the 
mouse, the major differentiation markers used are CD44 (for antigen-experienced) 
and CD62L (for Naïve and memory), as well as IL7Ra (naïve and memory including 
MPECs) and KLRG1 (terminally differentiated effectors and SLECs). Human CD8 T 
cell subsets are classically defined on the basis of CCR7 and CD45RA (as detailed in 
the introduction). The SCM subset was first identified in the mouse as cells within the 
classic naïve-like gate that distinctly express IL2Rb, Bcl-2, CXCR3, and SCA-1 (32). 
Human SCM are distinguished from Naïve by the positive expression of CD95 and 
CD58, but these two markers are not used in mice. Conversely, the mouse SCA-1 has 
no human ortholog. The markers CXCR3, IL2Rb and Bcl-2 used in mice are also 
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considered positive in human SCM (9,10,36,44). However, these three later markers 
are poorly discriminative to distinguish SCM from Naïve cells: i) Bcl-2 is highly 
expressed in both Naïve and SCM(9) (in contrast to downregulation in cycling 
effectors cells(34)), ii) IL2Rb is higher in SCM but requires visualization with a 
second marker for Naïve/SCM discrimination, in contrast to the distinct CD95+ 
staining of SCM cells versus CD95- signal in naïve cells (9), and ii) CXCR3 shows 
high inter-donor variability and substantial positive signal even in cells that are CD58 
and CD95 negative such as Melan-A-specific CD8 T cells in healthy donors, which 
are presumably naïve (36). A major challenge is thus the availability and choice of 
markers to distinctly define and visualize memory subsets. Ontogeny questions that 
require adoptive transfer and tracing is extremely limited in humans (only studies in 
the context of bone marrow transplants have successfully traced SCM generation 
from transferred T cells(45)) and mouse models are largely used to study CD8 T cell 
differentiation. Nothwithstanding, the discrepancy of differentiation markers used in 
different model systems makes human data uniquely informative, as observations are 
complementary but not fully transferrable across systems such as mouse and human.  
 
Historically, it has been particularly challenging to distinguish SCM from Naïve cells: 
SCM cells represent the most recent memory subset to be identified, hidden within 
the classic Naïve (“naïve-like”) gates. Interestingly, in our experiments, we found that 
there was a relatively constant level of antigen-specific CD8 T cells that fell in the 
naïve gate (CCR7- CD45RA- CD95-) even following priming. A hypothesis could be 
that these post-vaccination Naïve-gated cells have not actually been primed – this 
would require a compensatory replenishment of naïve cells with this antigen 
specificity, sufficiently rapid to immediately replenish the cells that have been primed 
and therefore depleted from the naïve pool. Murray et al calculated that after age 20, 
the naïve pool is maintained by homeostatic proliferation rather than thymic output 
(46) – all our donors were aged over 20, and it would be undistinguishable to know 
whether the naïve-gated cells proliferate due to homeostasis or due to priming. To our 
knowledge, in fact, there is to date no marker that can definitely prove that a given 
CD8 T cell has been primed. In the mouse, CD44 is often used as a marker to 
distinguish differentiated cells, yet there is no proof that CD44 expression is truly 
correlative of antigen priming experience; there is neither no such equivalent marker 
conventionally used in human experiments. In previous studies including ours, there 
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is evidence mainly substantiated from whole transcriptomic profiles, epigenetic 
imprints and functional assays, that subsets are arranged in a gradient, ordered from 
Naïve to SCM, CM, EM and EMRA (3,9,18,36). Intriguingly, we did observe that a 
substantial portion of cells in the naïve gate were undergoing activation, clearly 
visible at the peak of the response. In line with the argument that SCM amongst 
antigen-experienced cells preserve highest “naïveness”, we hypothesize that the cells 
that remain in the naïve gate after priming may have been effectively primed but are 
memory cells that preserve a phenotype that is very close to the naïve, even closer 
than SCM. Recently, Costa del Amo et al. found subpopulations of SCM cells with 
distinct turn-over rates in vivo (47), which highlights further potential heterogeneity 
within subset gates, and in support of the differentiation continuum from naïve to 
memory to effector.  
 
In our animated longitudinal tSNE analyses on nine different activation and 
differentiation markers, it was particularly visible that a fraction of cells stayed 
permanently allocated in the region where cells (Naïve) located at baseline. This 
permanence region was observed in samples across the longitudinal series including 
the acute phase and prolonged in samples in the range of years-to-decades after 
vaccination. We observed cells with phenotypes of naïve, memory (CM and SCM, 
CCR7+) or effector / effector memory (EM or EMRA, CCR7+), and each of these 
showed activation at the peak of the response and downregulated activation markers 
at later time-points - this observation highlights the importance of distinguishing 
between displaying a memory or effector phenotype and being in an activated or 
resting state. The progressive differentiation model does account for activated / 
effector phenotypes that may rise from each of the subsets (18). To-date, 
methodologies used in the study of CD8 T cell differentiation include the definition of 
memory cells solely on the basis of the time of sampling (meaning that all cells that 
are detected after the acute phase are memory cells), including studies in humans 
vaccinated with YF-17D (20). In fact, our analyses show that there is wide 
heterogeneity in differentiation phenotypes very early on, within the acute phase; and 
particularly also in the very long-term, evidenced by the fact that EMRA cells are 
detectable decades after vaccination as a fraction of cells separate from SCM cells 
(Figure 1, Figure S3) (36). Even though they are phenotypically quite distinct (SCM 
vs EMRA), stem cell features such as long-term persistence and self-renewal are 
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likely shared in these long-term populations, at least in a fraction of them. 
Interestingly, we found that it is the cells that express TCF1 that preferentially 
persisted in the range of years-to-decades. This was pertinent not only for the SCM 
subset (TCF1 high from baseline and permanently thereafter) but also particularly 
visible in the fraction of TCF1+ cells within the EMRA subset that preferentially 
persisted long-term over TCF1- EMRA. The latter suggests that TCF1 may generally 
support cellular persistence and thus also the maintenance of long-term effector cells 
that are readily available in the event of reinfection. 
 
Another historical challenge is that the classic differentiation subset nomenclature 
based on CCR7 and CD45RA was defined for resting human T cells, and all non-
naïve subsets are termed “memory”. As a consequence, this marker-nomenclature 
criterium does not phenotypically distinguish acutely activated effectors (CCR7-) 
from the “memory”-termed effector subsets EM (CCR7- CD45RA-) and EMRA 
(CCR7- CD45RA+) (18). Activation and cycling markers may distinguish acute 
phase effectors versus resting / long-term EM and EMRA: activated CCR7- cells 
(HLA-DR+ CD38+) would be effectors, and CCR7- cells that are HLA-DR- and 
CD38- would be EM/EMRA. However, how do we define the cells that show a 
combined memory (CCR7+) and activated phenotype, such as the SCM and CM 
subsets that we detected in the acute phase being as activated as effector CCR7- 
subsets? The longitudinal phenotyping we hereby present clearly warrants the need 
for a revision of the nomenclature and marker definition of human CD8 T cell subsets 
with considerations of activated (acute phase) versus resting states in complement 
with memory and/or effector markers.  
 
Altogether, based on clinical studies on YF-17D vaccination, we provide first 
evidence in humans, in vivo, on the early appearance of SCM CD8 T cells. The SCM 
phenotype that predominantly and stably persists in the decade long-term is detectable 
within the first week, and shows activation and expansion during the early acute 
phase. The results support differentiation models where memory cells arise very early 
without an obligatory transition through a full effector phenotype stage, yet showing 
an activated state on top of a memory phenotype. This would be in line with the 
existence of a continuum of differentiation phenotypes, where long-term memory 
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cells diverge from the full-blown effector burst and persist by preserving highest 
“naïveness” (proximity to the Naïve). 
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Figure legends 
 
Figure 1. Quantification of A2/LLW-specific CD8 T cell subsets during the first 
six months after YF-17D vaccination. (A) Flow cytometry gating strategy to define 
CD8 T cell subsets : Central memory (CM : CCR7+ CD45RA-), Effector memory 
(EM : CCR7- CD45RA-) and Effector memory CD45RA+ (EMRA : CCR7- 
CD45RA+) cells; CCR7 and CD45RA double positive (DP) cells are further 
subdivided into Naïve (CD95-) and stem cell-like (SCM, CD95+) subsets. (B) Flow 
cytometry analysis of A2/LLW tetramer+ CD8 T cells, showing the 7 longitudinal 
time-points of the representative donor (LAU 5089) : CD8+ A2/LLW tetramer+ cells 
were analysed for subset distribution as in A. (C) and (D) Quantification of the 
frequency of A2/LLW tetramer+ within total peripheral CD8 T cells, in N=8 donors 
with 7 longitudinal time-points. In C, frequencies are shown for total A2/LLW+ or 
per A2/LLW+ subset, and each donor is line-connected across its dotted time-points. 
In D, the data is pooled showing average and standard error of the mean (N=8) per 
population as indicated (left y-axis) ; viral load data is complemented (right y-axis). 
The dotted line in C and D indicates the multimer detection threshold of 0.01% of 
total CD8 T cells. Time-points are BL : baseline, D3 : Day 3, D7 : Day 7, D14 : Day 
14, D28 : Day 28, M3 : circa 3 months, M6 : circa 6 months (Table S1 shows full 
details of the cohort).  
 
Figure 2. Activation of A2/LLW-specific CD8 T cell subsets at the peak of the 
response. (A) Flow cytometry profiles at day 14 showing each activation marker and 
subset, as indicated ; total CD8 T cells are shown as a reference. The data are from 
donor LAU 5089.  
(B) Pie charts showing frequencies of the combinatorial expression of the four 
indicated activation markers, per subset : each arc designates one marker, each slice a 
number of markers co-expressed (representation based on SPICE software). N=7 
donors were analysed at day 14 post-vaccination and only detectable populations were 
quantified : in Naïve (n=4/7), SCM (n=7/7), CM (n=7/7), EM (n=7/7), EMRA 
(n=7/7). P-values (built-in t-test in SPICE) : ns = not significant, * < 0.05, ** < 0.01, 
*** < 0.001. 
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Figure 3. Patterns of subset distribution and TCF1 expression in human CD8 T 
cells across donors. (A) and (B) Flow cytometry analyses of CD8 T cells for subset 
composition (in A) and offset overlay histograms for TCF1 expression amongst 
subsets (in B), showing n=3 examples. (C) Frequencies for subset composition and 
TCF1 expression in peripheral total CD8 T cells from N=33 donors; these correspond 
to non-activated cells (unvaccinated or over 6 months after vaccination). Comparative 
p-values are shown in matrix format below each x-axis label, based on a Fridman test 
(non-parametric, paired) : ns = not significant, trend = 0.05 to <0.10, * < 0.05, ** < 
0.01, *** < 0.001. 
 
Figure 4. Dynamics of TCF1 expression in A2/LLW-specific CD8 T cell subsets 
in the early and late phases after YF-17D vaccination. (A) Flow cytometry profiles 
of TCF1 expression, longitudinally in the first 6 months after vaccination, in each 
subset. Overlay histograms show the A2/LLW multimer+ CD8 T cells in open line 
(colored per subset; absence denotes a non-detectable population) and the total CD8 T 
cell reference in grey fill below. Donor LAU 5081 is shown. (B) Frequencies of TCF1 
expression in the various A2/LLW-specific CD8 T cell subsets, longitudinally in N=8 
vaccinees in the early phase (first six months, line-connected dots per donor) and N= 
26 vaccinees for the late phase (cross-sectional cohort: from 4 months to 23.7 years); 
total N=82 samples. P-values are based on Kruskal-Wallis (unpaired, non-parametric) 
for multiple comparisons amongst time-line groups, distributed as shown in Figure 
S4. (C) Statistical comparison of the % of TCF1+ cells per subset based on 
longitudinal modeling of the data (same dataset as in panel B) and Bonferroni 
adjustment of the pairwise p-values. (D) and (E) Frequencies of TCF1+ and TCF1- 
populations of A2/LLW-specific EM or EMRA subsets amongst total peripheral CD8 
T cells. Corresponding linear regressions with least squares fit are shown for data 
from the peak of the response (at day 14). In D, the best-fit and standard error of the 
slopes from TCF1+ or TCF1- are compared, within each effector subset, with t-test p-
values indicated. ns = not significant, trend = 0.05 to <0.10, * < 0.05, ** < 0.01, *** < 
0.001. 
 
Figure 5. IL7Ra co-enriches with TCF1 in the long-term in A2/LLW-specific 
EMRA cells. Pie charts showing frequencies of the combinatorial expression of 
IL7Ra and TCF1 in the EMRA subset. Baseline EMRA correspond to EMRA from 
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total CD8 T cells. Thereafter, post-vaccination EMRA populations that are A2/LLW-
specific are shown (these are non- or insufficiently detectable for analysis before day 
14). P-values (built-in t-test in SPICE, comparing to baseline) : ns = not significant, * 
< 0.05, ** < 0.01, *** < 0.001. 
 
Figure 6. Gradient of differentiation in total CD8 T cells validated by t-
Stochastic Neighbor Embedding (tSNE) of flow cytometry data. Total CD8 T cells 
from N=13 donors (ranging from 8.5 months to 23.7 years after vaccination, i.e. no 
acute phase samples) were analysed with the tSNE plugin from FlowJo (A) Analysis 
strategy : single live CD8 T cells from each donor were downsampled to 5'000 events 
and the sum of N=13 donors were concatenated into a single file (70'000 events). This 
file was then gated and color-coded for the differentiation subsets as previously 
described (Figure 1A). (B) and (C) The N=13 concatenate was analysed by tSNE 
using the plugin from FlowJo v10, reducing nine parameters (CCR7, CD45RA, 
CD95, TCF1, IL7Ra, PD1, CD69, HLA-DR, CD38) to two dimensions (tSNE x- and 
y- axes). Shown is the resulting unsupervised clustering tSNE plot, with the overlay 
(in B) or individual plots (in C) of the differentiation subsets gated as in panel A. (D) 
The tSNE plots showing the heatmap (based on median) of each marker, as indicated. 
 
Figure 7. Time-lapse dynamics of CD8 T cell differentiation showing effector cell 
burst and permanent memory cell establishment during YF-17D vaccination. (A) 
N=7 donors were individually analysed, performing tSNE analyses on the 
longitudinal data series : for each donor dataset, all the single live A2/LLW-specific 
CD8 T cell flow cytometry events acquired were concatenated and individually ran 
for tSNE. The resulting tSNE plots are shown for each time-point (gated based on 
sample ID). Samples from donor LAU 5096 were stained with a different antibody 
panel (« panel D ») compared to all other donors (stained with « panel C »), as 
detailed in Table S2. (B) Single live A2/LLW-specific CD8 T cells from a pool of 
N=55 samples acquired with the same flow cytometry panel and instrument 
configuration were concatenated and ran for tSNE. These included: N=6 donors (D1 
to D6) with longitudinal data (7 time-points: BL, D3, D7, D14, D28, M3 and M6 in 
each sequence) together with N=13 donors from the cross-sectional cohort (grouped 
according to years since vaccination), as indicated. Shown are the plots of the 
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calculated tSNE (either x- or y- dimension) versus sample ID. The black-bordered 
rectangle indicates the areas of permanency throughout vaccination. 
 
Video 1. “N=7 subsets”: Dynamics of the differentiation of A2/LLW-specific 
CD8 T cells during YF-17D vaccination, showing subset composition for N=7 
donors. Time-lapse animation of the longitudinal tSNE analysis with subset overlays 
in N=7 donors, as indicated. Each donor sequence is spaced by 1 second, showing 
subset composition, and starting from Baseline, then Day 3, Day 7, Day 14, Day 28, 
circa 3 Months and circa 6 Months after YF-17D vaccination. For each donor, all the 
single live A2/LLW-specific CD8 T cell events acquired were concatenated and ran 
for the 9-marker tSNE. 
 
Video 2. “LAU 5089 markers”: Dynamics of the differentiation of A2/LLW-
specific CD8 T cells during YF-17D vaccination, showing each of the 9 markers 
for vaccinee LAU 5089. Time-lapse animation of the longitudinal tSNE analysis of 
donor LAU5089, showing sequences starting from Baseline, then Day 3, Day 7, Day 
14, Day 28, Day 84 (ca. 3 months) and Day 185 (ca. 6 months) after YF-17D 
vaccination. Each sequence is spaced by 1 second, and shows subset overlay or the 
indicated heatmapped marker. All the single live A2/LLW-specific CD8 T cell events 
acquired were concatenated and ran for the 9-marker tSNE. 
 
Figure S1. Longitudinal differentiation of A2/LLW-specific CD8 T cells in 
donors with detectable Yellow Fever viral load. Data are quantified as in Figure 
1D, showed for each individual donor that showed positive Yellow Fever viral load 
(N=5 out of 8 donors). 
 
Figure S2. Longitudinal analysis of activation markers in A2/LLW-specific CD8 
T cell subsets. The analysis is performed as in Figure 2, showing all time-points. The 
pie charts are translucent for the time-points and subsets with less than 3 donors with 
interpretable data. N values are indicated below each pie chart. P-values (built-in t-
test in SPICE, comparing subsets within each time-point) : ns = not significant, * < 
0.05, ** < 0.01, *** < 0.001. 
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Figure S3. Frequencies of A2/LLW-specific CD8 T cell subsets in subjects of the 
cross-sectional cohort. The frequency of A2/LLW-specific CD8 T cells within each 
subset is shown for the cross-sectional donors (analyzed in Figures 3 to 7 in 
combination with donors of the longitudinal cohort). 
 
Figure S4: Expression of TCF1 in A2/LLW-specific CD8 T cells of donors from 
the longitudinal and cross-sectional cohorts. Donors were grouped according to 
various time intervals since vaccination, each dot representing one donor. P-values: ns 
= not significant, trend = 0.05 to <0.10, * < 0.05, ** < 0.01, *** < 0.001, after 
Kruskal-Wallis multiple comparisons (unpaired, non-parametric). 
 
Figure S5. TCF1 and IL7Ra co-expression in total and A2/LLW-specific EMRA 
cells early and long-term after YF-17D vaccination. Data are analyzed as in Figure 
5, showing the data corresponding to either total or A2/LLW-specific EMRA cells, in 
the various time-point groups. P-values (built-in t-test in SPICE, comparing total 
vesus A2/LLW-specific within each time-point group) : ns = not significant, trend = 
0.05 to <0.10, * < 0.05, ** < 0.01, *** < 0.001. 
 
Figure S6. Individual yet conserved tSNE pattern of differentiation subsets in 
total CD8 T cells. A downsample of 75’000 single live total CD8 T cells was 
exported for each of the N=16 donors, individually running tSNE and analyzing each 
donor (gated and represented as in Figure 6B). The first N=13 donors correspond to 
the group analyzed in Figure 6 (ranging from 8.5 months to 23.7 years after 
vaccination, i.e. no acute phase samples); data of N=3 additional donors (ranging 
from 10.5 to 13.8 years after vaccination) originate from a different antibody panel 
configuration (“panel D”, see Table S2). 
 
Figure S7. Longitudinal dynamics of subset composition and marker expression 
from the tSNE analysis of donor LAU 5089. (A) For each donor dataset, all the 
single live A2/LLW-specific CD8 T cell flow cytometry events were concatenated 
and individually ran for tSNE : this generates a tSNE plot of all events. Each time-
point is then gated based on sample ID, and subsets further gated and color-coded as 
detailed in Figure 6A. (B) Longitudinal tSNE plots showing the heatmap (based on 
median) of each marker, as indicated.  
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Conferences 
 
Poster presentations: 
- Wolfsberg meeting of Swiss PhD students in Immunology, 2015 
- International Congress of Immunology, Melbourne, Australia, 2016 
- EACR-AACR-SIC Special Conference, Florence, Italy, 2017 
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French Mother language 
English Certificate of Advanced English, grade B 
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Miscellaneous 
 
Running 
Horse riding (show jumping AVSH Merit Award 2011) 
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